@article{aertsDecodingTumourPhenotype2014,
  title   = {Decoding Tumour Phenotype by Noninvasive Imaging Using a Quantitative Radiomics Approach},
  author  = {Aerts, Hugo J. W. L. and Velazquez, Emmanuel Rios and Leijenaar, Ralph T. H. and Parmar, Chintan and Grossmann, Patrick and Carvalho, Sara and Bussink, Johan and Monshouwer, Ren{\'e} and {Haibe-Kains}, Benjamin and Rietveld, Derek and Hoebers, Frank and Rietbergen, Michelle M. and Leemans, C. Ren{\'e} and Dekker, Andre and Quackenbush, John and Gillies, Robert J. and Lambin, Philippe},
  year    = 2014,
  month   = jun,
  journal = {Nature Communications},
  volume  = {5},
  number  = {1},
  pages   = {4006},
  issn    = {2041-1723},
  doi     = {10.1038/ncomms5006},
  urldate = {2026-01-20},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\CQTHZLGG\Aerts et al. - 2014 - Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.pdf}
}

@article{anderssonHowCorrectSusceptibility2003,
  title      = {How to Correct Susceptibility Distortions in Spin-Echo Echo-Planar Images: Application to Diffusion Tensor Imaging},
  shorttitle = {How to Correct Susceptibility Distortions in Spin-Echo Echo-Planar Images},
  author     = {Andersson, Jesper L.R. and Skare, Stefan and Ashburner, John},
  year       = 2003,
  month      = oct,
  journal    = {NeuroImage},
  volume     = {20},
  number     = {2},
  pages      = {870--888},
  issn       = {10538119},
  doi        = {10.1016/S1053-8119(03)00336-7},
  urldate    = {2025-12-11},
  langid     = {english}
}

@article{andrePembrolizumabChemotherapyMicrosatellite2025,
  title      = {Pembrolizumab versus Chemotherapy in Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer: 5-Year Follow-up from the Randomized Phase {{III KEYNOTE-177}} Study},
  shorttitle = {Pembrolizumab versus Chemotherapy in Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer},
  author     = {Andr{\'e}, T. and Shiu, K.-K. and Kim, T.W. and Jensen, B.V. and Jensen, L.H. and Punt, C.J.A. and Smith, D. and {Garcia-Carbonero}, R. and {Alcaide-Garcia}, J. and Gibbs, P. and De La Fouchardiere, C. and Rivera, F. and Elez, E. and Le, D.T. and Yoshino, T. and Zuo, Y. and Fogelman, D. and Adelberg, D. and Diaz, L.A.},
  year       = 2025,
  month      = mar,
  journal    = {Annals of Oncology},
  volume     = {36},
  number     = {3},
  pages      = {277--284},
  issn       = {09237534},
  doi        = {10.1016/j.annonc.2024.11.012},
  urldate    = {2026-01-18},
  langid     = {english}
}

@article{arnoldGlobalPatternsTrends2017,
  title    = {Global Patterns and Trends in Colorectal Cancer Incidence and Mortality},
  author   = {Arnold, Melina and Sierra, M{\'o}nica S and Laversanne, Mathieu and Soerjomataram, Isabelle and Jemal, Ahmedin and Bray, Freddie},
  year     = 2017,
  month    = apr,
  journal  = {Gut},
  volume   = {66},
  number   = {4},
  pages    = {683--691},
  issn     = {0017-5749, 1468-3288},
  doi      = {10.1136/gutjnl-2015-310912},
  urldate  = {2025-12-15},
  abstract = {Objective               The global burden of colorectal cancer (CRC) is expected to increase by 60\% to more than 2.2\>million new cases and 1.1\>million deaths by 2030. In this study, we aim to describe the recent CRC incidence and mortality patterns and trends linking the findings to the prospects of reducing the burden through cancer prevention and care.                                         Design                                Estimates of sex-specific CRC incidence and mortality rates in 2012 were extracted from the GLOBOCAN database. Temporal patterns were assessed for 37 countries using data from                 Cancer Incidence in Five Continents                 (CI5) volumes I--X and the WHO mortality database. Trends were assessed via the annual percentage change using joinpoint regression and discussed in relation to human development levels.                                                        Results               CRC incidence and mortality rates vary up to 10-fold worldwide, with distinct gradients across human development levels, pointing towards widening disparities and an increasing burden in countries in transition. Generally, CRC incidence and mortality rates are still rising rapidly in many low-income and middle-income countries; stabilising or decreasing trends tend to be seen in highly developed countries where rates remain among the highest in the world.                                         Conclusions               Patterns and trends in CRC incidence and mortality correlate with present human development levels and their incremental changes might reflect the adoption of more western lifestyles. Targeted resource-dependent interventions, including primary prevention in low-income, supplemented with early detection in high-income settings, are needed to reduce the number of patients with CRC in future decades.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\YVZ3K7C3\Arnold et al. - 2017 - Global patterns and trends in colorectal cancer incidence and mortality.pdf}
}

@article{avantsSymmetricDiffeomorphicImage2008,
  title      = {Symmetric Diffeomorphic Image Registration with Cross-Correlation: {{Evaluating}} Automated Labeling of Elderly and Neurodegenerative Brain},
  shorttitle = {Symmetric Diffeomorphic Image Registration with Cross-Correlation},
  author     = {Avants, B and Epstein, C and Grossman, M and Gee, J},
  year       = 2008,
  month      = feb,
  journal    = {Medical Image Analysis},
  volume     = {12},
  number     = {1},
  pages      = {26--41},
  issn       = {13618415},
  doi        = {10.1016/j.media.2007.06.004},
  urldate    = {2025-12-11},
  copyright  = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\XFI89CA6\Avants et al. - 2008 - Symmetric diffeomorphic image registration with cross-correlation Evaluating automated labeling of.pdf}
}

@article{balaguer-monteroCTbasedDeepLearningdriven2025,
  title   = {A {{CT-based}} Deep Learning-Driven Tool for Automatic Liver Tumor Detection and Delineation in Patients with Cancer},
  author  = {{Balaguer-Montero}, Maria and Marcos Morales, Adri{\`a} and Ligero, Marta and Zatse, Christina and Leiva, David and Atlagich, Luz M. and Staikoglou, Nikolaos and Viaplana, Cristina and Monreal, Camilo and Mateo, Joaquin and Hernando, Jorge and {Garc{\'i}a-{\'A}lvarez}, Alejandro and Salv{\`a}, Francesc and Capdevila, Jaume and Elez, Elena and Dienstmann, Rodrigo and Garralda, Elena and {Perez-Lopez}, Raquel},
  year    = 2025,
  month   = apr,
  journal = {Cell Reports Medicine},
  volume  = {6},
  number  = {4},
  pages   = {102032},
  issn    = {26663791},
  doi     = {10.1016/j.xcrm.2025.102032},
  urldate = {2025-12-11},
  langid  = {english}
}

@article{bankheadQuPathOpenSource2017,
  title      = {{{QuPath}}: {{Open}} Source Software for Digital Pathology Image Analysis},
  shorttitle = {{{QuPath}}},
  author     = {Bankhead, Peter and Loughrey, Maurice B. and Fern{\'a}ndez, Jos{\'e} A. and Dombrowski, Yvonne and McArt, Darragh G. and Dunne, Philip D. and McQuaid, Stephen and Gray, Ronan T. and Murray, Liam J. and Coleman, Helen G. and James, Jacqueline A. and {Salto-Tellez}, Manuel and Hamilton, Peter W.},
  year       = 2017,
  month      = dec,
  journal    = {Scientific Reports},
  volume     = {7},
  number     = {1},
  pages      = {16878},
  issn       = {2045-2322},
  doi        = {10.1038/s41598-017-17204-5},
  urldate    = {2025-12-11},
  abstract   = {Abstract             QuPath is new bioimage analysis software designed to meet the growing need for a user-friendly, extensible, open-source solution for digital pathology and whole slide image analysis. In addition to offering a comprehensive panel of tumor identification and high-throughput biomarker evaluation tools, QuPath provides researchers with powerful batch-processing and scripting functionality, and an extensible platform with which to develop and share new algorithms to analyze complex tissue images. Furthermore, QuPath's flexible design makes it suitable for a wide range of additional image analysis applications across biomedical research.},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\URUKHA7K\Bankhead et al. - 2017 - QuPath Open source software for digital pathology image analysis.pdf}
}

@article{bariPracticePatternsSurvival2025,
  title    = {Practice {{Patterns}} and {{Survival Outcomes}} of {{Immunotherapy}} for {{Metastatic Colorectal Cancer}}},
  author   = {Bari, Shahla and Matejcic, Marco and Kim, Richard D. and Xie, Hao and Sahin, Ibrahim H. and Powers, Benjamin D. and Teer, Jamie K. and Chan, Timothy A. and Felder, Seth I. and Schmit, Stephanie L.},
  year     = 2025,
  month    = mar,
  journal  = {JAMA Network Open},
  volume   = {8},
  number   = {3},
  pages    = {e251186},
  issn     = {2574-3805},
  doi      = {10.1001/jamanetworkopen.2025.1186},
  urldate  = {2026-01-18},
  abstract = {Importance               Immune checkpoint inhibitors (ICIs) have been approved for treatment of microsatellite instable (MSI-H) metastatic colorectal cancer (mCRC), but factors associated with receipt and efficacy of ICIs in routine clinical practice remain largely unknown.                                         Objective               To identify factors associated with receipt of ICIs and associated survival outcomes among patients with mCRC in routine clinical practice.                                         Design, Setting, and Participants               This population-based cohort study used deidentified data from a nationwide electronic health record--derived database to include 18\,932 patients diagnosed with mCRC between January 2013 and June 2019. Population-based patients were diagnosed with de novo mCRC and had at least 2 documented clinical visits on or after the date of diagnosis. The study analyses were performed between September 2020 and April 2021.                                         Exposure               Patients received ICI therapy and/or chemotherapy as part of a systemic treatment for mCRC.                                         Main Outcomes and Measures               The outcomes were receipt of ICI therapy, overall survival (OS), and time to treatment discontinuation (TTD).                                         Results                                In this cohort study of 18\,932 patients diagnosed with mCRC (10\,537 [55.7\%] male; 546 [2.9\%] Asian, 2005 [10.6\%] Black or African American, 1674 [8.8\%] Hispanic, 12\,338 [65.2\%] White, 4043 [21.4\%] unknown race or ethnicity; median [IQR] age at metastatic diagnosis, 64.6 [55.0-73.3] years), patients with MSI-H tumors had a significantly higher probability of receiving ICIs than those with microsatellite stable (MSS) tumors (odds ratio [OR], 22.66 [95\% CI, 17.30-29.73];                 P                 \,\&amp;lt;\,.001), whereas patients initially diagnosed with synchronous mCRC had significantly lower odds of receiving ICIs than patients with metachronous mCRC (OR, 0.57 [95\% CI, 0.45-0.73];                 P                 \,\&amp;lt;\,.001). Patients with MSI-H tumors who received ICIs as first line of therapy had significantly longer OS than those receiving chemotherapy only (HR, 0.37 [95\% CI, 0.25-0.56];                 P                 \,\&amp;lt;\,.001). Among patients with MSS tumors, ICI-based therapy was associated with significantly longer OS for patients with high albumin level (vs low: HR, 0.28 [95\% CI, 0.18-0.45];                 P                 \,\&amp;lt;\,.001) and antibiotic use (vs nonuse: HR, 0.43 [95\% CI, 0.27-0.67];                 P                 \,\&amp;lt;\,.001), but a significantly shorter OS for patients with synchronous mCRC (vs metachronous: HR, 1.90 [95\% CI, 1.24-2.89];                 P                 \,=\,.003). In addition, 29 out of 235 patients with MSS tumors (12.3\%) experienced durable responses on ICI-based therapy. Similar patterns of associations with TTD were observed.                                                        Conclusions and Relevance               In this cohort study of patients with mCRC, clinical characteristics were associated with different survival outcomes in patients treated with ICI-based therapy, with important clinical implications for patients with MSS tumors who are generally unresponsive to immunotherapy.},
  langid   = {english}
}

@article{bartkoVariousIntraclassCorrelation1976,
  title   = {On Various Intraclass Correlation Reliability Coefficients.},
  author  = {Bartko, John J.},
  year    = 1976,
  month   = sep,
  journal = {Psychological Bulletin},
  volume  = {83},
  number  = {5},
  pages   = {762--765},
  issn    = {1939-1455, 0033-2909},
  doi     = {10.1037/0033-2909.83.5.762},
  urldate = {2025-12-10},
  langid  = {english}
}

@article{benjaminiControllingFalseDiscovery1995,
  title      = {Controlling the {{False Discovery Rate}}: {{A Practical}} and {{Powerful Approach}} to {{Multiple Testing}}},
  shorttitle = {Controlling the {{False Discovery Rate}}},
  author     = {Benjamini, Yoav and Hochberg, Yosef},
  year       = 1995,
  month      = jan,
  journal    = {Journal of the Royal Statistical Society Series B: Statistical Methodology},
  volume     = {57},
  number     = {1},
  pages      = {289--300},
  issn       = {1369-7412, 1467-9868},
  doi        = {10.1111/j.2517-6161.1995.tb02031.x},
  urldate    = {2026-01-08},
  abstract   = {SUMMARY             The common approach to the multiplicity problem calls for controlling the familywise error rate (FWER). This approach, though, has faults, and we point out a few. A different approach to problems of multiple significance testing is presented. It calls for controlling the expected proportion of falsely rejected hypotheses --- the false discovery rate. This error rate is equivalent to the FWER when all hypotheses are true but is smaller otherwise. Therefore, in problems where the control of the false discovery rate rather than that of the FWER is desired, there is potential for a gain in power. A simple sequential Bonferronitype procedure is proved to control the false discovery rate for independent test statistics, and a simulation study shows that the gain in power is substantial. The use of the new procedure and the appropriateness of the criterion are illustrated with examples.},
  copyright  = {https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model},
  langid     = {english}
}

@article{berenguerRadiomicsCTFeatures2018,
  title      = {Radiomics of {{CT Features May Be Nonreproducible}} and {{Redundant}}: {{Influence}} of {{CT Acquisition Parameters}}},
  shorttitle = {Radiomics of {{CT Features May Be Nonreproducible}} and {{Redundant}}},
  author     = {Berenguer, Roberto and {Pastor-Juan}, Mar{\'i}a Del Rosario and {Canales-V{\'a}zquez}, Jes{\'u}s and {Castro-Garc{\'i}a}, Miguel and Villas, Mar{\'i}a Victoria and Mansilla Legorburo, Francisco and Sabater, Sebasti{\`a}},
  year       = 2018,
  month      = aug,
  journal    = {Radiology},
  volume     = {288},
  number     = {2},
  pages      = {407--415},
  issn       = {0033-8419, 1527-1315},
  doi        = {10.1148/radiol.2018172361},
  urldate    = {2025-12-01},
  langid     = {english}
}

@article{bernatowiczRobustImagingHabitat2021,
  title    = {Robust Imaging Habitat Computation Using Voxel-Wise Radiomics Features},
  author   = {Bernatowicz, Kinga and Grussu, Francesco and Ligero, Marta and Garcia, Alonso and Delgado, Eric and {Perez-Lopez}, Raquel},
  year     = 2021,
  month    = oct,
  journal  = {Scientific Reports},
  volume   = {11},
  number   = {1},
  pages    = {20133},
  issn     = {2045-2322},
  doi      = {10.1038/s41598-021-99701-2},
  urldate  = {2025-12-01},
  abstract = {Abstract             Tumor heterogeneity has been postulated as a hallmark of treatment resistance and a cure constraint in cancer patients. Conventional quantitative medical imaging (radiomics) can be extended to computing voxel-wise features and aggregating tumor subregions with similar radiological phenotypes (imaging habitats) to elucidate the distribution of tumor heterogeneity within and among tumors. Despite the promising applications of imaging habitats, they may be affected by variability of radiomics features, preventing comparison and generalization of imaging habitats techniques. We performed a comprehensive repeatability and reproducibility analysis of voxel-wise radiomics features in more than 500 lung cancer patients with computed tomography (CT) images and demonstrated the effect of voxel-wise radiomics variability on imaging habitats computation in 30 lung cancer patients with test--retest images. Repeatable voxel-wise features characterized texture heterogeneity and were reproducible regardless of the applied feature extraction parameters. Imaging habitats computed using robust radiomics features were more stable than those computed using all features in test--retest CTs from the same patient. Nine voxel-wise radiomics features (joint energy, joint entropy, sum entropy, maximum probability, difference entropy, Imc1, Imc2, Idn and Idmn) were repeatable and reproducible. This supports their application for computing imaging habitats in lung tumors towards the discovery of previously unseen tumor heterogeneity and the development of novel non-invasive imaging biomarkers for precision medicine.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\JB2KGHU7\Bernatowicz et al. - 2021 - Robust imaging habitat computation using voxel-wise radiomics features.pdf}
}

@article{bibeauCommentHistopathologicEvaluation2013,
  title     = {Comment on '{{Histopathologic}} Evaluation of Liver Metastases from Colorectal Cancer in Patients Treated with {{FOLFOXIRI}} plus Bevacizumab'},
  author    = {Bibeau, F and Gil, H and Castan, F and {Boissi{\`e}re-Michot}, F},
  year      = 2013,
  month     = dec,
  journal   = {Br. J. Cancer},
  volume    = {109},
  number    = {12},
  pages     = {3127--3129},
  publisher = {{Springer Science and Business Media LLC}},
  issn      = {0007-0920},
  doi       = {10.1038/bjc.2013.651}
}

@article{birdBiologyColorectalLiver2006,
  title      = {Biology of Colorectal Liver Metastases: {{A}} Review},
  shorttitle = {Biology of Colorectal Liver Metastases},
  author     = {Bird, Nigel C. and Mangnall, David and Majeed, Ali W.},
  year       = 2006,
  month      = jul,
  journal    = {Journal of Surgical Oncology},
  volume     = {94},
  number     = {1},
  pages      = {68--80},
  issn       = {0022-4790, 1096-9098},
  doi        = {10.1002/jso.20558},
  urldate    = {2026-01-18},
  copyright  = {http://doi.wiley.com/10.1002/tdm\_license\_1.1},
  langid     = {english}
}

@book{bishopPatternRecognitionMachine2006,
  title     = {Pattern Recognition and Machine Learning},
  author    = {Bishop, Christopher M.},
  year      = 2006,
  series    = {Information Science and Statistics},
  publisher = {Springer},
  address   = {New York},
  isbn      = {978-0-387-31073-2},
  langid    = {english},
  lccn      = {006.4}
}

@misc{bommasaniOpportunitiesRisksFoundation2021,
  title     = {On the {{Opportunities}} and {{Risks}} of {{Foundation Models}}},
  author    = {Bommasani, Rishi and Hudson, Drew A. and Adeli, Ehsan and others},
  year      = 2021,
  publisher = {arXiv},
  doi       = {10.48550/ARXIV.2108.07258},
  urldate   = {2026-01-19},
  abstract  = {AI is undergoing a paradigm shift with the rise of models (e.g., BERT, DALL-E, GPT-3) that are trained on broad data at scale and are adaptable to a wide range of downstream tasks. We call these models foundation models to underscore their critically central yet incomplete character. This report provides a thorough account of the opportunities and risks of foundation models, ranging from their capabilities (e.g., language, vision, robotics, reasoning, human interaction) and technical principles(e.g., model architectures, training procedures, data, systems, security, evaluation, theory) to their applications (e.g., law, healthcare, education) and societal impact (e.g., inequity, misuse, economic and environmental impact, legal and ethical considerations). Though foundation models are based on standard deep learning and transfer learning, their scale results in new emergent capabilities,and their effectiveness across so many tasks incentivizes homogenization. Homogenization provides powerful leverage but demands caution, as the defects of the foundation model are inherited by all the adapted models downstream. Despite the impending widespread deployment of foundation models, we currently lack a clear understanding of how they work, when they fail, and what they are even capable of due to their emergent properties. To tackle these questions, we believe much of the critical research on foundation models will require deep interdisciplinary collaboration commensurate with their fundamentally sociotechnical nature.},
  copyright = {Creative Commons Attribution 4.0 International},
  keywords  = {Artificial Intelligence (cs.AI),Computers and Society (cs.CY),FOS: Computer and information sciences,Machine Learning (cs.LG)}
}

@article{brayGlobalCancerStatistics2024,
  title      = {Global Cancer Statistics 2022: {{GLOBOCAN}} Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries},
  shorttitle = {Global Cancer Statistics 2022},
  author     = {Bray, Freddie and Laversanne, Mathieu and Sung, Hyuna and Ferlay, Jacques and Siegel, Rebecca L. and Soerjomataram, Isabelle and Jemal, Ahmedin},
  year       = 2024,
  month      = may,
  journal    = {CA: A Cancer Journal for Clinicians},
  volume     = {74},
  number     = {3},
  pages      = {229--263},
  issn       = {0007-9235, 1542-4863},
  doi        = {10.3322/caac.21834},
  urldate    = {2026-01-21},
  abstract   = {Abstract             This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC). There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4\% of all cancers globally), followed by cancers of the female breast (11.6\%), colorectum (9.6\%), prostate (7.3\%), and stomach (4.9\%). Lung cancer was also the leading cause of cancer death, with an estimated 1.8 million deaths (18.7\%), followed by colorectal (9.3\%), liver (7.8\%), female breast (6.9\%), and stomach (6.8\%) cancers. Breast cancer and lung cancer were the most frequent cancers in women and men, respectively (both cases and deaths). Incidence rates (including NMSC) varied from four-fold to five-fold across world regions, from over 500 in Australia/New Zealand (507.9 per 100,000) to under 100 in Western Africa (97.1 per 100,000) among men, and from over 400 in Australia/New Zealand (410.5 per 100,000) to close to 100 in South-Central Asia (103.3 per 100,000) among women. The authors examine the geographic variability across 20 world regions for the 10 leading cancer types, discussing recent trends, the underlying determinants, and the prospects for global cancer prevention and control. With demographics-based predictions indicating that the number of new cases of cancer will reach 35 million by 2050, investments in prevention, including the targeting of key risk factors for cancer (including smoking, overweight and obesity, and infection), could avert millions of future cancer diagnoses and save many lives worldwide, bringing huge economic as well as societal dividends to countries over the forthcoming decades.},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\EMI8USFK\Bray et al. - 2024 - Global cancer statistics 2022 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer.pdf}
}

@article{budcziesLandscapeMetastaticProgression2015,
  title    = {The Landscape of Metastatic Progression Patterns across Major Human Cancers},
  author   = {Budczies, Jan and {von Winterfeld}, Moritz and Klauschen, Frederick and Bockmayr, Michael and Lennerz, Jochen K. and Denkert, Carsten and Wolf, Thomas and Warth, Arne and Dietel, Manfred and Anagnostopoulos, Ioannis and Weichert, Wilko and Wittschieber, Daniel and Stenzinger, Albrecht},
  year     = 2015,
  month    = jan,
  journal  = {Oncotarget},
  volume   = {6},
  number   = {1},
  pages    = {570--583},
  issn     = {1949-2553},
  doi      = {10.18632/oncotarget.2677},
  abstract = {The majority of patients with solid malignancies die from metastatic burden. However, our current understanding of the mechanisms and resulting patterns of dissemination is limited. Here, we analyzed patterns of metastatic progression across 16 major cancer types in a cohort of 1008 patients with metastatic cancer autopsied between 2000 and 2013 to assess cancer specific progression patterns of disease and related risk predictions. The frequency and location of metastases were evaluated in and across 1) 16 major cancers, 2) smoking- and non-smoking-related cancers and 3) adeno- and squamous cell carcinoma. Associations between primary and secondary sites were analyzed by the fractional and the relative risk methods. We detected significantly different cancer specific patterns of metastatic progression with specific relative risk profiles for secondary site involvement. Histology and smoking etiology influenced these patterns. Backward analysis showed that metastatic patterns help to predict unknown primary sites. Solid malignancies maintain a unique and recurrent organ tropism to specific secondary sites which does not appear to be strongly influenced by advances in cancer medicine as shown by comparison with previous data sets. The delineated landscape of metastatic progression patterns is a comprehensive data resource to both clinical and basic scientists which aids fostering new hypotheses for cancer research and cancer therapies.},
  langid   = {english},
  pmcid    = {PMC4381616},
  pmid     = {25402435},
  keywords = {Adenocarcinoma,Carcinoma Squamous Cell,Cluster Analysis,Disease Progression,Female,Humans,Male,Neoplasm Metastasis,Neoplasms,Retrospective Studies,Risk Factors,Smoking},
  file     = {C:\Users\oprio\Zotero\storage\8CX9IJEG\Budczies et al. - 2015 - The landscape of metastatic progression patterns across major human cancers.pdf}
}

@article{burtonRECISTRightTime2007,
  title      = {{{RECIST}}: Right Time to Renovate?},
  shorttitle = {{{RECIST}}},
  author     = {Burton, Adrian},
  year       = 2007,
  month      = jun,
  journal    = {The Lancet Oncology},
  volume     = {8},
  number     = {6},
  pages      = {464--465},
  issn       = {14702045},
  doi        = {10.1016/S1470-2045(07)70155-9},
  urldate    = {2026-01-18},
  langid     = {english}
}

@article{campanellaClinicalBenchmarkPublic2025,
  title   = {A Clinical Benchmark of Public Self-Supervised Pathology Foundation Models},
  author  = {Campanella, Gabriele and Chen, Shengjia and Singh, Manbir and Verma, Ruchika and Muehlstedt, Silke and Zeng, Jennifer and Stock, Aryeh and Croken, Matt and Veremis, Brandon and Elmas, Abdulkadir and Shujski, Ivan and Neittaanm{\"a}ki, Noora and Huang, Kuan-lin and Kwan, Ricky and Houldsworth, Jane and Schoenfeld, Adam J. and Vanderbilt, Chad},
  year    = 2025,
  month   = apr,
  journal = {Nature Communications},
  volume  = {16},
  number  = {1},
  pages   = {3640},
  issn    = {2041-1723},
  doi     = {10.1038/s41467-025-58796-1},
  urldate = {2026-01-12},
  langid  = {english}
}

@misc{CancerFactsFigures,
  author       = {{American Cancer Society}},
  year         = 2025,
  title        = {Cancer {{Facts}} \& {{Figures}} 2025},
  urldate      = {2026-01-13},
  abstract     = {The 2025 annual report provides estimated numbers of new cancer cases, deaths, survivors and statistics on prevention, early detection, and treatment.},
  howpublished = {https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2025-cancer-facts-figures.html},
  langid       = {english}
}

@article{caoLabelfreeIntraoperativeHistology2023,
  title    = {Label-Free Intraoperative Histology of Bone Tissue via Deep-Learning-Assisted Ultraviolet Photoacoustic Microscopy},
  author   = {Cao, Rui and Nelson, Scott D and Davis, Samuel and Liang, Yu and Luo, Yilin and Zhang, Yide and Crawford, Brooke and Wang, Lihong V},
  year     = 2023,
  month    = feb,
  journal  = {Nat Biomed Eng},
  volume   = {7},
  number   = {2},
  pages    = {124--134},
  issn     = {2157-846X},
  doi      = {10.1038/s41551-022-00940-z},
  abstract = {Obtaining frozen sections of bone tissue for intraoperative examination is challenging. To identify the bony edge of resection, orthopaedic oncologists therefore rely on pre-operative X-ray computed tomography or magnetic resonance imaging. However, these techniques do not allow for accurate diagnosis or for intraoperative confirmation of the tumour margins, and in bony sarcomas, they can lead to bone margins up to 10-fold wider (1,000-fold volumetrically) than necessary. Here, we show that real-time three-dimensional contour-scanning of tissue via ultraviolet photoacoustic microscopy in reflection mode can be used to intraoperatively evaluate undecalcified and decalcified thick bone specimens, without the need for tissue sectioning. We validate the technique with gold-standard haematoxylin-and-eosin histology images acquired via a traditional optical microscope, and also show that an unsupervised generative adversarial network can virtually stain the ultraviolet-photoacoustic-microscopy images, allowing pathologists to readily identify cancerous features. Label-free and slide-free histology via ultraviolet photoacoustic microscopy may allow for rapid diagnoses of bone-tissue pathologies and aid the intraoperative determination of tumour margins.}
}

@article{caranoQuantificationTumorTissue2004,
  title    = {Quantification of Tumor Tissue Populations by Multispectral Analysis},
  author   = {Carano, Richard A.D. and Ross, Adrienne L. and Ross, Jed and Williams, Simon P. and Koeppen, Hartmut and Schwall, Ralph H. and Van Bruggen, Nicholas},
  year     = 2004,
  month    = mar,
  journal  = {Magnetic Resonance in Medicine},
  volume   = {51},
  number   = {3},
  pages    = {542--551},
  issn     = {0740-3194, 1522-2594},
  doi      = {10.1002/mrm.10731},
  urldate  = {2026-01-19},
  abstract = {Abstract                            Tumor heterogeneity complicates the quantification of a therapeutic response by MRI. To address this issue, a novel approach has been developed that combines MR diffusion imaging with multispectral (MS) analysis to quantify tumor tissue populations. K-means (KM) clustering of the apparent diffusion coefficient (ADC),               T               2               , and proton density (               M               0               ) was employed to estimate the volumes of viable tumor tissue, necrosis, and neighboring subcutaneous adipose tissue in a human colorectal tumor xenograft mouse model. In a second set of experiments, the temporal evolution of the MS tissue classes in response to therapeutic intervention Apo2L/TRAIL and CPT-11 was observed. The multiple parameters played complementary roles in identifying the various tissues. The ADC was the dominant parameter for identifying regions of necrosis, whereas               T               2               identified two necrotic subpopulations, and               M               0               contributed to the differentiation of viable tumor from subcutaneous adipose tissue. MS viable tumor estimates (mean volume = 275 \textpm{} 147 mm               3               ) were highly correlated (r = 0.81,               P               {$<$} 0.01) with histological estimates (117 \textpm{} 51 mm               3               ). In the treatment study, MS viable tumor volume (at day 10) was 77 \textpm{} 67 mm               3               for the Apo2L/TRAIL+CPT-11 group, and was significantly reduced relative to the control group (292 \textpm{} 127 mm               3               ,               P               {$<$} 0.01). This method shows promise as a means of detecting an early therapeutic response in vivo. Magn Reson Med 51:542--551, 2004. \copyright{} 2004 Wiley-Liss, Inc.},
  langid   = {english}
}

@article{cervantesMetastaticColorectalCancer2023,
  title      = {Metastatic Colorectal Cancer: {{ESMO Clinical Practice Guideline}} for Diagnosis, Treatment and Follow-Up},
  shorttitle = {Metastatic Colorectal Cancer},
  author     = {Cervantes, A. and Adam, R. and Rosell{\'o}, S. and Arnold, D. and Normanno, N. and Ta{\"i}eb, J. and Seligmann, J. and De Baere, T. and Osterlund, P. and Yoshino, T. and Martinelli, E.},
  year       = 2023,
  month      = jan,
  journal    = {Annals of Oncology},
  volume     = {34},
  number     = {1},
  pages      = {10--32},
  issn       = {09237534},
  doi        = {10.1016/j.annonc.2022.10.003},
  urldate    = {2026-01-10},
  langid     = {english}
}

@article{chafferPerspectiveCancerCell2011,
  title    = {A {{Perspective}} on {{Cancer Cell Metastasis}}},
  author   = {Chaffer, Christine L. and Weinberg, Robert A.},
  year     = 2011,
  month    = mar,
  journal  = {Science},
  volume   = {331},
  number   = {6024},
  pages    = {1559--1564},
  issn     = {0036-8075, 1095-9203},
  doi      = {10.1126/science.1203543},
  urldate  = {2026-01-21},
  abstract = {Metastasis causes most cancer deaths, yet this process remains one of the most enigmatic aspects of the disease. Building on new mechanistic insights emerging from recent research, we offer our perspective on the metastatic process and reflect on possible paths of future exploration. We suggest that metastasis can be portrayed as a two-phase process: The first phase involves the physical translocation of a cancer cell to a distant organ, whereas the second encompasses the ability of the cancer cell to develop into a metastatic lesion at that distant site. Although much remains to be learned about the second phase, we feel that an understanding of the first phase is now within sight, due in part to a better understanding of how cancer cell behavior can be modified by a cell-biological program called the epithelial-to-mesenchymal transition.},
  langid   = {english}
}

@article{changHallmarksArtificialIntelligence2025,
  title   = {Hallmarks of Artificial Intelligence Contributions to Precision Oncology},
  author  = {Chang, Tian-Gen and Park, Seongyong and Sch{\"a}ffer, Alejandro A. and Jiang, Peng and Ruppin, Eytan},
  year    = 2025,
  month   = mar,
  journal = {Nature Cancer},
  volume  = {6},
  number  = {3},
  pages   = {417--431},
  issn    = {2662-1347},
  doi     = {10.1038/s43018-025-00917-2},
  urldate = {2025-08-13},
  langid  = {english}
}

@article{changInfarctlikeNecrosisDistinct2012,
  title     = {Infarct-like Necrosis: A Distinct Form of Necrosis Seen in Colorectal Carcinoma Liver Metastases Treated with Perioperative Chemotherapy},
  author    = {Chang, Hector H Li and Leeper, W Robert and Chan, Gabriel and Quan, Douglas and Driman, David Kevin},
  year      = 2012,
  month     = apr,
  journal   = {Am. J. Surg. Pathol.},
  volume    = {36},
  number    = {4},
  pages     = {570--576},
  publisher = {Am J Surg Pathol},
  issn      = {1532-0979},
  doi       = {10.1097/PAS.0b013e31824057e7},
  urldate   = {2025-04-12},
  abstract  = {The response of colorectal adenocarcinoma liver metastases to perioperative chemotherapy can be assessed histologically in partial hepatectomy specimens. Necrosis in this scenario may represent a lack of treatment effect or a therapeutic response to chemotherapy. This study sought to validate the histologic classification of necrosis into 2 types: usual necrosis (UN) representing an absence of treatment effect, and infarct-like necrosis (ILN) representing a therapeutic response to chemotherapy. Tumor regression grade (TRG) is a previously described prognosticating method that estimates tumor replacement by fibrosis. We incorporated ILN into a modified TRG (mTRG) and compared its performance as a prognostic factor against TRG. A retrospective clinical and histologic review was undertaken of all partial hepatectomies performed for colorectal liver metastases at our center between 2004 and 2010. Clinicopathologic features were compared between the 2 types of necrosis, including survival stratified by TRG and mTRG. A total of 109 cases were reviewed, with 46 patients receiving perioperative chemotherapy. ILN was identified in 12 cases, and all of these cases were associated with perioperative chemotherapy. ILN was significantly associated with perioperative treatment with bevacizumab. In patients receiving perioperative chemotherapy, those with ILN had superior disease-free survival compared with those with UN (P=0.047). mTRG1 to 2 scores were associated with significantly better survival compared with mTRG3 to 5 scores. In contrast, use of TRG did not demonstrate a significant difference in disease-free and overall survival. ILN represents a form of treatment effect and should be distinguished from UN. A modified grading system that incorporates ILN may enhance the prognostic utility of TRG.}
}

@inproceedings{chaudhuryIdentifyingMetastaticBreast2015,
  title     = {Identifying Metastatic Breast Tumors Using Textural Kinetic Features of a Contrast Based Habitat in {{DCE-MRI}}},
  booktitle = {{{SPIE Medical Imaging}}},
  author    = {Chaudhury, Baishali and Zhou, Mu and Goldgof, Dmitry B. and Hall, Lawrence O. and Gatenby, Robert A. and Gillies, Robert J. and Drukteinis, Jennifer S.},
  editor    = {Hadjiiski, Lubomir M. and Tourassi, Georgia D.},
  year      = 2015,
  month     = mar,
  pages     = {941415},
  address   = {Orlando, Florida, United States},
  doi       = {10.1117/12.2081386},
  urldate   = {2026-01-19}
}

@article{chenCorrelationApparentDiffusion2013,
  title      = {The {{Correlation}} between {{Apparent Diffusion Coefficient}} and {{Tumor Cellularity}} in {{Patients}}: {{A Meta-Analysis}}},
  shorttitle = {The {{Correlation}} between {{Apparent Diffusion Coefficient}} and {{Tumor Cellularity}} in {{Patients}}},
  author     = {Chen, Lihua and Liu, Min and Bao, Jing and Xia, Yunbao and Zhang, Jiuquan and Zhang, Lin and Huang, Xuequan and Wang, Jian},
  editor     = {Hess, Christopher P.},
  year       = 2013,
  month      = nov,
  journal    = {PLoS ONE},
  volume     = {8},
  number     = {11},
  pages      = {e79008},
  issn       = {1932-6203},
  doi        = {10.1371/journal.pone.0079008},
  urldate    = {2025-12-23},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\KJSVTGN9\Chen et al. - 2013 - The Correlation between Apparent Diffusion Coefficient and Tumor Cellularity in Patients A Meta-Ana.pdf}
}

@article{chenUnsupervisedClusteringQuantitative2019,
  title     = {Unsupervised {{Clustering}} of {{Quantitative Imaging Phenotypes}} Using {{Autoencoder}} and {{Gaussian Mixture Model}}},
  author    = {Chen, Jianan and Milot, Laurent and Cheung, Helen M. C. and Martel, Anne L.},
  year      = 2019,
  publisher = {arXiv},
  doi       = {10.48550/ARXIV.1909.02953},
  urldate   = {2025-12-10},
  abstract  = {Quantitative medical image computing (radiomics) has been widely applied to build prediction models from medical images. However, overfitting is a significant issue in conventional radiomics, where a large number of radiomic features are directly used to train and test models that predict genotypes or clinical outcomes. In order to tackle this problem, we propose an unsupervised learning pipeline composed of an autoencoder for representation learning of radiomic features and a Gaussian mixture model based on minimum message length criterion for clustering. By incorporating probabilistic modeling, disease heterogeneity has been taken into account. The performance of the proposed pipeline was evaluated on an institutional MRI cohort of 108 patients with colorectal cancer liver metastases. Our approach is capable of automatically selecting the optimal number of clusters and assigns patients into clusters (imaging subtypes) with significantly different survival rates. Our method outperforms other unsupervised clustering methods that have been used for radiomics analysis and has comparable performance to a state-of-the-art imaging biomarker.},
  copyright = {arXiv.org perpetual, non-exclusive license},
  keywords  = {Computer Vision and Pattern Recognition (cs.CV),FOS: Biological sciences,FOS: Computer and information sciences,FOS: Electrical engineering electronic engineering information engineering,Image and Video Processing (eess.IV),Quantitative Methods (q-bio.QM)}
}

@article{choiCorrelationComputedTomography2007,
  title      = {Correlation of {{Computed Tomography}} and {{Positron Emission Tomography}} in {{Patients With Metastatic Gastrointestinal Stromal Tumor Treated}} at a {{Single Institution With Imatinib Mesylate}}: {{Proposal}} of {{New Computed Tomography Response Criteria}}},
  shorttitle = {Correlation of {{Computed Tomography}} and {{Positron Emission Tomography}} in {{Patients With Metastatic Gastrointestinal Stromal Tumor Treated}} at a {{Single Institution With Imatinib Mesylate}}},
  author     = {Choi, Haesun and Charnsangavej, Chuslip and Faria, Silvana C. and Macapinlac, Homer A. and Burgess, Michael A. and Patel, Shreyaskumar R. and Chen, Lei L. and Podoloff, Donald A. and Benjamin, Robert S.},
  year       = 2007,
  month      = may,
  journal    = {Journal of Clinical Oncology},
  volume     = {25},
  number     = {13},
  pages      = {1753--1759},
  issn       = {0732-183X, 1527-7755},
  doi        = {10.1200/JCO.2006.07.3049},
  urldate    = {2026-01-19},
  abstract   = {Purpose                                Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates whether computed tomography (CT) findings of GIST after imatinib treatment correlate with tumor responses by [                 18                 F]fluorodeoxyglucose (FDG) positron emission tomography (PET) and develops reliable, quantitative, CT response criteria.                                                        Patients and Methods                                A total of 172 lesions selected by RECIST were evaluated in 40 patients with metastatic GISTs treated with imatinib. All patients had pretreatment and 2-month follow-up CTs and FDG-PETs. Multivariate analysis was performed using tumor size and density (Hounsfield unit [HU]) on CT and maximum standardized uptake value (SUV                 max                 ) on FDG-PET. Patients were observed up to 28 months.                                                        Results                                Mean baseline tumor size and density on CT were 5.3 cm and 72.8 HU, respectively, and mean baseline SUV                 max                 on FDG-PET was 5.8. Thirty-three patients had good response on FDG-PET. A decrease in tumor size of more than 10\% or a decrease in tumor density of more than 15\% on CT had a sensitivity of 97\% and a specificity of 100\% in identifying PET responders versus 52\% and 100\% by RECIST. Good responders on CT at 2 months had significantly longer time to progression than those who did not respond (P = .01).                                                        Conclusion               Small changes in tumor size or density on CT are sensitive and specific methods of assessing the response of GISTs. If the prognostic value of our proposed CT response criteria can be confirmed prospectively, the criteria should be employed in future studies of patients with GIST.},
  langid     = {english}
}

@article{chunAssociationComputedTomography2009,
  title   = {Association of {{Computed Tomography Morphologic Criteria With Pathologic Response}} and {{Survival}} in {{Patients Treated With Bevacizumab}} for {{Colorectal Liver Metastases}}},
  author  = {Chun, Yun Shin},
  year    = 2009,
  month   = dec,
  journal = {JAMA},
  volume  = {302},
  number  = {21},
  pages   = {2338},
  issn    = {0098-7484},
  doi     = {10.1001/jama.2009.1755},
  urldate = {2025-08-20},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\JEMQRGPY\Chun - 2009 - Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Pat.pdf}
}

@article{cinerUniqueImmuneMicroenvironment2021,
  title    = {The Unique Immune Microenvironment of Liver Metastases: {{Challenges}} and Opportunities},
  author   = {Ciner, Aaron T and Jones, Keaton and Muschel, Ruth J and Brodt, Pnina},
  year     = 2021,
  month    = jun,
  journal  = {Semin. Cancer Biol.},
  volume   = {71},
  pages    = {143--156},
  issn     = {1044-579X},
  doi      = {10.1016/j.semcancer.2020.06.003},
  abstract = {Liver metastases from gastrointestinal and non-gastrointestinal malignancies remain a major cause of cancer-related mortality and a major clinical challenge. The liver has unique properties that facilitate metastatic expansion, including a complex immune system that evolved to dampen immunity to neoantigens entering the liver from the gut, through the portal circulation. In this review, we describe the unique microenvironment encountered by cancer cells in the liver, focusing on elements of the innate and adaptive immune response that can act as a double-edge sword, contributing to the elimination of cancer cells on the one hand and promoting their survival and growth, on the other. We discuss this microenvironment in a clinical context, particularly for colorectal carcinoma, and highlight how a better understanding of the role of the microenvironment has spurred an intense effort to develop novel and innovative strategies for targeting liver metastatic disease, some of which are currently being tested in the clinic.},
  keywords = {Clinical trials,Immune cells,Immune tolerance,Liver metastasis,Microenvironment,Therapeutic targets}
}

@article{cohenPowerPrimer1992,
  title   = {A Power Primer.},
  author  = {Cohen, Jacob},
  year    = 1992,
  journal = {Psychological Bulletin},
  volume  = {112},
  number  = {1},
  pages   = {155--159},
  issn    = {1939-1455, 0033-2909},
  doi     = {10.1037/0033-2909.112.1.155},
  urldate = {2025-12-01},
  langid  = {english}
}

@article{coxPDLIM2MarkerAdhesion2019,
  title    = {{{PDLIM2 Is}} a {{Marker}} of {{Adhesion}} and {$\beta$}-{{Catenin Activity}} in {{Triple-Negative Breast Cancer}}},
  author   = {Cox, Orla T. and Edmunds, Shelley J. and {Simon-Keller}, Katja and Li, Bo and Moran, Bruce and Buckley, Niamh E. and {Bustamante-Garrido}, Milan and Healy, Nollaig and O'Flanagan, Ciara H. and Gallagher, William M. and Kennedy, Richard D. and Bernards, Ren{\'e} and Caldas, Carlos and Chin, Suet-Feung and Marx, Alexander and O'Connor, Rosemary},
  year     = 2019,
  month    = may,
  journal  = {Cancer Research},
  volume   = {79},
  number   = {10},
  pages    = {2619--2633},
  issn     = {0008-5472, 1538-7445},
  doi      = {10.1158/0008-5472.CAN-18-2787},
  urldate  = {2025-12-01},
  abstract = {Abstract                                           The PDLIM2 protein regulates stability of transcription factors including NF-{$\kappa$}B and STATs in epithelial and hemopoietic cells. PDLIM2 is strongly expressed in certain cancer cell lines that exhibit an epithelial-to-mesenchymal phenotype, and its suppression is sufficient to reverse this phenotype. PDLIM2 supports the epithelial polarity of nontransformed breast cells, suggesting distinct roles in tumor suppression and oncogenesis. To better understand its overall function, we investigated PDLIM2 expression and activity in breast cancer. PDLIM2 protein was present in 60\% of tumors diagnosed as triple-negative breast cancer (TNBC), and only 20\% of other breast cancer subtypes. High PDLIM2 expression in TNBC was positively correlated with adhesion signaling and {$\beta$}-catenin activity. Interestingly, PDLIM2 was restricted to the cytoplasm/membrane of TNBC cells and excluded from the nucleus. In breast cell lines, PDLIM2 retention in the cytoplasm was controlled by cell adhesion, and translocation to the nucleus was stimulated by insulin-like growth factor-1 or TGF{$\beta$}. Cytoplasmic PDLIM2 was associated with active {$\beta$}-catenin and ectopic expression of PDLIM2 was sufficient to increase {$\beta$}-catenin levels and its transcriptional activity in reporter assays. Suppression of PDLIM2 inhibited tumor growth in vivo, whereas overexpression of PDLIM2 disrupted growth in 3D cultures. These results suggest that PDLIM2 may serve as a predictive biomarker for a large subset of TNBC whose phenotype depends on adhesion-regulated {$\beta$}-catenin activity and which may be amenable to therapies that target these pathways.                                         Significance:               This study shows that PDLIM2 expression defines a subset of triple-negative breast cancer that may benefit from targeting the {$\beta$}-catenin and adhesion signaling pathways.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\6YLZ4X44\Cox et al. - 2019 - PDLIM2 Is a Marker of Adhesion and Î²-Catenin Activity in Triple-Negative Breast Cancer.pdf}
}

@article{coxRegressionModelsLifeTables1972,
  title     = {Regression {{Models}} and {{Life-Tables}}},
  author    = {Cox, D. R.},
  year      = 1972,
  month     = jan,
  journal   = {Journal of the Royal Statistical Society Series B: Statistical Methodology},
  volume    = {34},
  number    = {2},
  pages     = {187--202},
  issn      = {1369-7412, 1467-9868},
  doi       = {10.1111/j.2517-6161.1972.tb00899.x},
  urldate   = {2026-01-08},
  abstract  = {Summary             The analysis of censored failure times is considered. It is assumed that on each individual are available values of one or more explanatory variables. The hazard function (age-specific failure rate) is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time. A conditional likelihood is obtained, leading to inferences about the unknown regression coefficients. Some generalizations are outlined.},
  copyright = {https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model},
  langid    = {english}
}

@article{davidson-pilonLifelinesSurvivalAnalysis2019,
  title      = {Lifelines: Survival Analysis in {{Python}}},
  shorttitle = {Lifelines},
  author     = {{Davidson-Pilon}, Cameron},
  year       = 2019,
  month      = aug,
  journal    = {Journal of Open Source Software},
  volume     = {4},
  number     = {40},
  pages      = {1317},
  issn       = {2475-9066},
  doi        = {10.21105/joss.01317},
  urldate    = {2026-01-08},
  copyright  = {http://creativecommons.org/licenses/by/4.0/},
  file       = {C:\Users\oprio\Zotero\storage\98EQIWV8\Davidson-Pilon - 2019 - lifelines survival analysis in Python.pdf}
}

@article{delombaerdeIntrafractionMotionMonitoring2021,
  title   = {Intra-Fraction Motion Monitoring during Fast Modulated Radiotherapy Delivery in a Closed-Bore Gantry Linac},
  author  = {Delombaerde, Laurence and Petillion, Saskia and Weltens, Caroline and Depuydt, Tom},
  year    = 2021,
  month   = oct,
  journal = {Physics and Imaging in Radiation Oncology},
  volume  = {20},
  pages   = {51--55},
  issn    = {24056316},
  doi     = {10.1016/j.phro.2021.10.005},
  urldate = {2025-12-01},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\QL2KXK9H\Delombaerde et al. - 2021 - Intra-fraction motion monitoring during fast modulated radiotherapy delivery in a closed-bore gantry.pdf}
}

@article{demirciogluEffectPreprocessingFilters2022,
  title    = {The Effect of Preprocessing Filters on Predictive Performance in Radiomics},
  author   = {Demircio{\u g}lu, Aydin},
  year     = 2022,
  month    = sep,
  journal  = {European Radiology Experimental},
  volume   = {6},
  number   = {1},
  pages    = {40},
  issn     = {2509-9280},
  doi      = {10.1186/s41747-022-00294-w},
  urldate  = {2025-12-01},
  abstract = {Abstract                            Background               Radiomics is a noninvasive method using machine learning to support personalised medicine. Preprocessing filters such as wavelet and Laplacian-of-Gaussian filters are commonly used being thought to increase predictive performance. However, the use of preprocessing filters increases the number of features by up to an order of magnitude and can produce many correlated features. Both substantially increase the dataset complexity, which in turn makes modeling with machine learning techniques more challenging, possibly leading to poorer performance. We investigated the impact of these filters on predictive performance.                                         Methods               Using seven publicly available radiomic datasets, we measured the impact of adding features preprocessed with eight different preprocessing filters to the unprocessed features on the predictive performance of radiomic models. Modeling was performed using five feature selection methods and five classifiers, while predictive performance was measured using area-under-the-curve at receiver operating characteristics analysis (AUC-ROC) with nested, stratified 10-fold cross-validation.                                         Results                                Significant improvements of up to 0.08 in AUC-ROC were observed when all image preprocessing filters were applied compared to using only the original features (up to                 p                 = 0.024). Decreases of -0.04 and -0.10 were observed on some data sets, but these were not statistically significant (                 p                 {$>$} 0.179). Tuning of the image preprocessing filters did not result in decreases in AUC-ROC but further improved results by up to 0.1; however, these improvements were not statistically significant (                 p                 {$>$} 0.086) except for one data set (                 p                 = 0.023).                                                        Conclusions               Preprocessing filters can have a significant impact on the predictive performance and should be used in radiomic studies.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\NQ5KQZ38\DemircioÄlu - 2022 - The effect of preprocessing filters on predictive performance in radiomics.pdf}
}

@misc{demirMultiGradICONFoundationModel2025,
  title         = {{{multiGradICON}}: {{A Foundation Model}} for {{Multimodal Medical Image Registration}}},
  shorttitle    = {{{multiGradICON}}},
  author        = {Demir, Basar and Tian, Lin and Greer, Thomas Hastings and Kwitt, Roland and Vialard, Francois-Xavier and Estepar, Raul San Jose and Bouix, Sylvain and Rushmore, Richard Jarrett and Ebrahim, Ebrahim and Niethammer, Marc},
  year          = 2025,
  month         = feb,
  number        = {arXiv:2408.00221},
  eprint        = {2408.00221},
  primaryclass  = {eess},
  publisher     = {arXiv},
  doi           = {10.48550/arXiv.2408.00221},
  urldate       = {2025-12-14},
  abstract      = {Modern medical image registration approaches predict deformations using deep networks. These approaches achieve state-of-the-art (SOTA) registration accuracy and are generally fast. However, deep learning (DL) approaches are, in contrast to conventional non-deep-learning-based approaches, anatomy-specific. Recently, a universal deep registration approach, uniGradICON, has been proposed. However, uniGradICON focuses on monomodal image registration. In this work, we therefore develop multiGradICON as a first step towards universal *multimodal* medical image registration. Specifically, we show that 1) we can train a DL registration model that is suitable for monomodal *and* multimodal registration; 2) loss function randomization can increase multimodal registration accuracy; and 3) training a model with multimodal data helps multimodal generalization. Our code and the multiGradICON model are available at https://github.com/uncbiag/uniGradICON.},
  archiveprefix = {arXiv},
  keywords      = {Computer Science - Computer Vision and Pattern Recognition,Electrical Engineering and Systems Science - Image and Video Processing},
  file          = {C\:\\Users\\oprio\\Zotero\\storage\\E75WSIAN\\Demir et al. - 2025 - multiGradICON A Foundation Model for Multimodal Medical Image Registration.pdf;C\:\\Users\\oprio\\Zotero\\storage\\RM3DK7YE\\2408.html}
}

@book{DigitalImagingCommunications2025,
  author    = {{National Electrical Manufacturers Association (NEMA)}},
  title     = {Digital {{Imaging}} and {{Communications}} in {{Medicine}} ({{DICOM}}) {{Standard}}},
  year      = 2025,
  publisher = {National Electrical Manufacturers Association (NEMA)},
  address   = {Rosslyn, VA, USA}
}

@article{dinicolantonioPrecisionOncologyMetastatic2021,
  title   = {Precision Oncology in Metastatic Colorectal Cancer --- from Biology to Medicine},
  author  = {Di Nicolantonio, Federica and Vitiello, Pietro Paolo and Marsoni, Silvia and Siena, Salvatore and Tabernero, Josep and Trusolino, Livio and Bernards, Rene and Bardelli, Alberto},
  year    = 2021,
  month   = aug,
  journal = {Nature Reviews Clinical Oncology},
  volume  = {18},
  number  = {8},
  pages   = {506--525},
  issn    = {1759-4774, 1759-4782},
  doi     = {10.1038/s41571-021-00495-z},
  urldate = {2026-01-18},
  langid  = {english}
}

@article{divinePopulationBasedGaussianMixture2016,
  title   = {A {{Population-Based Gaussian Mixture Model Incorporating}}{\textsuperscript{18}} {{F-FDG PET}} and {{Diffusion-Weighted MRI Quantifies Tumor Tissue Classes}}},
  author  = {Divine, Mathew R. and Katiyar, Prateek and Kohlhofer, Ursula and {Quintanilla-Martinez}, Leticia and Pichler, Bernd J. and Disselhorst, Jonathan A.},
  year    = 2016,
  month   = mar,
  journal = {Journal of Nuclear Medicine},
  volume  = {57},
  number  = {3},
  pages   = {473--479},
  issn    = {0161-5505, 2159-662X},
  doi     = {10.2967/jnumed.115.163972},
  urldate = {2025-12-01},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\EBZC79PG\Divine et al. - 2016 - A Population-Based Gaussian Mixture Model Incorporating18 F-FDG PET and Diffusion-Weighte.pdf}
}

@article{eisenhauerNewResponseEvaluation2009,
  title      = {New Response Evaluation Criteria in Solid Tumours: {{Revised RECIST}} Guideline (Version 1.1)},
  shorttitle = {New Response Evaluation Criteria in Solid Tumours},
  author     = {Eisenhauer, E.A. and Therasse, P. and Bogaerts, J. and Schwartz, L.H. and Sargent, D. and Ford, R. and Dancey, J. and Arbuck, S. and Gwyther, S. and Mooney, M. and Rubinstein, L. and Shankar, L. and Dodd, L. and Kaplan, R. and Lacombe, D. and Verweij, J.},
  year       = 2009,
  month      = jan,
  journal    = {European Journal of Cancer},
  volume     = {45},
  number     = {2},
  pages      = {228--247},
  issn       = {09598049},
  doi        = {10.1016/j.ejca.2008.10.026},
  urldate    = {2025-12-01},
  copyright  = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid     = {english}
}

@article{engstrandColorectalCancerLiver2018,
  title   = {Colorectal Cancer Liver Metastases -- a Population-Based Study on Incidence, Management and Survival},
  author  = {Engstrand, Jennie and Nilsson, Henrik and Str{\"o}mberg, Cecilia and Jonas, Eduard and Freedman, Jacob},
  year    = 2018,
  month   = dec,
  journal = {BMC Cancer},
  volume  = {18},
  number  = {1},
  pages   = {78},
  issn    = {1471-2407},
  doi     = {10.1186/s12885-017-3925-x},
  urldate = {2026-01-18},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\ZB9FT3YL\Engstrand et al. - 2018 - Colorectal cancer liver metastases â a population-based study on incidence, management and survival.pdf}
}

@misc{estebanNipyNipype1832022,
  title        = {Nipy/Nipype: 1.8.3},
  shorttitle   = {Nipy/Nipype},
  author       = {Esteban, Oscar and Markiewicz, Christopher J. and Burns, Christopher and others},
  year         = 2022,
  month        = jul,
  doi          = {10.5281/ZENODO.6834519},
  urldate      = {2025-12-10},
  abstract     = {Release Notes Bug-fix release in the 1.8.x series. This release includes compatibility fixes for nibabel 4.x and resolves a denial-of-service bug when the etelemetry server is down that resulted in excessive (blocking) network hits that would cause any tools using nipype interfaces to take a very long time. What's Changed FIX: Argument order to {$<$}code{$>$}numpy.save(){$<$}/code{$>$} (https://github.com/nipy/nipype/pull/3485) FIX: Add tolerance parameter to ComputeDVARS (https://github.com/nipy/nipype/pull/3489) FIX: Delay access of nibabel.trackvis until actually needed (https://github.com/nipy/nipype/pull/3488) FIX: Avoid excessive etelemetry pings (https://github.com/nipy/nipype/pull/3484) ENH: Added outputs' generation to DWIBiascorrect interface (https://github.com/nipy/nipype/pull/3476) New Contributors @LostBenjamin made their first contribution in https://github.com/nipy/nipype/pull/3485 {$<$}strong{$>$}Full Changelog{$<$}/strong{$>$}: https://github.com/nipy/nipype/compare/1.8.2...1.8.3},
  copyright    = {Apache License 2.0, Open Access},
  howpublished = {Zenodo},
  keywords     = {neuroimaging,pipeline,workflow}
}

@book{ewingNeoplasticDiseases1919,
  title     = {Neoplastic Diseases},
  author    = {Ewing, James},
  year      = 1919,
  publisher = {Philadelphia: W.B. Saunders Company.}
}

@book{ewingNEOPLASTICDISEASESTEXTBOOK2025,
  title      = {{{NEOPLASTIC DISEASES}}, {{A TEXT-BOOK ON TUMORS}}, {{JAMES EWING}} ... {{WITH}} 479 {{ILLUSTRATIONS}}},
  author     = {EWING, JAMES 1866-1943},
  year       = 2025,
  publisher  = {HUTSON STREET PRESS},
  address    = {S.l.},
  isbn       = {978-1-02-519112-6},
  langid     = {english},
  annotation = {OCLC: 1538475493}
}

@article{federauPerfusionMeasurementBrain2014,
  title   = {Perfusion {{Measurement}} in {{Brain Gliomas}} with {{Intravoxel Incoherent Motion MRI}}},
  author  = {Federau, C. and Meuli, R. and O'Brien, K. and Maeder, P. and Hagmann, P.},
  year    = 2014,
  month   = feb,
  journal = {American Journal of Neuroradiology},
  volume  = {35},
  number  = {2},
  pages   = {256--262},
  issn    = {0195-6108, 1936-959X},
  doi     = {10.3174/ajnr.A3686},
  urldate = {2025-12-23},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\SCKEGUBC\Federau et al. - 2014 - Perfusion Measurement in Brain Gliomas with Intravoxel Incoherent Motion MRI.pdf}
}

@article{fedorov3DSlicerImage2012,
  title     = {{{3D Slicer}} as an Image Computing Platform for the {{Quantitative Imaging Network}}},
  author    = {Fedorov, Andriy and Beichel, Reinhard and {Kalpathy-Cramer}, Jayashree and Finet, Julien and {Fillion-Robin}, Jean-Christophe and Pujol, Sonia and Bauer, Christian and Jennings, Dominique and Fennessy, Fiona and Sonka, Milan and Buatti, John and Aylward, Stephen and Miller, James V. and Pieper, Steve and Kikinis, Ron},
  year      = 2012,
  month     = nov,
  journal   = {Magnetic Resonance Imaging},
  volume    = {30},
  number    = {9},
  pages     = {1323--1341},
  issn      = {0730725X},
  doi       = {10.1016/j.mri.2012.05.001},
  urldate   = {2025-12-01},
  copyright = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid    = {english},
  file      = {C:\Users\oprio\Zotero\storage\H8J3PBFM\Fedorov et al. - 2012 - 3D Slicer as an image computing platform for the Quantitative Imaging Network.pdf}
}

@article{fernandezmoroIdiosyncraticZonatedStroma2023,
  title    = {An Idiosyncratic Zonated Stroma Encapsulates Desmoplastic Liver Metastases and Originates from Injured Liver},
  author   = {Fern{\'a}ndez Moro, Carlos and Geyer, Natalie and Harrizi, Sara and Hamidi, Yousra and S{\"o}derqvist, Sara and Kuznyecov, Danyil and Tidholm Qvist, Evelina and Salmonson Schaad, Media and Hermann, Laura and Lindberg, Amanda and Heuchel, Rainer L and {Mart{\'i}n-Bernab{\'e}}, Alfonso and Dhanjal, Soniya and Navis, Anna C and Villard, Christina and Del Valle, Andrea C and Boz{\'o}ky, Lorand and Sparrelid, Ernesto and Dirix, Luc and Strell, Carina and {\"O}stman, Arne and Schmierer, Bernhard and Vermeulen, Peter B and Engstrand, Jennie and Boz{\'o}ky, B{\'e}la and Gerling, Marco},
  year     = 2023,
  month    = aug,
  journal  = {Nat. Commun.},
  volume   = {14},
  number   = {1},
  pages    = {5024},
  issn     = {2041-1723},
  doi      = {10.1038/s41467-023-40688-x},
  abstract = {A perimetastatic capsule is a strong positive prognostic factor in liver metastases, but its origin remains unclear. Here, we systematically quantify the capsule's extent and cellular composition in 263 patients with colorectal cancer liver metastases to investigate its clinical significance and origin. We show that survival improves proportionally with increasing encapsulation and decreasing tumor-hepatocyte contact. Immunostaining reveals the gradual zonation of the capsule, transitioning from benign-like NGFRhigh stroma at the liver edge to FAPhigh stroma towards the tumor. Encapsulation correlates with decreased tumor viability and preoperative chemotherapy. In mice, chemotherapy and tumor cell ablation induce capsule formation. Our results suggest that encapsulation develops where tumor invasion into the liver plates stalls, representing a reparative process rather than tumor-induced desmoplasia. We propose a model of metastases growth, where the efficient tumor colonization of the liver parenchyma and a reparative liver injury reaction are opposing determinants of metastasis aggressiveness.},
  file     = {C:\Users\oprio\Zotero\storage\US2XCWVD\FernÃ¡ndez Moro et al. - 2023 - An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injur.pdf}
}

@article{fornacon-woodReliabilityPrognosticValue2020,
  title    = {Reliability and Prognostic Value of Radiomic Features Are Highly Dependent on Choice of Feature Extraction Platform},
  author   = {{Fornacon-Wood}, Isabella and Mistry, Hitesh and Ackermann, Christoph J. and Blackhall, Fiona and McPartlin, Andrew and {Faivre-Finn}, Corinne and Price, Gareth J. and O'Connor, James P. B.},
  year     = 2020,
  month    = nov,
  journal  = {European Radiology},
  volume   = {30},
  number   = {11},
  pages    = {6241--6250},
  issn     = {0938-7994, 1432-1084},
  doi      = {10.1007/s00330-020-06957-9},
  urldate  = {2025-12-10},
  abstract = {Abstract                            Objective               To investigate the effects of Image Biomarker Standardisation Initiative (IBSI) compliance, harmonisation of calculation settings and platform version on the statistical reliability of radiomic features and their corresponding ability to predict clinical outcome.                                         Methods               The statistical reliability of radiomic features was assessed retrospectively in three clinical datasets (patient numbers: 108 head and neck cancer, 37 small-cell lung cancer, 47 non-small-cell lung cancer). Features were calculated using four platforms (PyRadiomics, LIFEx, CERR and IBEX). PyRadiomics, LIFEx and CERR are IBSI-compliant, whereas IBEX is not. The effects of IBSI compliance, user-defined calculation settings and platform version were assessed by calculating intraclass correlation coefficients and confidence intervals. The influence of platform choice on the relationship between radiomic biomarkers and survival was evaluated using univariable cox regression in the largest dataset.                                         Results               The reliability of radiomic features calculated by the different software platforms was only excellent (ICC {$>$} 0.9) for 4/17 radiomic features when comparing all four platforms. Reliability improved to ICC {$>$} 0.9 for 15/17 radiomic features when analysis was restricted to the three IBSI-compliant platforms. Failure to harmonise calculation settings resulted in poor reliability, even across the IBSI-compliant platforms. Software platform version also had a marked effect on feature reliability in CERR and LIFEx. Features identified as having significant relationship to survival varied between platforms, as did the direction of hazard ratios.                                         Conclusion               IBSI compliance, user-defined calculation settings and choice of platform version all influence the statistical reliability and corresponding performance of prognostic models in radiomics.                                         Key Points                                {$\bullet$} Reliability of radiomic features varies between feature calculation platforms and with choice of software version.                                               {$\bullet$} Image Biomarker Standardisation Initiative (IBSI) compliance improves reliability of radiomic features across platforms, but only when calculation settings are harmonised.                                               {$\bullet$} IBSI compliance, user-defined calculation settings and choice of platform version collectively affect the prognostic value of features.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\Z7IWUEEI\Fornacon-Wood et al. - 2020 - Reliability and prognostic value of radiomic features are highly dependent on choice of feature extr.pdf}
}

@article{fortinHarmonizationCorticalThickness2018,
  title   = {Harmonization of Cortical Thickness Measurements across Scanners and Sites},
  author  = {Fortin, Jean-Philippe and Cullen, Nicholas and Sheline, Yvette I. and Taylor, Warren D. and Aselcioglu, Irem and Cook, Philip A. and Adams, Phil and Cooper, Crystal and Fava, Maurizio and McGrath, Patrick J. and McInnis, Melvin and Phillips, Mary L. and Trivedi, Madhukar H. and Weissman, Myrna M. and Shinohara, Russell T.},
  year    = 2018,
  month   = feb,
  journal = {NeuroImage},
  volume  = {167},
  pages   = {104--120},
  issn    = {10538119},
  doi     = {10.1016/j.neuroimage.2017.11.024},
  urldate = {2025-12-11},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\ZW83RNPI\Fortin et al. - 2018 - Harmonization of cortical thickness measurements across scanners and sites.pdf}
}

@article{franklinTumourSubregionAnalysis2020,
  title      = {Tumour Subregion Analysis of Colorectal Liver Metastases Using Semi-Automated Clustering Based on {{DCE-MRI}}: {{Comparison}} with Histological Subregions and Impact on Pharmacokinetic Parameter Analysis},
  shorttitle = {Tumour Subregion Analysis of Colorectal Liver Metastases Using Semi-Automated Clustering Based on {{DCE-MRI}}},
  author     = {Franklin, James M. and Irving, Benjamin and Papiez, Bartlomiej W. and Kallehauge, Jesper F. and Wang, Lai Mun and Goldin, Robert D. and Harris, Adrian L. and Anderson, Ewan M. and Schnabel, Julia A. and Chappell, Michael A. and Brady, Michael and Sharma, Ricky A. and Gleeson, Fergus V.},
  year       = 2020,
  month      = may,
  journal    = {European Journal of Radiology},
  volume     = {126},
  pages      = {108934},
  issn       = {0720048X},
  doi        = {10.1016/j.ejrad.2020.108934},
  urldate    = {2026-01-19},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\H6UYB5N2\Franklin et al. - 2020 - Tumour subregion analysis of colorectal liver metastases using semi-automated clustering based on DC.pdf}
}

@article{frentzasVesselCooptionMediates2016,
  title   = {Vessel Co-Option Mediates Resistance to Anti-Angiogenic Therapy in Liver Metastases},
  author  = {Frentzas, Sophia and Simoneau, Eve and Bridgeman, Victoria L and Vermeulen, Peter B and Foo, Shane and Kostaras, Eleftherios and Nathan, Mark R and Wotherspoon, Andrew and Gao, Zu-hua and Shi, Yu and Van Den Eynden, Gert and Daley, Frances and Peckitt, Clare and Tan, Xianming and Salman, Ayat and Lazaris, Anthoula and Gazinska, Patrycja and Berg, Tracy J and Eltahir, Zak and Ritsma, Laila and Van Rheenen, Jacco and Khashper, Alla and Brown, Gina and Nystr{\"o}m, Hanna and Sund, Malin and Van Laere, Steven and Loyer, Evelyne and Dirix, Luc and Cunningham, David and Metrakos, Peter and Reynolds, Andrew R},
  year    = 2016,
  month   = nov,
  journal = {Nature Medicine},
  volume  = {22},
  number  = {11},
  pages   = {1294--1302},
  issn    = {1078-8956, 1546-170X},
  doi     = {10.1038/nm.4197},
  urldate = {2026-01-18},
  langid  = {english}
}

@article{garyfallidisDipyLibraryAnalysis2014,
  title   = {Dipy, a Library for the Analysis of Diffusion {{MRI}} Data},
  author  = {Garyfallidis, Eleftherios and Brett, Matthew and Amirbekian, Bagrat and Rokem, Ariel and Van Der Walt, Stefan and Descoteaux, Maxime and {Nimmo-Smith}, Ian and {Dipy Contributors}},
  year    = 2014,
  month   = feb,
  journal = {Frontiers in Neuroinformatics},
  volume  = {8},
  issn    = {1662-5196},
  doi     = {10.3389/fninf.2014.00008},
  urldate = {2025-12-11},
  file    = {C:\Users\oprio\Zotero\storage\3TEJNUDY\Garyfallidis et al. - 2014 - Dipy, a library for the analysis of diffusion MRI data.pdf}
}

@article{gatenbyQuantitativeImagingCancer2013,
  title     = {Quantitative {{Imaging}} in {{Cancer Evolution}} and {{Ecology}}},
  author    = {Gatenby, Robert A. and Grove, Olya and Gillies, Robert J.},
  year      = 2013,
  month     = oct,
  journal   = {Radiology},
  volume    = {269},
  number    = {1},
  pages     = {8--14},
  publisher = {Radiological Society of North America (RSNA)},
  issn      = {0033-8419, 1527-1315},
  doi       = {10.1148/radiol.13122697},
  urldate   = {2025-07-24},
  langid    = {english},
  file      = {C:\Users\oprio\Zotero\storage\C82RBD7R\Gatenby et al. - 2013 - Quantitative Imaging in Cancer Evolution and Ecology.pdf}
}

@article{gerwingBeginningEndConventional2019,
  title   = {The Beginning of the End for Conventional {{RECIST}} --- Novel Therapies Require Novel Imaging Approaches},
  author  = {Gerwing, Mirjam and Herrmann, Ken and Helfen, Anne and Schliemann, Christoph and Berdel, Wolfgang E. and Eisenbl{\"a}tter, Michel and Wildgruber, Moritz},
  year    = 2019,
  month   = jul,
  journal = {Nature Reviews Clinical Oncology},
  volume  = {16},
  number  = {7},
  pages   = {442--458},
  issn    = {1759-4774, 1759-4782},
  doi     = {10.1038/s41571-019-0169-5},
  urldate = {2026-01-18},
  langid  = {english}
}

@article{gilliesRadiomicsImagesAre2016,
  title      = {Radiomics: {{Images Are More}} than {{Pictures}}, {{They Are Data}}},
  shorttitle = {Radiomics},
  author     = {Gillies, Robert J. and Kinahan, Paul E. and Hricak, Hedvig},
  year       = 2016,
  month      = feb,
  journal    = {Radiology},
  volume     = {278},
  number     = {2},
  pages      = {563--577},
  issn       = {0033-8419, 1527-1315},
  doi        = {10.1148/radiol.2015151169},
  urldate    = {2025-12-01},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\6MDRHWHD\Gillies et al. - 2016 - Radiomics Images Are More than Pictures, They Are Data.pdf}
}

@article{goldbergCetuximab2005,
  title   = {Cetuximab},
  author  = {Goldberg, Richard and Kirkpatrick, Peter},
  year    = 2005,
  month   = may,
  journal = {Nature Reviews Drug Discovery},
  volume  = {4},
  number  = {5},
  pages   = {S10-S11},
  issn    = {1474-1776, 1474-1784},
  doi     = {10.1038/nrd1728},
  urldate = {2026-01-18}
}

@book{goodfellowDeepLearning2016,
  title     = {Deep Learning},
  author    = {Goodfellow, Ian and Courville, Aaron and Bengio, Yoshua},
  year      = 2016,
  series    = {Adaptive Computation and Machine Learning},
  publisher = {The MIT Press},
  address   = {Cambridge, Massachusetts},
  isbn      = {978-0-262-33737-3},
  langid    = {english}
}

@book{goodsellMachineryLife2009,
  title     = {The {{Machinery}} of {{Life}}},
  author    = {Goodsell, David S.},
  year      = 2009,
  publisher = {Springer New York},
  address   = {New York, NY},
  doi       = {10.1007/978-0-387-84925-6},
  urldate   = {2025-08-09},
  copyright = {http://www.springer.com/tdm},
  isbn      = {978-0-387-84924-9 978-0-387-84925-6},
  langid    = {english}
}

@article{grussuClinicallyFeasibleLiver2025,
  title   = {Clinically Feasible Liver Tumour Cell Size Measurement through Histology-Informed in Vivo Diffusion {{MRI}}},
  author  = {Grussu, Francesco and Grigoriou, Athanasios and Bernatowicz, Kinga and Palombo, Marco and {Casanova-Salas}, Irene and {Navarro-Garcia}, Daniel and Barba, Ignasi and Simonetti, Sara and Serna, Garazi and Macarro, Carlos and Voronova, Anna Kira and Garay, Valezka and Corral, Juan Francisco and Vidorreta, Marta and {Garc{\'i}a-Polo Garc{\'i}a}, Pablo and Merino, Xavier and Mast, Richard and Ros{\'o}n, N{\'u}ria and Escobar, Manuel and Vieito, Maria and Toledo, Rodrigo and Nuciforo, Paolo and Mateo, Joaquin and Garralda, Elena and {Perez-Lopez}, Raquel},
  year    = 2025,
  month   = nov,
  journal = {Communications Medicine},
  issn    = {2730-664X},
  doi     = {10.1038/s43856-025-01246-2},
  urldate = {2025-12-11},
  langid  = {english}
}

@article{guptaPredictingProgressionFreeSurvival2021,
  title   = {Predicting {{Progression-Free Survival Using Primary}} and {{Nodal Radiomic Features}} in {{Head}} and {{Neck Cancer}}},
  author  = {Gupta, H. and Deek, M.P. and McNutt, T.R. and Lee, J. and Quon, H. and Sheikh, K.},
  year    = 2021,
  month   = nov,
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  volume  = {111},
  number  = {3},
  pages   = {e130-e131},
  issn    = {03603016},
  doi     = {10.1016/j.ijrobp.2021.07.563},
  urldate = {2025-12-10},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\Q47A9EMF\Gupta et al. - 2021 - Predicting Progression-Free Survival Using Primary and Nodal Radiomic Features in Head and Neck Canc.pdf}
}

@article{haralickTexturalFeaturesImage1973,
  title   = {Textural {{Features}} for {{Image Classification}}},
  author  = {Haralick, Robert M. and Shanmugam, K. and Dinstein, Its'Hak},
  year    = 1973,
  month   = nov,
  journal = {IEEE Transactions on Systems, Man, and Cybernetics},
  volume  = {SMC-3},
  number  = {6},
  pages   = {610--621},
  issn    = {0018-9472, 2168-2909},
  doi     = {10.1109/TSMC.1973.4309314},
  urldate = {2026-01-19}
}

@article{harrellEvaluatingYieldMedical1982,
  title   = {Evaluating the {{Yield}} of {{Medical Tests}}},
  author  = {Harrell, Frank E.},
  year    = 1982,
  month   = may,
  journal = {JAMA: The Journal of the American Medical Association},
  volume  = {247},
  number  = {18},
  pages   = {2543},
  issn    = {0098-7484},
  doi     = {10.1001/jama.1982.03320430047030},
  urldate = {2026-01-08},
  langid  = {english}
}

@article{harrellMULTIVARIABLEPROGNOSTICMODELS1996,
  title      = {{{MULTIVARIABLE PROGNOSTIC MODELS}}: {{ISSUES IN DEVELOPING MODELS}}, {{EVALUATING ASSUMPTIONS AND ADEQUACY}}, {{AND MEASURING AND REDUCING ERRORS}}},
  shorttitle = {{{MULTIVARIABLE PROGNOSTIC MODELS}}},
  author     = {Harrell, Frank E. and Lee, Kerry L. and Mark, Daniel B.},
  year       = 1996,
  month      = feb,
  journal    = {Statistics in Medicine},
  volume     = {15},
  number     = {4},
  pages      = {361--387},
  issn       = {02776715, 10970258},
  doi        = {10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4},
  urldate    = {2026-01-08},
  copyright  = {http://doi.wiley.com/10.1002/tdm\_license\_1.1}
}

@misc{hartungAbdominalCTPhases2024,
  title        = {Abdominal {{CT}}: {{Phases}}},
  shorttitle   = {Abdominal {{CT}}},
  author       = {Hartung, Michael P. and Brown, Adam and Brown, Michael P. Hartung {and} Adam},
  year         = 2024,
  month        = feb,
  journal      = {Life in the Fast Lane {$\bullet$} LITFL},
  urldate      = {2026-01-15},
  abstract     = {To make sense of CT exams, we need to understand what happens after we inject IV contrast and how it results in tailored CT examinations},
  howpublished = {https://litfl.com/abdominal-ct-phases/},
  langid       = {american}
}

@article{hazhirkarzarCurrentStateArt2020,
  title     = {Current State of the Art Imaging Approaches for Colorectal Liver Metastasis},
  author    = {Hazhirkarzar, Bita and Khoshpouri, Pegah and Shaghaghi, Mohammadreza and Ghasabeh, Mounes Aliyari and Pawlik, Timothy M and Kamel, Ihab R},
  year      = 2020,
  month     = feb,
  journal   = {Hepatobiliary Surg. Nutr.},
  volume    = {9},
  number    = {1},
  pages     = {35--48},
  publisher = {AME Publishing Company},
  issn      = {2304-3881},
  doi       = {10.21037/hbsn.2019.05.11},
  urldate   = {2025-04-12},
  abstract  = {One of the most common cancers worldwide, colorectal cancer (CRC) has been associated with significant morbidity and mortality and therefore represents an enormous burden to the health care system. Recent advances in CRC treatments have provided patients with primary and metastatic CRC a better long-term prognosis. The presence of synchronous or metachronous metastasis has been associated, however, with worse survival. The most common site of metastatic disease is the liver. A variety of treatment modalities aimed at targeting colorectal liver metastases (CRLM) has been demonstrated to improve the prognosis of these patients. Loco-regional approaches such as surgical resection and tumor ablation (operative and percutaneous) can provide patients with a chance at long-term disease control and even cure in select populations. Patient selection is important in defining the most suitable treatment option for CRLM in order to provide the best possible survival benefit while avoiding unnecessary interventions and adverse events. Medical imaging plays a crucial role in evaluating the characteristics of CRLMs and disease resectability. Size of tumors, proximity to adjacent anatomical structures, and volume of the unaffected liver are among the most important imaging parameters to determine the suitability of patients for surgical management or other appropriate treatment approaches. We herein provide a comprehensive overview of current-state-of-the-art imaging in the management of CRLM, including staging, treatment planning, response and survival assessment, and post-treatment surveillance. Computed tomography (CT) scan and magnetic resonance imaging (MRI) are two most commonly used techniques, which can be used solely or in combination with functional imaging modalities such as positron emission tomography (PET) and diffusion weighted imaging (DWI). Providing up-to-date evidence on advantages and disadvantages of imaging modalities and tumor assessment criteria, the current review offers a practice guide to assist providers in choosing the most suitable imaging approach for patients with CRLM.},
  keywords  = {Colorectal,imaging,liver,metastasis,tumor response}
}

@article{henningMultispectralQuantificationTissue2007,
  title    = {Multispectral Quantification of Tissue Types in a {{RIF-1}} Tumor Model with Histological Validation. {{Part I}}},
  author   = {Henning, Erica C and Azuma, Chieko and Sotak, Christopher H and Helmer, Karl G},
  year     = 2007,
  month    = mar,
  journal  = {Magn. Reson. Med.},
  volume   = {57},
  number   = {3},
  pages    = {501--512},
  issn     = {0740-3194},
  doi      = {10.1002/mrm.21161},
  abstract = {Accurate assessments of therapeutic efficacy are confounded by intra- and intertumor heterogeneity. To address this issue we employed multispectral (MS) analysis using the apparent diffusion coefficient (ADC), T(2), proton density (M(0)), and k-means (KM) clustering algorithm to identify multiple compartments within both viable and necrotic tissue in a radiation-induced fibrosarcoma (RIF-1) tumor model receiving single-dose (1000 cGy) radiotherapy. Optimization of the KM method was achieved through histological validation by hematoxylin-eosin (H\& and E) staining and hypoxia-inducible factor-1alpha (HIF-1alpha) immunohistochemistry. The optimum KM method was determined to be a two-feature (ADC, T(2)) and four-cluster (two clusters each of viable tissue and necrosis) segmentation. KM volume estimates for both viable (r = 0.94, P {$<$} 0.01) and necrotic (r = 0.69, P = 0.07) tissue were highly correlated with their H\&E counterparts. HIF-1alpha immunohistochemistry showed that the intensity of HIF-1alpha expression tended to be concentrated in perinecrotic regions, supporting the subdivision of the viable tissue into well-oxygenated and hypoxic regions. Since both necrosis and hypoxia have been implicated in poor treatment response and reduced patient survival, the ability to quantify the degree of necrosis and the severity of hypoxia with this method may aid in the planning and modification of treatment regimens.}
}

@article{hessMetastaticPatternsAdenocarcinoma2006,
  title     = {Metastatic Patterns in Adenocarcinoma},
  author    = {Hess, Kenneth R. and Varadhachary, Gauri R. and Taylor, Sarah H. and Wei, Wei and Raber, Martin N. and Lenzi, Renato and Abbruzzese, James L.},
  year      = 2006,
  month     = apr,
  journal   = {Cancer},
  volume    = {106},
  number    = {7},
  pages     = {1624--1633},
  issn      = {0008-543X, 1097-0142},
  doi       = {10.1002/cncr.21778},
  urldate   = {2026-01-18},
  abstract  = {Abstract                            BACKGROUND               Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports. The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.                                         METHODS               Tumor registry data were collected between 1994-1996 on 11 primary tumor sites and 15 metastatic sites from 4399 patients. The primary and metastatic sites were cross-tabulated in various ways to identify patterns, and the authors developed algorithms by using multinomial logistic regression analysis to predict the locations of primary tumors based on metastatic patterns.                                         RESULTS               Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91\%), prostate to bone (90\%), and pancreas to liver (85\%). The liver was the dominant metastatic site for gastrointestinal (GI) primary tumors (71\% of patients), whereas bone and lung metastases were noted most frequently in non-GI primary tumors (43\% and 29\%, respectively). In a study of combinations of liver, abdominal cavity, and bone metastases, 86\% of prostate primary tumors had only bone metastases, 80\% of ovarian primary tumors had only abdominal cavity metastases, and 74\% of pancreas primary tumors had only liver metastases. A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97\%), intestinal lymph node from the colon (84\%), thoracic lymph node from the lung (66\%), brain from the lung (64\%), mediastinal lymph node from the lung (62\%), supraclavicular lymph node from the breast (51\%), and adrenal gland from the lung (51\%).                                         CONCLUSIONS               The algorithms that the authors developed achieved a cross-validated accuracy of 64\% and an accuracy of 64\% on an 1851-patient independent test set, compared with 9\% accuracy when a random classifier was used. Cancer 2006. \copyright{} 2006 American Cancer Society.                        ,                                            By using clinical data from greater than 4000 patients, well known, distinct metastatic patterns were confirmed that have been associated previously with distant-stage adenocarcinoma primary tumors. The authors developed algorithms for predicting the location of primary tumors based on these distinct metastatic patterns and achieved 64\% accuracy, compared with 9\% accuracy when a random classifier was used.},
  copyright = {http://onlinelibrary.wiley.com/termsAndConditions\#vor},
  langid    = {english}
}

@article{hugenAdvancesCarePatients2016,
  title   = {Advances in the Care of Patients with Mucinous Colorectal Cancer},
  author  = {Hugen, Niek and Brown, Gina and {Glynne-Jones}, Robert and De Wilt, Johannes H. W. and Nagtegaal, Iris D.},
  year    = 2016,
  month   = jun,
  journal = {Nature Reviews Clinical Oncology},
  volume  = {13},
  number  = {6},
  pages   = {361--369},
  issn    = {1759-4774, 1759-4782},
  doi     = {10.1038/nrclinonc.2015.140},
  urldate = {2026-01-18},
  langid  = {english}
}

@article{ishidaCorrelationCTMorphologic2018,
  title     = {Correlation between {{CT}} Morphologic Appearance and Histologic Findings in Colorectal Liver Metastasis after Preoperative Chemotherapy},
  author    = {Ishida, Kazuyuki and Tamura, Akio and Kato, Kenichi and Uesugi, Noriyuki and Osakabe, Mitsumasa and Eizuka, Makoto and Hasegawa, Yasushi and Nitta, Hiroyuki and Otsuka, Koki and Sasaki, Akira and Ehara, Shigeru and Sugai, Tamotsu},
  year      = 2018,
  month     = nov,
  journal   = {Abdom. Radiol. (NY)},
  volume    = {43},
  number    = {11},
  pages     = {2991--3000},
  publisher = {Springer Nature America, Inc},
  issn      = {2366-004X},
  doi       = {10.1007/s00261-018-1588-y},
  urldate   = {2025-04-12},
  abstract  = {PURPOSE: Radiological evaluation of the efficacy of preoperative chemotherapy for colorectal liver metastasis (CRLM) is the most important tool for determining treatment strategies. The aim of this study was to identify a correlation between morphologic appearance on computed tomography (CT) and histologic findings of CRLM after preoperative chemotherapy. METHODS: We examined 47 patients who had undergone a first hepatic resection for CRLM after preoperative chemotherapy and had received contrast-enhanced CT scans. We assessed the morphologic appearance of the overall attenuation based on metastases changing from heterogeneous to mixed and homogenous lesions, the tumor-liver interface, and the peripheral rim enhancement on CT. Histologic parameters included usual necrosis (UN), infarct-like necrosis (ILN), three-zonal change, dangerous halo, mucous lake, shape of ILN, dominant type of necrosis, and presence of viable tumor cells. The relationship between morphologic appearance and histologic findings was evaluated. RESULTS: CT overall attenuation revealed that UN predominance was more common in the heterogeneous group than in the mixed and homogeneous groups (P = 0.011). The frequency of ILN increased sequentially from ill-defined to variable and sharp at the tumor-liver interface (P = 0.038), and the frequency of UN decreased sequentially from present to partially resolved and completely resolved in the peripheral rim enhancement (P = 0.023). The histologic presence of viable tumor cells was closely associated with the tumor-liver interface (P = 0.0003) and the peripheral rim enhancement (P = 0.004). CONCLUSIONS: CT morphologic appearance of CRLM after preoperative chemotherapy is correlated with histologic findings regarding necrosis.},
  keywords  = {Colorectal carcinoma,Comparative histology,Computed tomography,Liver neoplasms,Metastasis,X-ray}
}

@article{jacksonImagingTumorVascular2007,
  title    = {Imaging {{Tumor Vascular Heterogeneity}} and {{Angiogenesis}} Using {{Dynamic Contrast-Enhanced Magnetic Resonance Imaging}}},
  author   = {Jackson, Alan and O'Connor, James P.B. and Parker, Geoff J.M. and Jayson, Gordon C.},
  year     = 2007,
  month    = jun,
  journal  = {Clinical Cancer Research},
  volume   = {13},
  number   = {12},
  pages    = {3449--3459},
  issn     = {1078-0432, 1557-3265},
  doi      = {10.1158/1078-0432.CCR-07-0238},
  urldate  = {2025-12-23},
  abstract = {Abstract             This article reviews the application of dynamic contrast-enhanced magnetic resonance imaging in both clinical studies and early-phase trials of angiogenesis inhibitors. Emphasis is placed on how variation in image acquisition and analysis affects the meaning and use of derived variables. We then review the potential for future developments, with particular reference to the application of dynamic contrast-enhanced magnetic resonance imaging to evaluate the heterogeneity of tumor tissues.},
  langid   = {english}
}

@article{janPixelsInsightsMachine2024,
  title      = {From Pixels to Insights: {{Machine}} Learning and Deep Learning for Bioimage Analysis},
  shorttitle = {From Pixels to Insights},
  author     = {Jan, Mahta and Spangaro, Allie and Lenartowicz, Michelle and Mattiazzi Usaj, Mojca},
  year       = 2024,
  month      = feb,
  journal    = {BioEssays},
  volume     = {46},
  number     = {2},
  publisher  = {Wiley},
  issn       = {0265-9247, 1521-1878},
  doi        = {10.1002/bies.202300114},
  urldate    = {2025-07-24},
  abstract   = {AbstractBioimage analysis plays a critical role in extracting information from biological images, enabling deeper insights into cellular structures and processes. The integration of machine learning and deep learning techniques has revolutionized the field, enabling the automated, reproducible, and accurate analysis of biological images. Here, we provide an overview of the history and principles of machine learning and deep learning in the context of bioimage analysis. We discuss the essential steps of the bioimage analysis workflow, emphasizing how machine learning and deep learning have improved preprocessing, segmentation, feature extraction, object tracking, and classification. We provide examples that showcase the application of machine learning and deep learning in bioimage analysis. We examine user-friendly software and tools that enable biologists to leverage these techniques without extensive computational expertise. This review is a resource for researchers seeking to incorporate machine learning and deep learning in their bioimage analysis workflows and enhance their research in this rapidly evolving field.},
  copyright  = {http://creativecommons.org/licenses/by-nc/4.0/},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\VCK43RHX\Jan et al. - 2024 - From pixels to insights Machine learning and deep learning for bioimage analysis.pdf}
}

@article{jardim-perassiMultiparametricMRICoregistered2019,
  title    = {Multiparametric {{MRI}} and {{Coregistered Histology Identify Tumor Habitats}} in {{Breast Cancer Mouse Models}}},
  author   = {{Jardim-Perassi}, Bruna V. and Huang, Suning and {Dominguez-Viqueira}, William and Poleszczuk, Jan and Budzevich, Mikalai M. and Abdalah, Mahmoud A. and Pillai, Smitha R. and Ruiz, Epifanio and Bui, Marilyn M. and Zuccari, Debora A.P.C. and Gillies, Robert J. and Martinez, Gary V.},
  year     = 2019,
  month    = aug,
  journal  = {Cancer Research},
  volume   = {79},
  number   = {15},
  pages    = {3952--3964},
  issn     = {0008-5472, 1538-7445},
  doi      = {10.1158/0008-5472.CAN-19-0213},
  urldate  = {2025-12-01},
  abstract = {Abstract                                           It is well-recognized that solid tumors are genomically, anatomically, and physiologically heterogeneous. In general, more heterogeneous tumors have poorer outcomes, likely due to the increased probability of harboring therapy-resistant cells and regions. It is hypothesized that the genomic and physiologic heterogeneity are related, because physiologically distinct regions will exert variable selection pressures leading to the outgrowth of clones with variable genomic/proteomic profiles. To investigate this, methods must be in place to interrogate and define, at the microscopic scale, the cytotypes that exist within physiologically distinct subregions (``habitats'') that are present at mesoscopic scales. MRI provides a noninvasive approach to interrogate physiologically distinct local environments, due to the biophysical principles that govern MRI signal generation. Here, we interrogate different physiologic parameters, such as perfusion, cell density, and edema, using multiparametric MRI (mpMRI). Signals from six different acquisition schema were combined voxel-by-voxel into four clusters identified using a Gaussian mixture model. These were compared with histologic and IHC characterizations of sections that were coregistered using MRI-guided 3D printed tumor molds. Specifically, we identified a specific set of MRI parameters to classify viable-normoxic, viable-hypoxic, nonviable-hypoxic, and nonviable-normoxic tissue types within orthotopic 4T1 and MDA-MB-231 breast tumors. This is the first coregistered study to show that mpMRI can be used to define physiologically distinct tumor habitats within breast tumor models.                                         Significance:               This study demonstrates that noninvasive imaging metrics can be used to distinguish subregions within heterogeneous tumors with histopathologic correlation.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\TMPWGFRZ\Jardim-Perassi et al. - 2019 - Multiparametric MRI and Coregistered Histology Identify Tumor Habitats in Breast Cancer Mouse Models.pdf}
}

@article{jhaRepeatabilityReproducibilityStudy2021,
  title    = {Repeatability and Reproducibility Study of Radiomic Features on a Phantom and Human Cohort},
  author   = {Jha, A. K. and Mithun, S. and Jaiswar, V. and Sherkhane, U. B. and Purandare, N. C. and Prabhash, K. and Rangarajan, V. and Dekker, A. and Wee, L. and Traverso, A.},
  year     = 2021,
  month    = jan,
  journal  = {Scientific Reports},
  volume   = {11},
  number   = {1},
  pages    = {2055},
  issn     = {2045-2322},
  doi      = {10.1038/s41598-021-81526-8},
  urldate  = {2025-12-01},
  abstract = {Abstract             The repeatability and reproducibility of radiomic features extracted from CT scans need to be investigated to evaluate the temporal stability of imaging features with respect to a controlled scenario (test--retest), as well~as their dependence on acquisition parameters such as slice thickness, or tube current. Only robust and stable features should be used in prognostication/prediction models to improve generalizability across multiple institutions. In this study, we investigated the repeatability and reproducibility of radiomic features with respect to three different scanners, variable slice thickness, tube current, and use of intravenous (IV) contrast medium, combining phantom studies and human subjects with non-small cell lung cancer. In all, half of the radiomic features showed good repeatability (ICC\,{$>$}\,0.9) independent of scanner model. Within acquisition protocols, changes in slice thickness was associated with poorer reproducibility compared to the use of IV contrast. Broad feature classes exhibit different behaviors, with only few features appearing to be the most stable. 108 features presented both good repeatability and reproducibility in all the experiments, most of them being wavelet and Laplacian of Gaussian features.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\AMVX3BBT\Jha et al. - 2021 - Repeatability and reproducibility study of radiomic features on a phantom and human cohort.pdf}
}

@article{juan-albarracinGlioblastomaVascularHabitats2018,
  title      = {Glioblastoma: {{Vascular Habitats Detected}} at {{Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival}}},
  shorttitle = {Glioblastoma},
  author     = {{Juan-Albarrac{\'i}n}, Javier and {Fuster-Garcia}, Elies and {P{\'e}rez-Girb{\'e}s}, Alexandre and {Aparici-Robles}, Fernando and {Alberich-Bayarri}, {\'A}ngel and {Revert-Ventura}, Antonio and {Mart{\'i}-Bonmat{\'i}}, Luis and {Garc{\'i}a-G{\'o}mez}, Juan M.},
  year       = 2018,
  month      = jun,
  journal    = {Radiology},
  volume     = {287},
  number     = {3},
  pages      = {944--954},
  issn       = {0033-8419, 1527-1315},
  doi        = {10.1148/radiol.2017170845},
  urldate    = {2026-01-19},
  langid     = {english}
}

@article{kaplanNonparametricEstimationIncomplete1958,
  title   = {Nonparametric {{Estimation}} from {{Incomplete Observations}}},
  author  = {Kaplan, E. L. and Meier, Paul},
  year    = 1958,
  month   = jun,
  journal = {Journal of the American Statistical Association},
  volume  = {53},
  number  = {282},
  pages   = {457--481},
  issn    = {0162-1459, 1537-274X},
  doi     = {10.1080/01621459.1958.10501452},
  urldate = {2026-01-08},
  langid  = {english}
}

@article{kashyapQuantificationTumorHeterogeneity2022,
  title      = {Quantification of Tumor Heterogeneity: From Data Acquisition to Metric Generation},
  shorttitle = {Quantification of Tumor Heterogeneity},
  author     = {Kashyap, Aditya and Rapsomaniki, Maria Anna and Barros, Vesna and {Fomitcheva-Khartchenko}, Anna and Martinelli, Adriano Luca and Rodriguez, Antonio Foncubierta and Gabrani, Maria and {Rosen-Zvi}, Michal and Kaigala, Govind},
  year       = 2022,
  month      = jun,
  journal    = {Trends in Biotechnology},
  volume     = {40},
  number     = {6},
  pages      = {647--676},
  issn       = {01677799},
  doi        = {10.1016/j.tibtech.2021.11.006},
  urldate    = {2025-08-21},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\UFXBXJNJ\Kashyap et al. - 2022 - Quantification of tumor heterogeneity from data acquisition to metric generation.pdf}
}

@article{katiyarNovelUnsupervisedSegmentation2017,
  title      = {A {{Novel Unsupervised Segmentation Approach Quantifies Tumor Tissue Populations Using Multiparametric MRI}}: {{First Results}} with {{Histological Validation}}},
  shorttitle = {A {{Novel Unsupervised Segmentation Approach Quantifies Tumor Tissue Populations Using Multiparametric MRI}}},
  author     = {Katiyar, Prateek and Divine, Mathew R. and Kohlhofer, Ursula and {Quintanilla-Martinez}, Leticia and Sch{\"o}lkopf, Bernhard and Pichler, Bernd J. and Disselhorst, Jonathan A.},
  year       = 2017,
  month      = jun,
  journal    = {Molecular Imaging and Biology},
  volume     = {19},
  number     = {3},
  pages      = {391--397},
  issn       = {1860-2002},
  doi        = {10.1007/s11307-016-1009-y},
  abstract   = {PURPOSE: We aimed to precisely estimate intra-tumoral heterogeneity using spatially regularized spectral clustering (SRSC) on multiparametric MRI data and compare the efficacy of SRSC with the previously reported segmentation techniques in MRI studies. PROCEDURES: Six NMRI nu/nu mice bearing subcutaneous human glioblastoma U87 MG tumors were scanned using a dedicated small animal 7T magnetic resonance imaging (MRI) scanner. The data consisted of T2 weighted images, apparent diffusion coefficient maps, and pre- and post-contrast T2 and T2* maps. Following each scan, the tumors were excised into 2-3-mm thin slices parallel to the axial field of view and processed for histological staining. The MRI data were segmented using SRSC, K-means, fuzzy C-means, and Gaussian mixture modeling to estimate the fractional population of necrotic, peri-necrotic, and viable regions and validated with the fractional population obtained from histology. RESULTS: While the aforementioned methods overestimated peri-necrotic and underestimated viable fractions, SRSC accurately predicted the fractional population of all three tumor tissue types and exhibited strong correlations (rnecrotic~=~0.92, rperi-necrotic~=~0.82 and rviable~=~0.98) with the histology. CONCLUSIONS: The precise identification of necrotic, peri-necrotic and viable areas using SRSC may greatly assist in cancer treatment planning and add a new dimension to MRI-guided tumor biopsy procedures.},
  langid     = {english},
  pmcid      = {PMC5332060},
  pmid       = {27734253},
  keywords   = {Algorithms,Animals,Biomarkers Tumor,Cluster Analysis,Fuzzy C-means,Gaussian mixture modeling,Image Processing Computer-Assisted,K-means,Magnetic Resonance Imaging,Mice Nude,Multiparametric MRI,Neoplasms,Reproducibility of Results,Spectral clustering,Tumor heterogeneity},
  file       = {C:\Users\oprio\Zotero\storage\3GIKHQX6\Katiyar et al. - 2017 - A Novel Unsupervised Segmentation Approach Quantifies Tumor Tissue Populations Using Multiparametric.pdf}
}

@article{katiyarQuantificationIntratumouralHeterogeneity2023,
  title   = {Quantification of Intratumoural Heterogeneity in Mice and Patients via Machine-Learning Models Trained on {{PET}}--{{MRI}} Data},
  author  = {Katiyar, Prateek and Schwenck, Johannes and Frauenfeld, Leonie and Divine, Mathew R. and Agrawal, Vaibhav and Kohlhofer, Ursula and Gatidis, Sergios and Kontermann, Roland and K{\"o}nigsrainer, Alfred and {Quintanilla-Martinez}, Leticia and La Foug{\`e}re, Christian and Sch{\"o}lkopf, Bernhard and Pichler, Bernd J. and Disselhorst, Jonathan A.},
  year    = 2023,
  month   = jun,
  journal = {Nature Biomedical Engineering},
  volume  = {7},
  number  = {8},
  pages   = {1014--1027},
  issn    = {2157-846X},
  doi     = {10.1038/s41551-023-01047-9},
  urldate = {2026-01-19},
  langid  = {english}
}

@article{kawataQuantitativeClassificationBased2012,
  title      = {Quantitative Classification Based on {{CT}} Histogram Analysis of Non-Small Cell Lung Cancer: {{Correlation}} with Histopathological Characteristics and Recurrence-Free Survival: {{Quantitative}} Classification Based on {{CT}} Histogram Analysis},
  shorttitle = {Quantitative Classification Based on {{CT}} Histogram Analysis of Non-Small Cell Lung Cancer},
  author     = {Kawata, Yoshiki and Niki, Noboru and Ohmatsu, Hironobu and Kusumoto, Masahiko and Tsuchida, Takaaki and Eguchi, Kenji and Kaneko, Masahiro and Moriyama, Noriyuki},
  year       = 2012,
  month      = feb,
  journal    = {Medical Physics},
  volume     = {39},
  number     = {2},
  pages      = {988--1000},
  issn       = {00942405},
  doi        = {10.1118/1.3679017},
  urldate    = {2026-01-19},
  copyright  = {http://doi.wiley.com/10.1002/tdm\_license\_1},
  langid     = {english}
}

@article{kellnerGibbsringingArtifactRemoval2016,
  title    = {Gibbs-ringing Artifact Removal Based on Local Subvoxel-shifts},
  author   = {Kellner, Elias and Dhital, Bibek and Kiselev, Valerij G. and Reisert, Marco},
  year     = 2016,
  month    = nov,
  journal  = {Magnetic Resonance in Medicine},
  volume   = {76},
  number   = {5},
  pages    = {1574--1581},
  issn     = {0740-3194, 1522-2594},
  doi      = {10.1002/mrm.26054},
  urldate  = {2025-12-11},
  abstract = {Purpose               To develop a fast and stable method for correcting the gibbs-ringing artifact.                                         Methods               Gibbs-ringing is a well-known artifact which manifests itself as spurious oscillations in the vicinity of sharp image gradients at tissue boundaries. The origin can be seen in the truncation of k-space during MRI data-acquisition. Correction techniques like Gegenbauer reconstruction or extrapolation methods aim at recovering these missing data. Here, we present a simple and robust method which exploits a different view on the Gibbs-phenomenon: The truncation in k-space can be interpreted as a convolution of the underlying image with a sinc-function. As the image is reconstructed on a discretized grid, the severity of the ringing artifacts depends on how this grid is located with respect to the edge and the oscillation pattern of the function. We propose to reinterpolate the image based on local, subvoxel-shifts to sample the ringing pattern at the zero-crossings of the oscillating sinc-function.                                         Results               With the proposed method, the artifact can simply, effectively, and robustly be removed with a minimal amount of image smoothing.                                         Conclusions               The robustness of the method suggests it as a suitable candidate for an implementation in the standard image processing pipeline in clinical routine. Magn Reson Med 76:1574--1581, 2016. \copyright{} 2015 International Society for Magnetic Resonance in Medicine},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\YED99BTY\Kellner et al. - 2016 - Gibbsâringing artifact removal based on local subvoxelâshifts.pdf}
}

@article{kendallProblem$m$Rankings1939,
  title   = {The {{Problem}} of \$m\$ {{Rankings}}},
  author  = {Kendall, M. G. and Smith, B. Babington},
  year    = 1939,
  month   = sep,
  journal = {The Annals of Mathematical Statistics},
  volume  = {10},
  number  = {3},
  pages   = {275--287},
  issn    = {0003-4851},
  doi     = {10.1214/aoms/1177732186},
  urldate = {2025-12-21},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\LJIAF7LY\Kendall and Smith - 1939 - The Problem of $m$ Rankings.pdf}
}

@article{kesslerEmergingScienceQuantitative2015,
  title    = {The Emerging Science of Quantitative Imaging Biomarkers Terminology and Definitions for Scientific Studies and Regulatory Submissions},
  author   = {Kessler, Larry G and Barnhart, Huiman X and Buckler, Andrew J and Choudhury, Kingshuk Roy and Kondratovich, Marina V and Toledano, Alicia and Guimaraes, Alexander R and Filice, Ross and Zhang, Zheng and Sullivan, Daniel C and {QIBA Terminology Working Group}},
  year     = 2015,
  month    = feb,
  journal  = {Statistical Methods in Medical Research},
  volume   = {24},
  number   = {1},
  pages    = {9--26},
  issn     = {0962-2802, 1477-0334},
  doi      = {10.1177/0962280214537333},
  urldate  = {2025-12-01},
  abstract = {The development and implementation of quantitative imaging biomarkers has been hampered by the inconsistent and often incorrect use of terminology related to these markers. Sponsored by the Radiological Society of North America, an interdisciplinary group of radiologists, statisticians, physicists, and other researchers worked to develop a comprehensive terminology to serve as a foundation for quantitative imaging biomarker claims. Where possible, this working group adapted existing definitions derived from national or international standards bodies rather than invent new definitions for these terms. This terminology also serves as a foundation for the design of studies that evaluate the technical performance of quantitative imaging biomarkers and for studies of algorithms that generate the quantitative imaging biomarkers from clinical scans. This paper provides examples of research studies and quantitative imaging biomarker claims that use terminology consistent with these definitions as well as examples of the rampant confusion in this emerging field. We provide recommendations for appropriate use of quantitative imaging biomarker terminological concepts. It is hoped that this document will assist researchers and regulatory reviewers who examine quantitative imaging biomarkers and will also inform regulatory guidance. More consistent and correct use of terminology could advance regulatory science, improve clinical research, and provide better care for patients who undergo imaging studies.},
  langid   = {english}
}

@article{kokunovHeatBalanceElectric1978,
  title     = {Heat Balance in Electric Roller Kilns and Driers},
  author    = {Kokunov, A. I. and Berenshtein, P. I.},
  year      = 1978,
  month     = sep,
  journal   = {Glass and Ceramics},
  volume    = {35},
  number    = {9},
  pages     = {544--547},
  issn      = {0361-7610, 1573-8515},
  doi       = {10.1007/BF00695032},
  urldate   = {2025-12-11},
  copyright = {http://www.springer.com/tdm},
  langid    = {english}
}

@article{kooGuidelineSelectingReporting2016,
  title   = {A {{Guideline}} of {{Selecting}} and {{Reporting Intraclass Correlation Coefficients}} for {{Reliability Research}}},
  author  = {Koo, Terry K. and Li, Mae Y.},
  year    = 2016,
  month   = jun,
  journal = {Journal of Chiropractic Medicine},
  volume  = {15},
  number  = {2},
  pages   = {155--163},
  issn    = {15563707},
  doi     = {10.1016/j.jcm.2016.02.012},
  urldate = {2025-12-01},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\2AKUF5QJ\Koo and Li - 2016 - A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research.pdf}
}

@article{kopetzMolecularProfilingBRAFV600Emutant2024,
  title    = {Molecular Profiling of {{BRAF-V600E-mutant}} Metastatic Colorectal Cancer in the Phase 3 {{BEACON CRC}} Trial},
  author   = {Kopetz, Scott and Murphy, Danielle A. and Pu, Jie and Ciardiello, Fortunato and Desai, Jayesh and Van Cutsem, Eric and Wasan, Harpreet Singh and Yoshino, Takayuki and Saffari, Hedieh and Zhang, Xiaosong and Hamilton, Phineas and Xie, Tao and Yaeger, Rona and Tabernero, Josep},
  year     = 2024,
  month    = nov,
  journal  = {Nature Medicine},
  volume   = {30},
  number   = {11},
  pages    = {3261--3271},
  issn     = {1078-8956, 1546-170X},
  doi      = {10.1038/s41591-024-03235-9},
  urldate  = {2026-01-18},
  abstract = {Abstract                            The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)\textpm binimetinib (Bini) significantly improved overall survival (OS) versus Cetux\,+\,chemotherapy in previously treated patients with               BRAF               -V600E-mutant mCRC, providing the basis for the approval of the Enco+Cetux regimen in the United States and the European Union. A greater understanding of biomarkers predictive of response to Enco+Cetux\textpm Bini treatment is of clinical relevance. In this prespecified, exploratory biomarker analysis of the BEACON CRC study, we characterize genomic and transcriptomic correlates of clinical outcomes and acquired resistance mechanisms through integrated clinical and molecular analysis, including whole-exome and -transcriptome tissue sequencing and circulating tumor DNA genomic profiling. Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux.               RAS               ,               MAP2K1               and               MET               alterations were most commonly acquired with Enco+Cetux\textpm Bini, and more frequent in patients with a high baseline cell-cycle gene signature; baseline               TP53               mutation was associated with acquired               MET               amplification. Acquired mutations were subclonal and polyclonal, with evidence of increased tumor mutation rate with Enco+Cetux\textpm Bini and mutational signatures (SBS17a/b). These findings support treatment with Enco+Cetux\textpm Bini for patients with               BRAF               -V600E-mutant mCRC and provide insights into the biology of response and resistance to MAPK-pathway-targeted therapy. ClinicalTrials.gov registration:               NCT02928224},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\ZUVW3EQ4\Kopetz et al. - 2024 - Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC tria.pdf}
}

@article{koukourakisEarlyAntivascularEffects2007,
  title   = {Early {{Antivascular Effects}} of {{Bevacizumab Anti-VEGF Monoclonal Antibody}} on {{Colorectal Carcinomas Assessed With Functional CT Imaging}}},
  author  = {Koukourakis, Michael I. and Mavanis, Ioannis and Kouklakis, George and Pitiakoudis, Michael and Minopoulos, George and Manolas, Costantinos and Simopoulos, Costantinos},
  year    = 2007,
  month   = jun,
  journal = {American Journal of Clinical Oncology},
  volume  = {30},
  number  = {3},
  pages   = {315--318},
  issn    = {0277-3732},
  doi     = {10.1097/01.coc.0000258119.90805.ca},
  urldate = {2026-01-19},
  langid  = {english}
}

@book{kuhnFeatureEngineeringSelection2021,
  title      = {Feature Engineering and Selection: A Practical Approach for Predictive Models},
  shorttitle = {Feature Engineering and Selection},
  author     = {Kuhn, Max and Johnson, Kjell},
  year       = 2021,
  series     = {Chapman \& {{Hall}}/{{CRC}} Data Science Series},
  edition    = {First issued in paperback},
  publisher  = {CRC Press, Taylor \& Francis Group},
  address    = {Boca Raton London New York},
  isbn       = {978-1-032-09085-6},
  langid     = {english}
}

@article{kuhnHungarianMethodAssignment1955,
  title     = {The {{Hungarian}} Method for the Assignment Problem},
  author    = {Kuhn, H. W.},
  year      = 1955,
  month     = mar,
  journal   = {Naval Research Logistics Quarterly},
  volume    = {2},
  number    = {1-2},
  pages     = {83--97},
  issn      = {0028-1441, 1931-9193},
  doi       = {10.1002/nav.3800020109},
  urldate   = {2025-12-10},
  abstract  = {Abstract             Assuming that numerical scores are available for the performance of each of n persons on each of n jobs, the ``assignment problem'' is the quest for an assignment of persons to jobs so that the sum of the n scores so obtained is as large as possible. It is shown that ideas latent in the work of two Hungarian mathematicians may be exploited to yield a new method of solving this problem.},
  copyright = {http://onlinelibrary.wiley.com/termsAndConditions\#vor},
  langid    = {english}
}

@article{lakhaniDeepLearningChest2017,
  title      = {Deep {{Learning}} at {{Chest Radiography}}: {{Automated Classification}} of {{Pulmonary Tuberculosis}} by {{Using Convolutional Neural Networks}}},
  shorttitle = {Deep {{Learning}} at {{Chest Radiography}}},
  author     = {Lakhani, Paras and Sundaram, Baskaran},
  year       = 2017,
  month      = aug,
  journal    = {Radiology},
  volume     = {284},
  number     = {2},
  pages      = {574--582},
  issn       = {0033-8419, 1527-1315},
  doi        = {10.1148/radiol.2017162326},
  urldate    = {2026-01-20},
  langid     = {english}
}

@article{lambinRadiomicsBridgeMedical2017,
  title      = {Radiomics: The Bridge between Medical Imaging and Personalized Medicine},
  shorttitle = {Radiomics},
  author     = {Lambin, Philippe and Leijenaar, Ralph T.H. and Deist, Timo M. and Peerlings, Jurgen and De Jong, Evelyn E.C. and Van Timmeren, Janita and Sanduleanu, Sebastian and Larue, Ruben T.H.M. and Even, Aniek J.G. and Jochems, Arthur and Van Wijk, Yvonka and Woodruff, Henry and Van Soest, Johan and Lustberg, Tim and Roelofs, Erik and Van Elmpt, Wouter and Dekker, Andre and Mottaghy, Felix M. and Wildberger, Joachim E. and Walsh, Sean},
  year       = 2017,
  month      = dec,
  journal    = {Nature Reviews Clinical Oncology},
  volume     = {14},
  number     = {12},
  pages      = {749--762},
  issn       = {1759-4774, 1759-4782},
  doi        = {10.1038/nrclinonc.2017.141},
  urldate    = {2025-12-01},
  langid     = {english}
}

@article{lambinRadiomicsExtractingMore2012,
  title      = {Radiomics: {{Extracting}} More Information from Medical Images Using Advanced Feature Analysis},
  shorttitle = {Radiomics},
  author     = {Lambin, Philippe and {Rios-Velazquez}, Emmanuel and Leijenaar, Ralph and Carvalho, Sara and Van Stiphout, Ruud G.P.M. and Granton, Patrick and Zegers, Catharina M.L. and Gillies, Robert and Boellard, Ronald and Dekker, Andr{\'e} and Aerts, Hugo J.W.L.},
  year       = 2012,
  month      = mar,
  journal    = {European Journal of Cancer},
  volume     = {48},
  number     = {4},
  pages      = {441--446},
  issn       = {09598049},
  doi        = {10.1016/j.ejca.2011.11.036},
  urldate    = {2026-01-10},
  copyright  = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\UME49LM6\Lambin et al. - 2012 - Radiomics Extracting more information from medical images using advanced feature analysis.pdf}
}

@article{lataczCanMedicalImaging2021,
  title   = {Can Medical Imaging Identify the Histopathological Growth Patterns of Liver Metastases?},
  author  = {Latacz, Emily and Van Dam, Pieter-Jan and Vanhove, Christian and Llado, Laura and Descamps, Benedicte and Ruiz, N{\'u}ria and Joye, Ines and Gr{\"u}nhagen, Dirk and Van Laere, Steven and Dirix, Piet and Mollevi, David G. and Verhoef, Cornelis and Dirix, Luc and Vermeulen, Peter},
  year    = 2021,
  month   = jun,
  journal = {Seminars in Cancer Biology},
  volume  = {71},
  pages   = {33--41},
  issn    = {1044579X},
  doi     = {10.1016/j.semcancer.2020.07.002},
  urldate = {2025-12-11},
  langid  = {english}
}

@article{lataczHistopathologicalGrowthPatterns2022,
  title    = {Histopathological Growth Patterns of Liver Metastasis: Updated Consensus Guidelines for Pattern Scoring, Perspectives and Recent Mechanistic Insights},
  author   = {Latacz, Emily and H{\"o}ppener, Diederik and Bohlok, Ali and others},
  year     = 2022,
  month    = oct,
  journal  = {Br. J. Cancer},
  volume   = {127},
  number   = {6},
  pages    = {988--1013},
  issn     = {0007-0920},
  doi      = {10.1038/s41416-022-01859-7},
  abstract = {The first consensus guidelines for scoring the histopathological growth patterns (HGPs) of liver metastases were established in 2017. Since then, numerous studies have applied these guidelines, have further substantiated the potential clinical value of the HGPs in patients with liver metastases from various tumour types and are starting to shed light on the biology of the distinct HGPs. In the present guidelines, we give an overview of these studies, discuss novel strategies for predicting the HGPs of liver metastases, such as deep-learning algorithms for whole-slide histopathology images and medical imaging, and highlight liver metastasis animal models that exhibit features of the different HGPs. Based on a pooled analysis of large cohorts of patients with liver-metastatic colorectal cancer, we propose a new cut-off to categorise patients according to the HGPs. An up-to-date standard method for HGP assessment within liver metastases is also presented with the aim of incorporating HGPs into the decision-making processes surrounding the treatment of patients with liver-metastatic cancer. Finally, we propose hypotheses on the cellular and molecular mechanisms that drive the biology of the different HGPs, opening some exciting preclinical and clinical research perspectives.}
}

@article{lataczProspectiveCompleteHistopathological2024,
  title   = {Prospective Complete Histopathological Characterization of Liver Metastases from Colorectal and Breast Carcinoma to Predict the Histopathological Growth Patterns by Medical Imaging ({{POEM}})},
  author  = {Latacz, E. and Palomares, O. Prior and Roig, N. Ruiz and Povedano, I. Puig and Mils, K. and Ballabrera, F. Salv{\`a} and Joye, I. and Declercq, S. and Dirix, L. and Deckers, F. and Cools, P. and Boons, P. and Apers, T. and Dirix, P. and {Perez-Lopez}, R. and Mollevi, D. Garcia and Gypen, B. and Willemsen, P. and LLado, L. and Vermeulen, P.},
  year    = 2024,
  month   = dec,
  journal = {European Journal of Surgical Oncology},
  volume  = {50},
  pages   = {109241},
  issn    = {07487983},
  doi     = {10.1016/j.ejso.2024.109241},
  urldate = {2025-12-11},
  langid  = {english}
}

@article{lauterburImageFormationInduced1973,
  title      = {Image {{Formation}} by {{Induced Local Interactions}}: {{Examples Employing Nuclear Magnetic Resonance}}},
  shorttitle = {Image {{Formation}} by {{Induced Local Interactions}}},
  author     = {Lauterbur, P. C.},
  year       = 1973,
  month      = mar,
  journal    = {Nature},
  volume     = {242},
  number     = {5394},
  pages      = {190--191},
  issn       = {0028-0836, 1476-4687},
  doi        = {10.1038/242190a0},
  urldate    = {2026-01-13},
  copyright  = {http://www.springer.com/tdm},
  langid     = {english}
}

@article{lebihanDiffusionTensorImaging2001,
  title      = {Diffusion Tensor Imaging: {{Concepts}} and Applications},
  shorttitle = {Diffusion Tensor Imaging},
  author     = {Le Bihan, Denis and Mangin, Jean-Fran{\c c}ois and Poupon, Cyril and Clark, Chris A. and Pappata, Sabina and Molko, Nicolas and Chabriat, Hughes},
  year       = 2001,
  month      = apr,
  journal    = {Journal of Magnetic Resonance Imaging},
  volume     = {13},
  number     = {4},
  pages      = {534--546},
  issn       = {1053-1807, 1522-2586},
  doi        = {10.1002/jmri.1076},
  urldate    = {2025-12-23},
  abstract   = {Abstract             The success of diffusion magnetic resonance imaging (MRI) is deeply rooted in the powerful concept that during their random, diffusion-driven displacements molecules probe tissue structure at a microscopic scale well beyond the usual image resolution. As diffusion is truly a three-dimensional process, molecular mobility in tissues may be anisotropic, as in brain white matter. With diffusion tensor imaging (DTI), diffusion anisotropy effects can be fully extracted, characterized, and exploited, providing even more exquisite details on tissue microstructure. The most advanced application is certainly that of fiber tracking in the brain, which, in combination with functional MRI, might open a window on the important issue of connectivity. DTI has also been used to demonstrate subtle abnormalities in a variety of diseases (including stroke, multiple sclerosis, dyslexia, and schizophrenia) and is currently becoming part of many routine clinical protocols. The aim of this article is to review the concepts behind DTI and to present potential applications. J. Magn. Reson. Imaging 2001;13:534--546. \copyright{} 2001 Wiley-Liss, Inc.},
  copyright  = {http://onlinelibrary.wiley.com/termsAndConditions\#vor},
  langid     = {english}
}

@article{lebihandImagerieDiffusionVivo1985,
  title   = {Imagerie de Diffusion in Vivo Par R\'esonance Magn\'etique Nucl\'eaire},
  author  = {Le Bihan D, Breton E},
  year    = 1985,
  journal = {C R Acad Sci Paris.},
  number  = {301:1109--1112}
}

@article{lebihanSeparationDiffusionPerfusion1988,
  title   = {Separation of Diffusion and Perfusion in Intravoxel Incoherent Motion {{MR}} Imaging.},
  author  = {Le Bihan, D and Breton, E and Lallemand, D and Aubin, M L and Vignaud, J and {Laval-Jeantet}, M},
  year    = 1988,
  month   = aug,
  journal = {Radiology},
  volume  = {168},
  number  = {2},
  pages   = {497--505},
  issn    = {0033-8419, 1527-1315},
  doi     = {10.1148/radiology.168.2.3393671},
  urldate = {2026-01-14},
  langid  = {english}
}

@article{lecunDeepLearning2015,
  title   = {Deep Learning},
  author  = {LeCun, Yann and Bengio, Yoshua and Hinton, Geoffrey},
  year    = 2015,
  month   = may,
  journal = {Nature},
  volume  = {521},
  number  = {7553},
  pages   = {436--444},
  issn    = {0028-0836, 1476-4687},
  doi     = {10.1038/nature14539},
  urldate = {2026-01-12},
  langid  = {english}
}

@article{liFirstStepNeuroimaging2016,
  title      = {The First Step for Neuroimaging Data Analysis: {{DICOM}} to {{NIfTI}} Conversion},
  shorttitle = {The First Step for Neuroimaging Data Analysis},
  author     = {Li, Xiangrui and Morgan, Paul S. and Ashburner, John and Smith, Jolinda and Rorden, Christopher},
  year       = 2016,
  month      = may,
  journal    = {Journal of Neuroscience Methods},
  volume     = {264},
  pages      = {47--56},
  issn       = {01650270},
  doi        = {10.1016/j.jneumeth.2016.03.001},
  urldate    = {2025-12-11},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\VFHDHIS9\Li et al. - 2016 - The first step for neuroimaging data analysis DICOM to NIfTI conversion.pdf}
}

@article{liMRIbasedHabitatImaging2024,
  title      = {{{MRI-based}} Habitat Imaging in Cancer Treatment: Current Technology, Applications, and Challenges},
  shorttitle = {{{MRI-based}} Habitat Imaging in Cancer Treatment},
  author     = {Li, Shaolei and Dai, Yongming and Chen, Jiayi and Yan, Fuhua and Yang, Yingli},
  year       = 2024,
  month      = aug,
  journal    = {Cancer Imaging},
  volume     = {24},
  number     = {1},
  publisher  = {{Springer Science and Business Media LLC}},
  issn       = {1470-7330},
  doi        = {10.1186/s40644-024-00758-9},
  urldate    = {2025-07-24},
  abstract   = {AbstractExtensive efforts have been dedicated to exploring the impact of tumor heterogeneity on cancer treatment at both histological and genetic levels. To accurately measure intra-tumoral heterogeneity, a non-invasive imaging technique, known as habitat imaging, was developed. The technique quantifies intra-tumoral heterogeneity by dividing complex tumors into distinct sub- regions, called habitats. This article reviews the following aspects of habitat imaging in cancer treatment, with a focus on radiotherapy: (1) Habitat imaging biomarkers for assessing tumor physiology; (2) Methods for habitat generation; (3) Efforts to combine radiomics, another imaging quantification method, with habitat imaging; (4) Technical challenges and potential solutions related to habitat imaging; (5) Pathological validation of habitat imaging and how it can be utilized to evaluate cancer treatment by predicting treatment response including survival rate, recurrence, and pathological response as well as ongoing open clinical trials.},
  copyright  = {https://creativecommons.org/licenses/by/4.0},
  langid     = {english},
  file       = {C\:\\Users\\oprio\\Zotero\\storage\\52RIKRMB\\23c96291-5920-4693-9731-08a2f0425fcf.pdf;C\:\\Users\\oprio\\Zotero\\storage\\N9DAB5SN\\Li et al. - 2024 - MRI-based habitat imaging in cancer treatment current technology, applications, and challenges.pdf}
}

@article{lodwickCodingRoentgenImages1963,
  title   = {The {{Coding}} of {{Roentgen Images}} for {{Computer Analysis}} as {{Applied}} to {{Lung Cancer}}},
  author  = {Lodwick, Gwilym S. and Keats, Theodore E. and Dorst, John P.},
  year    = 1963,
  month   = aug,
  journal = {Radiology},
  volume  = {81},
  number  = {2},
  pages   = {185--200},
  issn    = {0033-8419, 1527-1315},
  doi     = {10.1148/81.2.185},
  urldate = {2026-01-20},
  langid  = {english}
}

@article{loupakisHistopathologicEvaluationLiver2013,
  title     = {Histopathologic Evaluation of Liver Metastases from Colorectal Cancer in Patients Treated with {{FOLFOXIRI}} plus Bevacizumab},
  author    = {Loupakis, F and Schirripa, M and Caparello, C and Funel, N and Pollina, L and Vasile, E and Cremolini, C and Salvatore, L and Morvillo, M and Antoniotti, C and Marmorino, F and Masi, G and Falcone, A},
  year      = 2013,
  month     = jun,
  journal   = {Br. J. Cancer},
  volume    = {108},
  number    = {12},
  pages     = {2549--2556},
  publisher = {{Springer Science and Business Media LLC}},
  issn      = {0007-0920},
  doi       = {10.1038/bjc.2013.245},
  abstract  = {BACKGROUND: The FOLFOXIRI regimen produces a high rate of radiological and histopathological responses. Bevacizumab added to chemotherapy showed an improvement in pathological response and necrosis of colorectal liver metastases (CLMs). FOLFOXIRI plus bevacizumab produced promising early clinical results and is under investigation in several randomised trials, although no data are currently available on its effects on response of CLMs and on liver toxicities. METHODS: Starting from 499 patients enrolled in first-line phase II/III trials, we selected on the basis of tissue sample availability 18 patients treated with FOLFOXIRI/XELOXIRI and 24 patients treated with FOLFOXIRI plus bevacizumab who underwent secondary resection of CLMs. The 28 untreated patients who underwent primary resection of CLMs were included as control group. Responses of CLMs and chemotherapy-induced toxicities were assessed. RESULTS: Among the patients, 63\% of those treated with FOLFOXIRI plus bevacizumab, as compared with 28\% of those treated with only FOLFOXIRI/XELOXIRI, showed a histopathological response (P=0.033). In the two groups, 52\% and 12.5\%, respectively, showed necrosis {$\geq$}50\% (P=0.017). The incidence of liver toxicities was not significantly increased in patients treated with FOLFOXIRI plus bevacizumab. CONCLUSION: The addition of bevacizumab to FOLFOXIRI produces high rates of pathologic responses and necrosis of CLM without increasing liver toxicity.},
  file      = {C:\Users\oprio\Zotero\storage\T7L98Q7P\Loupakis et al. - 2013 - Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFO.pdf}
}

@article{loupakisInitialTherapyFOLFOXIRI2014,
  title   = {Initial {{Therapy}} with {{FOLFOXIRI}} and {{Bevacizumab}} for {{Metastatic Colorectal Cancer}}},
  author  = {Loupakis, Fotios and Cremolini, Chiara and Masi, Gianluca and Lonardi, Sara and Zagonel, Vittorina and Salvatore, Lisa and Cortesi, Enrico and Tomasello, Gianluca and Ronzoni, Monica and Spadi, Rosella and Zaniboni, Alberto and Tonini, Giuseppe and Buonadonna, Angela and Amoroso, Domenico and Chiara, Silvana and Carlomagno, Chiara and Boni, Corrado and Allegrini, Giacomo and Boni, Luca and Falcone, Alfredo},
  year    = 2014,
  month   = oct,
  journal = {New England Journal of Medicine},
  volume  = {371},
  number  = {17},
  pages   = {1609--1618},
  issn    = {0028-4793, 1533-4406},
  doi     = {10.1056/NEJMoa1403108},
  urldate = {2026-01-18},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\M86EXQ7E\Loupakis et al. - 2014 - Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer.pdf}
}

@article{maherManagementColorectalLiver2017,
  title   = {The Management of Colorectal Liver Metastases},
  author  = {Maher, B. and Ryan, E. and Little, M. and Boardman, P. and Stedman, B.},
  year    = 2017,
  month   = aug,
  journal = {Clinical Radiology},
  volume  = {72},
  number  = {8},
  pages   = {617--625},
  issn    = {00099260},
  doi     = {10.1016/j.crad.2017.05.016},
  urldate = {2026-01-18},
  langid  = {english}
}

@article{mannTestWhetherOne1947,
  title   = {On a {{Test}} of {{Whether}} One of {{Two Random Variables}} Is {{Stochastically Larger}} than the {{Other}}},
  author  = {Mann, H. B. and Whitney, D. R.},
  year    = 1947,
  month   = mar,
  journal = {The Annals of Mathematical Statistics},
  volume  = {18},
  number  = {1},
  pages   = {50--60},
  issn    = {0003-4851},
  doi     = {10.1214/aoms/1177730491},
  urldate = {2026-01-08},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\NLUZPP38\Mann and Whitney - 1947 - On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other.pdf}
}

@article{milesColorectalCancerTexture2009,
  title      = {Colorectal {{Cancer}}: {{Texture Analysis}} of {{Portal Phase Hepatic CT Images}} as a {{Potential Marker}} of {{Survival}}},
  shorttitle = {Colorectal {{Cancer}}},
  author     = {Miles, Kenneth A. and Ganeshan, Balaji and Griffiths, Matthew R. and Young, Rupert C. D. and Chatwin, Christopher R.},
  year       = 2009,
  month      = feb,
  journal    = {Radiology},
  volume     = {250},
  number     = {2},
  pages      = {444--452},
  issn       = {0033-8419, 1527-1315},
  doi        = {10.1148/radiol.2502071879},
  urldate    = {2026-01-19},
  langid     = {english}
}

@article{morawskaAssessmentResponseSystemic2023,
  title     = {Assessment of the Response to Systemic Treatment of Colorectal Liver Metastases on Cross-Sectional Imaging - a Systematic Review},
  author    = {Morawska, Irmina and Cieszanowski, Andrzej},
  year      = 2023,
  month     = nov,
  journal   = {Pol. J. Radiol.},
  volume    = {88},
  number    = {1},
  pages     = {e512},
  publisher = {Termedia Sp. z.o.o.},
  issn      = {1733-134X},
  doi       = {10.5114/pjr.2023.132884},
  urldate   = {2025-04-12},
  abstract  = {Colorectal cancer (CRC) is one of the most common malignancies in the world. Nowadays many treatments are available to help control CRC, including surgery, radiation therapy, interventional radiology, and drug treatments. A multidisciplinary approach and the role of radiologists is needed to assist the surgeon in the management thanks to emerging technology and strategies. The Response Evaluation Criteria in Solid Tumours (RECIST) has been created to objectify and standardize cancer response assessment. Thus, in this article specific presumptions and practical aspects of evaluating responses according to the RECIST 1.1 are discussed. Furthermore, examples of possible response to systemic treatment of colorectal liver metastases (CRLM), including tumour necrosis, apparent diffusion coefficient (ADC) values, tumour calcification, tumour fibrosis and intratumoural fat deposition observed on cross-sectional imaging, are described. Disappearing liver metastases (DLM) presents a therapeutic dilemma. The optimal management of DLM remains controversial due to the uncertainty of residual microscopic disease and effective long-term outcomes. The article provides an overview of the CRLM phenomenon and current possible assessment methods of the response to systemic treatment.},
  keywords  = {colorectal liver metastases,diffusion-weighted imaging,intratumoural fat deposition,MRI,RECIST,systemic treatment}
}

@article{morganGlobalBurdenColorectal2023,
  title      = {Global Burden of Colorectal Cancer in 2020 and 2040: Incidence and Mortality Estimates from {{GLOBOCAN}}},
  shorttitle = {Global Burden of Colorectal Cancer in 2020 and 2040},
  author     = {Morgan, Eileen and Arnold, Melina and Gini, A and Lorenzoni, V and Cabasag, C J and Laversanne, Mathieu and Vignat, Jerome and Ferlay, Jacques and Murphy, Neil and Bray, Freddie},
  year       = 2023,
  month      = feb,
  journal    = {Gut},
  volume     = {72},
  number     = {2},
  pages      = {338--344},
  issn       = {0017-5749, 1468-3288},
  doi        = {10.1136/gutjnl-2022-327736},
  urldate    = {2026-01-18},
  abstract   = {Objective               Colorectal cancer (CRC) is the third most common cancer worldwide. The geographical and temporal burden of this cancer provides insights into risk factor prevalence and progress in cancer control strategies. We examine the current and future burden of CRC in 185 countries in 2020 and 2040.                                         Methods               Data on CRC cases and deaths were extracted from the GLOBOCAN database for the year 2020. Age-standardised incidence and mortality rates were calculated by sex, country, world region and Human Development Index (HDI) for 185 countries. Age-specific rates were also estimated. The predicted number of cases and deaths in 2040 were calculated based on global demographic projections by HDI.                                         Results               Over 1.9\,million new CRC cases and 930\,000 deaths were estimated in 2020. Incidence rates were highest in Australia/ New Zealand and European regions (40.6 per 100 000, males) and lowest in several African regions and Southern Asia (4.4 per 100 000, females). Similar patterns were observed for mortality rates, with the highest observed in Eastern Europe (20.2 per 100 000, males) and the lowest in Southern Asia (2.5 per 100 000, females). The burden of CRC is projected to increase to 3.2\,million new cases and 1.6\,million deaths by 2040 with most cases predicted to occur in high or very high HDI countries.                                         Conclusions               CRC is a highly frequent cancer worldwide, and largely preventable through changes in modifiable risk factors, alongside the detection and removal of precancerous lesions. With increasing rates in transitioning countries and younger adults, there is a pressing need to better understand and act on findings to avert future cases and deaths from the disease.},
  langid     = {english}
}

@article{morrisTreatmentMetastaticColorectal2023,
  title      = {Treatment of {{Metastatic Colorectal Cancer}}: {{ASCO Guideline}}},
  shorttitle = {Treatment of {{Metastatic Colorectal Cancer}}},
  author     = {Morris, Van K. and Kennedy, Erin B. and Baxter, Nancy N. and Benson, Al B. and Cercek, Andrea and Cho, May and Ciombor, Kristen K. and Cremolini, Chiara and Davis, Anjee and Deming, Dustin A. and Fakih, Marwan G. and Gholami, Sepideh and Hong, Theodore S. and Jaiyesimi, Ishmael and Klute, Kelsey and Lieu, Christopher and Sanoff, Hanna and Strickler, John H. and White, Sarah and Willis, Jason A. and Eng, Cathy},
  year       = 2023,
  month      = jan,
  journal    = {Journal of Clinical Oncology},
  volume     = {41},
  number     = {3},
  pages      = {678--700},
  issn       = {0732-183X, 1527-7755},
  doi        = {10.1200/JCO.22.01690},
  urldate    = {2026-01-18},
  abstract   = {PURPOSE               To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC).                                         METHODS               ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.                                         RESULTS               Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria.                                         RECOMMENDATIONS               Doublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti--vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti--epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC; chemotherapy and anti--vascular endothelial growth factor therapy is recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for patients with previously treated BRAF V600E--mutant mCRC that has progressed after at least one previous line of therapy. Cytoreductive surgery plus systemic chemotherapy may be recommended for selected patients with colorectal peritoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recommended. Stereotactic body radiation therapy may be recommended following systemic therapy for patients with oligometastases of the liver who are not considered candidates for resection. Selective internal radiation therapy is not routinely recommended for patients with unilobar or bilobar metastases of the liver. Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are recommended. Qualifying statements with further details related to implementation of guideline recommendations are also included. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\9QBIXMFV\Morris et al. - 2023 - Treatment of Metastatic Colorectal Cancer ASCO Guideline.pdf}
}

@article{mottolaReproducibilityCTbasedRadiomic2021,
  title    = {Reproducibility of {{CT-based}} Radiomic Features against Image Resampling and Perturbations for Tumour and Healthy Kidney in Renal Cancer Patients},
  author   = {Mottola, Margherita and Ursprung, Stephan and Rundo, Leonardo and Sanchez, Lorena Escudero and Klatte, Tobias and Mendichovszky, Iosif and Stewart, Grant D and Sala, Evis and Bevilacqua, Alessandro},
  year     = 2021,
  month    = jun,
  journal  = {Scientific Reports},
  volume   = {11},
  number   = {1},
  pages    = {11542},
  issn     = {2045-2322},
  doi      = {10.1038/s41598-021-90985-y},
  urldate  = {2025-12-01},
  abstract = {Abstract             Computed Tomography (CT) is widely used in oncology for morphological evaluation and diagnosis, commonly through visual assessments, often exploiting semi-automatic tools as well. Well-established automatic methods for quantitative imaging offer the opportunity to enrich the radiologist interpretation with a large number of radiomic features, which need to be highly reproducible to be used reliably in clinical practice. This study investigates feature reproducibility against noise, varying resolutions and segmentations (achieved by perturbing the regions of interest), in a CT dataset with heterogeneous voxel size of 98 renal cell carcinomas (RCCs) and 93 contralateral normal kidneys (CK). In particular, first order (FO) and second order texture features based on both 2D and 3D grey level co-occurrence matrices (GLCMs) were considered. Moreover, this study carries out a comparative analysis of three of the most commonly used interpolation methods, which need to be selected before any resampling procedure. Results showed that the Lanczos interpolation is the most effective at preserving original information in resampling, where the median slice resolution coupled with the native slice spacing allows the best reproducibility, with 94.6\% and 87.7\% of features, in RCC and CK, respectively. GLCMs show their maximum reproducibility when used at short distances.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\92H576FE\Mottola et al. - 2021 - Reproducibility of CT-based radiomic features against image resampling and perturbations for tumour.pdf}
}

@article{mousaBiomarkersAngiogenesisColorectal2015,
  title    = {Biomarkers of {{Angiogenesis}} in {{Colorectal Cancer}}},
  author   = {Mousa, Luay and Salem, Mohamed E. and Mikhail, Sameh},
  year     = 2015,
  journal  = {Biomarkers in Cancer},
  volume   = {7},
  number   = {Suppl 1},
  pages    = {13--19},
  issn     = {1179-299X},
  doi      = {10.4137/BIC.S25250},
  abstract = {Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 10\% of all new cancer diagnoses. Angiogenesis is a tightly regulated process that is mediated by a group of angiogenic factors such as vascular endothelial growth factor and its receptors. Given the widespread use of antiangiogenic agents in CRC, there has been considerable interest in the development of methods to identify novel markers that can predict outcome in the treatment of this disease with angiogenesis inhibitors. Multiple biomarkers are in various phases of development and include tissue, serum, and imaging biomarkers. The complexity of the angiogenesis pathway and the overlap between the various angiogenic factors present a significant challenge to biomarker discovery. In our review, we discuss the angiogenesis pathway and the most promising evolving concepts in biomarker discovery, as well as highlight the landmark studies that identify subgroups of patients with CRC who may preferentially benefit from angiogenesis inhibitors.},
  langid   = {english},
  pmcid    = {PMC4624093},
  pmid     = {26543385},
  keywords = {angiogenesis,circulating tumor cells,colorectal cancer,imaging biomarkers,microRNA},
  file     = {C:\Users\oprio\Zotero\storage\9HAMCPGH\Mousa et al. - 2015 - Biomarkers of Angiogenesis in Colorectal Cancer.pdf}
}

@article{napelQuantitativeImagingCancer2018,
  title      = {Quantitative Imaging of Cancer in the Postgenomic Era: {{Radio}}(Geno)Mics, Deep Learning, and Habitats},
  shorttitle = {Quantitative Imaging of Cancer in the Postgenomic Era},
  author     = {Napel, Sandy and Mu, Wei and Jardim-Perassi, Bruna V. and Aerts, Hugo J. W. L. and Gillies, Robert J.},
  year       = 2018,
  month      = dec,
  journal    = {Cancer},
  volume     = {124},
  number     = {24},
  pages      = {4633--4649},
  issn       = {0008-543X, 1097-0142},
  doi        = {10.1002/cncr.31630},
  urldate    = {2025-08-21},
  abstract   = {Although cancer often is referred to as ``a disease of the genes,'' it is indisputable that the (epi)genetic properties of individual cancer cells are highly variable, even within the same tumor. Hence, preexisting resistant clones will emerge and proliferate after therapeutic selection that targets sensitive clones. Herein, the authors propose that quantitative image analytics, known as ``radiomics,'' can be used to quantify and characterize this heterogeneity. Virtually every patient with cancer is imaged radiologically. Radiomics is predicated on the beliefs that these images reflect underlying pathophysiologies, and that they can be converted into mineable data for improved diagnosis, prognosis, prediction, and therapy monitoring. In the last decade, the radiomics of cancer has grown from a few laboratories to a worldwide enterprise. During this growth, radiomics has established a convention, wherein a large set of annotated image features (1-2000 features) are extracted from segmented regions of interest and used to build classifier models to separate individual patients into their appropriate class (eg, indolent vs aggressive disease). An extension of this conventional radiomics is the application of ``deep learning,'' wherein convolutional neural networks can be used to detect the most informative regions and features without human intervention. A further extension of radiomics involves automatically segmenting informative subregions (``habitats'') within tumors, which can be linked to underlying tumor pathophysiology. The goal of the radiomics enterprise is to provide informed decision support for the practice of precision oncology.           ,              Virtually every patient with cancer is radiologically imaged. The field of radiomics combines quantitative analysis of these images with machine learning to improve diagnosis, prognosis, prediction, and therapy monitoring. This review describes radiomics including novel artificial intelligence methods, and introduces the practice of defining subregions, or ``habitats,'' within tumors.},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\HTHM5AXW\Napel et al. - 2018 - Quantitative imaging of cancer in the postgenomic era Radio(geno)mics, deep learning, and habitats.pdf}
}

@article{ngAssessmentTumorHeterogeneity2013,
  title      = {Assessment of Tumor Heterogeneity by {{CT}} Texture Analysis: {{Can}} the Largest Cross-Sectional Area Be Used as an Alternative to Whole Tumor Analysis?},
  shorttitle = {Assessment of Tumor Heterogeneity by {{CT}} Texture Analysis},
  author     = {Ng, Francesca and Kozarski, Robert and Ganeshan, Balaji and Goh, Vicky},
  year       = 2013,
  month      = feb,
  journal    = {European Journal of Radiology},
  volume     = {82},
  number     = {2},
  pages      = {342--348},
  issn       = {0720048X},
  doi        = {10.1016/j.ejrad.2012.10.023},
  urldate    = {2025-12-01},
  copyright  = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\3CG3UMDZ\Ng et al. - 2013 - Assessment of tumor heterogeneity by CT texture analysis Can the largest cross-sectional area be us.pdf}
}

@article{nielsenMorphologicalGrowthPatterns2014,
  title   = {The Morphological Growth Patterns of Colorectal Liver Metastases Are Prognostic for Overall Survival},
  author  = {Nielsen, K{\aa}re and Rolff, Hans C and Eefsen, Rikke L and Vainer, Ben},
  year    = 2014,
  month   = dec,
  journal = {Modern Pathology},
  volume  = {27},
  number  = {12},
  pages   = {1641--1648},
  issn    = {08933952},
  doi     = {10.1038/modpathol.2014.4},
  urldate = {2026-01-12},
  langid  = {english}
}

@article{nishinoTumorResponseAssessment2018,
  title      = {Tumor {{Response Assessment}} for {{Precision Cancer Therapy}}: {{Response Evaluation Criteria}} in {{Solid Tumors}} and {{Beyond}}},
  shorttitle = {Tumor {{Response Assessment}} for {{Precision Cancer Therapy}}},
  author     = {Nishino, Mizuki},
  year       = 2018,
  month      = may,
  journal    = {American Society of Clinical Oncology Educational Book},
  number     = {38},
  pages      = {1019--1029},
  issn       = {1548-8748, 1548-8756},
  doi        = {10.1200/EDBK_201441},
  urldate    = {2026-01-18},
  abstract   = {Objective assessment of tumor responses and treatment results has been the basis for the advancement of cancer therapies, and imaging plays a key role to provide a ``common language'' to describe the results of cancer treatment. Although Response Evaluation Criteria in Solid Tumors (RECIST) has been the most widely accepted method for assessing tumor response in the past decades, the limitations of RECIST have increasingly becoming recognized, especially with the recent advances of precision-medicine approaches to cancer. This article reviews the current concept of tumor response evaluations based on RECIST, describes the limitations of RECIST, and proposes strategies to overcome the limitations. The article emphasizes specific limitations in the setting of precision cancer therapy and cancer immunotherapy and discusses the important insights provided by the cutting-edge investigations in the emerging fields.           ,              PRACTICAL APPLICATIONS             RECIST1.1 is the current version of tumor response criteria that are widely accepted as a standardized method in most trials of solid tumors in general; it uses unidimensional diameters of target lesions and the sum of measurements of all target lesions as a quantitative measure of tumor burden. Major limitations of RECIST that universally affect the response assessment regardless of tumor types or agents include variability of tumor size measurements and tumoral heterogeneity both within a lesion and among different lesions in a patient. Among the specific limitations of RECIST in precision cancer therapy, in patients treated with molecular targeting agents with antiangiogenic activity, decrease of CT tumor density may reflect response to therapy even without tumor size decrease meeting the criteria for RECIST response; Choi criteria can contribute to address the pitfall. In patients with tumors harboring specific genomic abnormalities treated with effective molecular targeting therapy, tumors tend to show marked initial response and then slowly grow back while the patients are receiving therapy, where RECIST progression does not necessarily indicate treatment failure and the tumor growth rate may contribute to help therapeutic decisions. In patients treated with cancer immunotherapy using immune checkpoint blockade, atypical response patterns or pseudoprogression, although rare, can be noted, and several criteria have been proposed to address the unmet needs in the emerging field.},
  langid     = {english}
}

@article{nishiokaRadiologicalMorphologyColorectal2015,
  title     = {Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes},
  author    = {Nishioka, Yujiro and Shindoh, Junichi and Yoshioka, Ryuji and Gonoi, Wataru and Abe, Hiroyuki and Okura, Naoki and Yoshida, Shuntaro and Oba, Masaru and Hashimoto, Masaji and Watanabe, Goro and Hasegawa, Kiyoshi and Kokudo, Norihiro},
  year      = 2015,
  month     = sep,
  journal   = {J. Gastrointest. Surg.},
  volume    = {19},
  number    = {9},
  pages     = {1653--1661},
  publisher = {Elsevier BV},
  issn      = {1091-255X},
  doi       = {10.1007/s11605-015-2836-x},
  abstract  = {INTRODUCTION: The computed tomography (CT) morphology after chemotherapy is reportedly correlated with the histopathologic response to chemotherapy and a better surgical outcome in patients with colorectal liver metastases (CLM). However, the true prognostic advantage of CT morphology remains uncertain. METHODS: The prognostic advantage of CT morphology was validated in 86 patients who underwent surgical resection for CLM after undergoing a 5-fluorouracil-based chemotherapy regimen with or without bevacizumab. RESULTS: An optimal morphologic response was observed in 18 (22.8\%) patients, and a strong correlation between the CT morphology and tumor viability was confirmed (P {$<$} 0.001). A multivariate analysis revealed that bevacizumab (odds ratio [OR], 6.8; P = 0.03) and chemotherapy cycles {$\geq$}6 (OR, 3.6; P = 0.04) were associated with an optimal morphologic response. Overall survival (OS) and recurrence-free survival (RFS) were also predicted by CT morphology with a higher sensitivity. Particularly, a group 1 morphology was associated with a higher OS rate (3-year OS 100\%) and RFS rate (3-year RFS, 57.0\%), and a multivariate analysis confirmed that group 2 and group 3 tumor morphology was a significant predictive factor for tumor recurrence (hazard ratio [HR], 2.5; P = 0.03 and HR, 3.2; P {$<$} 0.01, respectively). CONCLUSION: The CT morphology of CLM predicts tumor viability and long-term surgical outcomes after chemotherapy.}
}

@article{novikovModeling2018,
  title     = {On Modeling},
  author    = {Novikov, Dmitry S. and Kiselev, Valerij G. and Jespersen, Sune N.},
  year      = 2018,
  month     = jun,
  journal   = {Magnetic Resonance in Medicine},
  volume    = {79},
  number    = {6},
  pages     = {3172--3193},
  publisher = {Wiley},
  issn      = {0740-3194, 1522-2594},
  doi       = {10.1002/mrm.27101},
  urldate   = {2025-07-24},
  abstract  = {Mapping tissue microstructure with MRI holds great promise as a noninvasive window into tissue organization at the cellular level. Having originated within the realm of diffusion NMR in the late 1970s, this field is experiencing an exponential growth in the number of publications. At the same time, model-based approaches are also increasingly incorporated into advanced MRI acquisition and reconstruction techniques. However, after about two decades of intellectual and financial investment, microstructural mapping has yet to find a single commonly accepted clinical application. Here, we suggest that slow progress in clinical translation may signify unresolved fundamental problems. We outline such problems and related practical pitfalls, as well as review strategies for developing and validating tissue microstructure models, to provoke a discussion on how to bridge the gap between our scientific aspirations and the clinical reality. We argue for recalibrating the efforts of our community toward a more systematic focus on fundamental research aimed at identifying relevant degrees of freedom affecting the measured MR signal. Such a focus is essential for realizing the truly revolutionary potential of noninvasive three-dimensional in vivo microstructural mapping.},
  copyright = {http://onlinelibrary.wiley.com/termsAndConditions\#vor},
  langid    = {english},
  file      = {C\:\\Users\\oprio\\Zotero\\storage\\H7DN53Q5\\fc1d3ece-e98f-448a-839f-2a5565887277.pdf;C\:\\Users\\oprio\\Zotero\\storage\\IP74K85F\\Novikov et al. - 2018 - On modeling.pdf}
}

@article{oconnorCancerHeterogeneityImaging2017,
  title     = {Cancer Heterogeneity and Imaging},
  author    = {O'Connor, James P.B.},
  year      = 2017,
  month     = apr,
  journal   = {Seminars in Cell \& Developmental Biology},
  volume    = {64},
  pages     = {48--57},
  publisher = {Elsevier BV},
  issn      = {1084-9521},
  doi       = {10.1016/j.semcdb.2016.10.001},
  urldate   = {2025-07-24},
  abstract  = {There is interest in identifying and quantifying tumor heterogeneity at the genomic, tissue pathology and clinical imaging scales, as this may help better understand tumor biology and may yield useful biomarkers for guiding therapy-based decision making. This review focuses on the role and value of using x-ray, CT, MRI and PET based imaging methods that identify, measure and map tumor heterogeneity. In particular we highlight the potential value of these techniques and the key challenges required to validate and qualify these biomarkers for clinical use.},
  copyright = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid    = {english},
  file      = {C:\Users\oprio\Zotero\storage\Z56GNYQK\OâConnor - 2017 - Cancer heterogeneity and imaging.pdf}
}

@article{oconnorImagingBiomarkerRoadmap2017,
  title   = {Imaging Biomarker Roadmap for Cancer Studies},
  author  = {O'Connor, James P. B. and Aboagye, Eric O. and Adams, Judith E. and Aerts, Hugo J. W. L. and Barrington, Sally F. and Beer, Ambros J. and Boellaard, Ronald and Bohndiek, Sarah E. and Brady, Michael and Brown, Gina and Buckley, David L. and Chenevert, Thomas L. and Clarke, Laurence P. and Collette, Sandra and Cook, Gary J. and {deSouza}, Nandita M. and Dickson, John C. and Dive, Caroline and Evelhoch, Jeffrey L. and {Faivre-Finn}, Corinne and Gallagher, Ferdia A. and Gilbert, Fiona J. and Gillies, Robert J. and Goh, Vicky and Griffiths, John R. and Groves, Ashley M. and Halligan, Steve and Harris, Adrian L. and Hawkes, David J. and Hoekstra, Otto S. and Huang, Erich P. and Hutton, Brian F. and Jackson, Edward F. and Jayson, Gordon C. and Jones, Andrew and Koh, Dow-Mu and Lacombe, Denis and Lambin, Philippe and Lassau, Nathalie and Leach, Martin O. and Lee, Ting-Yim and Leen, Edward L. and Lewis, Jason S. and Liu, Yan and Lythgoe, Mark F. and Manoharan, Prakash and Maxwell, Ross J. and Miles, Kenneth A. and Morgan, Bruno and Morris, Steve and Ng, Tony and Padhani, Anwar R. and Parker, Geoff J. M. and Partridge, Mike and Pathak, Arvind P. and Peet, Andrew C. and Punwani, Shonit and Reynolds, Andrew R. and Robinson, Simon P. and Shankar, Lalitha K. and Sharma, Ricky A. and Soloviev, Dmitry and Stroobants, Sigrid and Sullivan, Daniel C. and Taylor, Stuart A. and Tofts, Paul S. and Tozer, Gillian M. and Van Herk, Marcel and {Walker-Samuel}, Simon and Wason, James and Williams, Kaye J. and Workman, Paul and Yankeelov, Thomas E. and Brindle, Kevin M. and McShane, Lisa M. and Jackson, Alan and Waterton, John C.},
  year    = 2017,
  month   = mar,
  journal = {Nature Reviews Clinical Oncology},
  volume  = {14},
  number  = {3},
  pages   = {169--186},
  issn    = {1759-4774, 1759-4782},
  doi     = {10.1038/nrclinonc.2016.162},
  urldate = {2026-01-19},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\LWHABTLM\O'Connor et al. - 2017 - Imaging biomarker roadmap for cancer studies.pdf}
}

@article{oconnorImagingIntratumorHeterogeneity2015,
  title      = {Imaging {{Intratumor Heterogeneity}}: {{Role}} in {{Therapy Response}}, {{Resistance}}, and {{Clinical Outcome}}},
  shorttitle = {Imaging {{Intratumor Heterogeneity}}},
  author     = {O'Connor, James P.B. and Rose, Chris J. and Waterton, John C. and Carano, Richard A.D. and Parker, Geoff J.M. and Jackson, Alan},
  year       = 2015,
  month      = jan,
  journal    = {Clinical Cancer Research},
  volume     = {21},
  number     = {2},
  pages      = {249--257},
  publisher  = {American Association for Cancer Research (AACR)},
  issn       = {1078-0432, 1557-3265},
  doi        = {10.1158/1078-0432.ccr-14-0990},
  urldate    = {2025-07-24},
  abstract   = {Abstract               Tumors exhibit genomic and phenotypic heterogeneity, which has prognostic significance and may influence response to therapy. Imaging can quantify the spatial variation in architecture and function of individual tumors through quantifying basic biophysical parameters such as CT density or MRI signal relaxation rate; through measurements of blood flow, hypoxia, metabolism, cell death, and other phenotypic features; and through mapping the spatial distribution of biochemical pathways and cell signaling networks using PET, MRI, and other emerging molecular imaging techniques. These methods can establish whether one tumor is more or less heterogeneous than another and can identify subregions with differing biology. In this article, we review the image analysis methods currently used to quantify spatial heterogeneity within tumors. We discuss how analysis of intratumor heterogeneity can provide benefit over more simple biomarkers such as tumor size and average function. We consider how imaging methods can be integrated with genomic and pathology data, instead of being developed in isolation. Finally, we identify the challenges that must be overcome before measurements of intratumoral heterogeneity can be used routinely to guide patient care. Clin Cancer Res; 21(2); 249--57. \copyright 2014 AACR.},
  langid     = {english},
  file       = {C\:\\Users\\oprio\\Zotero\\storage\\EFDJWY5G\\dc4b96c7-151d-48e1-864d-9b1c4e104bb8.pdf;C\:\\Users\\oprio\\Zotero\\storage\\G66JRAVC\\O'Connor et al. - 2015 - Imaging Intratumor Heterogeneity Role in Therapy Response, Resistance, and Clinical Outcome.pdf}
}

@article{oconnorQuantitativeImagingBiomarkers2008,
  title      = {Quantitative Imaging Biomarkers in the Clinical Development of Targeted Therapeutics: Current and Future Perspectives},
  shorttitle = {Quantitative Imaging Biomarkers in the Clinical Development of Targeted Therapeutics},
  author     = {O'Connor, James Pb and Jackson, Alan and Asselin, Marie-Claude and Buckley, David L and Parker, Geoff Jm and Jayson, Gordon C},
  year       = 2008,
  month      = aug,
  journal    = {The Lancet Oncology},
  volume     = {9},
  number     = {8},
  pages      = {766--776},
  publisher  = {Elsevier BV},
  issn       = {1470-2045},
  doi        = {10.1016/s1470-2045(08)70196-7},
  urldate    = {2025-07-24},
  copyright  = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\YFXXIMLV\O'Connor et al. - 2008 - Quantitative imaging biomarkers in the clinical development of targeted therapeutics current and fu.pdf}
}

@article{oconnorRethinkingRoleClinical2017,
  title     = {Rethinking the Role of Clinical Imaging},
  author    = {O'Connor, James Pb},
  year      = 2017,
  month     = sep,
  journal   = {eLife},
  volume    = {6},
  publisher = {eLife Sciences Publications, Ltd},
  issn      = {2050-084X},
  doi       = {10.7554/elife.30563},
  urldate   = {2025-07-24},
  abstract  = {Radiomics has the potential to improve the management of cancer patients, but further research is required before it can be adopted into routine clinical practice.},
  copyright = {http://creativecommons.org/licenses/by/4.0/},
  langid    = {english},
  file      = {C\:\\Users\\oprio\\Zotero\\storage\\52YVH2N8\\eb2efe32-901a-4e97-b0b8-e49cd1bd2256.pdf;C\:\\Users\\oprio\\Zotero\\storage\\8ZDNQKVT\\O'Connor - 2017 - Rethinking the role of clinical imaging.pdf}
}

@article{ongaroClinicalMolecularDeterminants2019,
  title   = {Clinical and Molecular Determinants of Extrahepatic Disease Progression in Patients with Metastatic Colorectal Cancer with Liver-Limited Metastases Deemed Initially Unresectable},
  author  = {Ongaro, Elena and Cremolini, Chiara and Rossini, Daniele and Corti, Francesca and Pagani, Filippo and Morelli, Luca and Urbani, Lucio and Masi, Gianluca and Sposito, Carlo and Filippi, Beatrice and Borelli, Beatrice and Zucchelli, Gemma and Moretto, Roberto and Boccaccino, Alessandra and Solaini, Leonardo and De Braud, Filippo and Mazzaferro, Vincenzo and Falcone, Alfredo and Cucchetti, Alessandro and Pietrantonio, Filippo},
  year    = 2019,
  journal = {ESMO Open},
  volume  = {4},
  number  = {2},
  pages   = {e000496},
  issn    = {20597029},
  doi     = {10.1136/esmoopen-2019-000496},
  urldate = {2025-12-15},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\74RW2W6G\Ongaro et al. - 2019 - Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic.pdf}
}

@article{ourselinReconstructing3DStructure2001,
  title     = {Reconstructing a {{3D}} Structure from Serial Histological Sections},
  author    = {Ourselin, S and Roche, A and Subsol, G and Pennec, X and Ayache, N},
  year      = 2001,
  month     = jan,
  journal   = {Image and Vision Computing},
  volume    = {19},
  number    = {1-2},
  pages     = {25--31},
  issn      = {02628856},
  doi       = {10.1016/S0262-8856(00)00052-4},
  urldate   = {2025-12-11},
  copyright = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid    = {english}
}

@article{ozakiLiverMetastasesCorrelation2022,
  title      = {Liver {{Metastases}}: {{Correlation}} between {{Imaging Features}} and {{Pathomolecular Environments}}},
  shorttitle = {Liver {{Metastases}}},
  author     = {Ozaki, Kumi and Higuchi, Shohei and Kimura, Hirohiko and Gabata, Toshifumi},
  year       = 2022,
  month      = nov,
  journal    = {RadioGraphics},
  volume     = {42},
  number     = {7},
  pages      = {1994--2013},
  issn       = {0271-5333, 1527-1323},
  doi        = {10.1148/rg.220056},
  urldate    = {2026-01-10},
  langid     = {english}
}

@article{pagetDistributionSecondaryGrowths1889,
  title    = {The Distribution of Secondary Growths in Cancer of the Breast. 1889},
  author   = {Paget, S.},
  year     = 1889,
  journal  = {Cancer Metastasis Reviews},
  volume   = {8},
  number   = {2},
  pages    = {98--101},
  issn     = {0167-7659},
  langid   = {english},
  pmid     = {2673568},
  keywords = {Breast Neoplasms,Female,History 19th Century,Humans,Neoplasm Metastasis}
}

@article{paiFoundationModelCancer2024,
  title    = {Foundation Model for Cancer Imaging Biomarkers},
  author   = {Pai, Suraj and Bontempi, Dennis and Hadzic, Ibrahim and Prudente, Vasco and Soka{\v c}, Mateo and Chaunzwa, Tafadzwa L. and Bernatz, Simon and Hosny, Ahmed and Mak, Raymond H. and Birkbak, Nicolai J. and Aerts, Hugo J. W. L.},
  year     = 2024,
  month    = mar,
  journal  = {Nature Machine Intelligence},
  volume   = {6},
  number   = {3},
  pages    = {354--367},
  issn     = {2522-5839},
  doi      = {10.1038/s42256-024-00807-9},
  urldate  = {2026-01-20},
  abstract = {Abstract             Foundation models in deep learning are characterized by a single large-scale model trained on vast amounts of data serving as the foundation for various downstream tasks. Foundation models are generally trained using self-supervised learning and excel in reducing the demand for training samples in downstream applications. This is especially important in medicine, where large labelled datasets are often scarce. Here, we developed a foundation model for cancer imaging biomarker discovery by training a convolutional encoder through self-supervised learning using a comprehensive dataset of 11,467 radiographic lesions. The foundation model was evaluated in distinct and clinically relevant applications of cancer imaging-based biomarkers. We found that it facilitated better and more efficient learning of imaging biomarkers and yielded task-specific models that significantly outperformed conventional supervised and other state-of-the-art pretrained implementations on downstream tasks, especially when training dataset sizes were very limited. Furthermore, the foundation model was more stable to input variations and showed strong associations with underlying biology. Our results demonstrate the tremendous potential of foundation models in discovering new imaging biomarkers that may extend to other clinical use cases and can accelerate the widespread translation of imaging biomarkers into clinical settings.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\IHMMAB96\Pai et al. - 2024 - Foundation model for cancer imaging biomarkers.pdf}
}

@misc{paiVisionFoundationModels2025,
  title     = {Vision {{Foundation Models}} for {{Computed Tomography}}},
  author    = {Pai, Suraj and Hadzic, Ibrahim and Bontempi, Dennis and Bressem, Keno and Kann, Benjamin H. and Fedorov, Andriy and Mak, Raymond H. and Aerts, Hugo J. W. L.},
  year      = 2025,
  publisher = {arXiv},
  doi       = {10.48550/ARXIV.2501.09001},
  urldate   = {2025-12-21},
  abstract  = {Foundation models (FMs) have shown transformative potential in radiology by performing diverse, complex tasks across imaging modalities. Here, we developed CT-FM, a large-scale 3D image-based pre-trained model designed explicitly for various radiological tasks. CT-FM was pre-trained using 148,000 computed tomography (CT) scans from the Imaging Data Commons through label-agnostic contrastive learning. We evaluated CT-FM across four categories of tasks, namely, whole-body and tumor segmentation, head CT triage, medical image retrieval, and semantic understanding, showing superior performance against state-of-the-art models. Beyond quantitative success, CT-FM demonstrated the ability to cluster regions anatomically and identify similar anatomical and structural concepts across scans. Furthermore, it remained robust across test-retest settings and indicated reasonable salient regions attached to its embeddings. This study demonstrates the value of large-scale medical imaging foundation models and by open-sourcing the model weights, code, and data, aims to support more adaptable, reliable, and interpretable AI solutions in radiology.},
  copyright = {Creative Commons Attribution 4.0 International},
  keywords  = {Computer Vision and Pattern Recognition (cs.CV),FOS: Computer and information sciences,FOS: Electrical engineering electronic engineering information engineering,Image and Video Processing (eess.IV)}
}

@article{pantanowitzWholeSlideImaging2015,
  title      = {Whole Slide Imaging in Pathology: Advantages, Limitations, and Emerging Perspectives},
  shorttitle = {Whole Slide Imaging in Pathology},
  author     = {Pantanowitz, Liron and Farahani, Navid and Parwani, Anil},
  year       = 2015,
  month      = jun,
  journal    = {Pathology and Laboratory Medicine International},
  pages      = {23},
  issn       = {1179-2698},
  doi        = {10.2147/PLMI.S59826},
  urldate    = {2026-01-12},
  copyright  = {http://creativecommons.org/licenses/by-nc/3.0/},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\VQGS5GGF\Pantanowitz et al. - 2015 - Whole slide imaging in pathology advantages, limitations, and emerging perspectives.pdf}
}

@article{parekhDeepLearningRadiomics2019,
  title   = {Deep Learning and Radiomics in Precision Medicine},
  author  = {Parekh, Vishwa S. and Jacobs, Michael A.},
  year    = 2019,
  month   = mar,
  journal = {Expert Review of Precision Medicine and Drug Development},
  volume  = {4},
  number  = {2},
  pages   = {59--72},
  issn    = {2380-8993},
  doi     = {10.1080/23808993.2019.1585805},
  urldate = {2025-08-21},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\S6FT3EY2\Parekh and Jacobs - 2019 - Deep learning and radiomics in precision medicine.pdf}
}

@article{paschaliFoundationModelsRadiology2025,
  title      = {Foundation {{Models}} in {{Radiology}}: {{What}}, {{How}}, {{Why}}, and {{Why Not}}},
  shorttitle = {Foundation {{Models}} in {{Radiology}}},
  author     = {Paschali, Magdalini and Chen, Zhihong and Blankemeier, Louis and Varma, Maya and Youssef, Alaa and Bluethgen, Christian and Langlotz, Curtis and Gatidis, Sergios and Chaudhari, Akshay},
  year       = 2025,
  month      = feb,
  journal    = {Radiology},
  volume     = {314},
  number     = {2},
  pages      = {e240597},
  issn       = {0033-8419, 1527-1315},
  doi        = {10.1148/radiol.240597},
  urldate    = {2026-01-21},
  abstract   = {This review focuses on foundation models in radiology and describes their key characteristics and methods for training, adapting, and evaluating; in addition, cautions and future directions associated with their responsible deployment in radiologic practices are discussed.           ,              Recent advances in artificial intelligence have witnessed the emergence of large-scale deep learning models capable of interpreting and generating both textual and imaging data. Such models, typically referred to as foundation models (FMs), are trained on extensive corpora of unlabeled data and demonstrate high performance across various tasks. FMs have recently received extensive attention from academic, industry, and regulatory bodies. Given the potentially transformative impact that FMs can have on the field of radiology, radiologists must be aware of potential pathways to train these radiology-specific FMs, including understanding both the benefits and challenges. Thus, this review aims to explain the fundamental concepts and terms of FMs in radiology, with a specific focus on the requirements of training data, model training paradigms, model capabilities, and evaluation strategies. Overall, the goal of this review is to unify technical advances and clinical needs for safe and responsible training of FMs in radiology to ultimately benefit patients, providers, and radiologists.             \copyright{} RSNA, 2025},
  langid     = {english}
}

@article{paulattoColorectalLiverMetastases2020,
  title     = {Colorectal Liver Metastases: Radiopathological Correlation},
  author    = {Paulatto, Luisa and Dioguardi Burgio, Marco and Sartoris, Riccardo and Beaufr{\`e}re, Aur{\'e}lie and Cauchy, Fran{\c c}ois and Paradis, Val{\'e}rie and Vilgrain, Val{\'e}rie and Ronot, Maxime},
  year      = 2020,
  month     = aug,
  journal   = {Insights Imaging},
  volume    = {11},
  number    = {1},
  pages     = {99},
  publisher = {{Springer Science and Business Media LLC}},
  issn      = {1869-4101},
  doi       = {10.1186/s13244-020-00904-4},
  urldate   = {2025-04-12},
  abstract  = {With the development of chemotherapy regimens, targeted therapies, and hepatic surgery, the survival of patients with colorectal liver metastases (CRLM) has dramatically improved. Imaging plays a central role for the diagnosis, staging, and treatment allocation in these patients. To interpret CRLM on imaging, radiologists must be familiar with the main imaging features of untreated tumors as well as the modifications induced by systemic therapies, and their meaning in relation to pathological tumor response and tumor biology. CRLM have the same histological features as the primary tumor. Most are "non-otherwise specified" (NOS) adenocarcinomas. The mucinous tumor is the most common of the rare subtypes. In NOS tumors, imaging usually differentiates central areas of necrosis from peripheral proliferating tumors and desmoplastic reaction. Areas of mucin mixed with fibrosis are seen in mucinous subtypes to help differentiate the metastases from other tumors cysts or hemangiomas. After treatment, the viable tumor is gradually replaced by ischemic-like necrosis and fibrosis, and remnants cells are mainly located on the periphery of tumors. Imaging can help predict the degree of tumor response, but changes can be difficult to differentiate from the pretherapeutic appearance. When chemotherapy is interrupted or in case of resistance to treatment, a peripheral infiltrating halo of tumor growth may appear. The purpose of the article is to illustrate the significance of the imaging features of colorectal liver metastases during systemic therapy, using radiopathological correlations.},
  keywords  = {Imaging,Metastasis,Radiopathological correlation}
}

@article{paxtonLeedsHistologyGuide2003,
  title   = {The {{Leeds Histology Guide}}},
  author  = {Paxton, Steve and Peckham, Michelle and Knibbs, Adele},
  year    = 2003,
  urldate = {2026-01-12},
  langid  = {english}
}

@article{peledSelectionFittingModel2019,
  title   = {Selection of {{Fitting Model}} and {{Arterial Input Function}} for {{Repeatability}} in {{Dynamic Contrast-Enhanced Prostate MRI}}},
  author  = {Peled, Sharon and Vangel, Mark and Kikinis, Ron and Tempany, Clare M. and Fennessy, Fiona M. and Fedorov, Andrey},
  year    = 2019,
  month   = sep,
  journal = {Academic Radiology},
  volume  = {26},
  number  = {9},
  pages   = {e241-e251},
  issn    = {10766332},
  doi     = {10.1016/j.acra.2018.10.018},
  urldate = {2025-12-11},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\WB9HXYXQ\Peled et al. - 2019 - Selection of Fitting Model and Arterial Input Function for Repeatability in Dynamic Contrast-Enhance.pdf}
}

@article{petoDesignAnalysisRandomized1976,
  title     = {Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient. {{I}}. {{Introduction}} and Design},
  author    = {Peto, R and Pike, M C and Armitage, P and Breslow, N E and Cox, D R and Howard, S V and Mantel, N and McPherson, K and Peto, J and Smith, P G},
  year      = 1976,
  month     = dec,
  journal   = {British Journal of Cancer},
  volume    = {34},
  number    = {6},
  pages     = {585--612},
  issn      = {0007-0920, 1532-1827},
  doi       = {10.1038/bjc.1976.220},
  urldate   = {2026-01-08},
  copyright = {http://www.springer.com/tdm},
  langid    = {english}
}

@article{petoDesignAnalysisRandomized1977,
  title     = {Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient. {{II}}. {{Analysis}} and Examples},
  author    = {Peto, R and Pike, M C and Armitage, P and Breslow, N E and Cox, D R and Howard, S V and Mantel, N and McPherson, K and Peto, J and Smith, P G},
  year      = 1977,
  month     = jan,
  journal   = {British Journal of Cancer},
  volume    = {35},
  number    = {1},
  pages     = {1--39},
  issn      = {0007-0920, 1532-1827},
  doi       = {10.1038/bjc.1977.1},
  urldate   = {2026-01-08},
  copyright = {http://www.springer.com/tdm},
  langid    = {english}
}

@article{pfaehlerSystematicReviewQuality2021,
  title   = {A Systematic Review and Quality of Reporting Checklist for Repeatability and Reproducibility of Radiomic Features},
  author  = {Pfaehler, Elisabeth and Zhovannik, Ivan and Wei, Lise and Boellaard, Ronald and Dekker, Andre and Monshouwer, Ren{\'e} and El Naqa, Issam and Bussink, Jan and Gillies, Robert and Wee, Leonard and Traverso, Alberto},
  year    = 2021,
  month   = oct,
  journal = {Physics and Imaging in Radiation Oncology},
  volume  = {20},
  pages   = {69--75},
  issn    = {24056316},
  doi     = {10.1016/j.phro.2021.10.007},
  urldate = {2025-12-01},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\2CU2RGHK\Pfaehler et al. - 2021 - A systematic review and quality of reporting checklist for repeatability and reproducibility of radi.pdf}
}

@article{pooleyFundamentalPhysicsMR2005,
  title   = {Fundamental {{Physics}} of {{MR Imaging}}},
  author  = {Pooley, Robert A.},
  year    = 2005,
  month   = jul,
  journal = {RadioGraphics},
  volume  = {25},
  number  = {4},
  pages   = {1087--1099},
  issn    = {0271-5333, 1527-1323},
  doi     = {10.1148/rg.254055027},
  urldate = {2026-01-13},
  langid  = {english}
}

@article{poultsidesPathologicResponsePreoperative2012,
  title      = {Pathologic {{Response}} to {{Preoperative Chemotherapy}} in {{Colorectal Liver Metastases}}: {{Fibrosis}}, Not {{Necrosis}}, {{Predicts Outcome}}},
  shorttitle = {Pathologic {{Response}} to {{Preoperative Chemotherapy}} in {{Colorectal Liver Metastases}}},
  author     = {Poultsides, George A. and Bao, Fei and Servais, Elliot L. and {Hernandez-Boussard}, Tina and DeMatteo, Ronald P. and Allen, Peter J. and Fong, Yuman and Kemeny, Nancy E. and Saltz, Leonard B. and Klimstra, David S. and Jarnagin, William R. and Shia, Jinru and D'Angelica, Michael I.},
  year       = 2012,
  month      = sep,
  journal    = {Annals of Surgical Oncology},
  volume     = {19},
  number     = {9},
  pages      = {2797--2804},
  issn       = {1068-9265, 1534-4681},
  doi        = {10.1245/s10434-012-2335-1},
  urldate    = {2025-12-15},
  copyright  = {http://www.springer.com/tdm},
  langid     = {english}
}

@article{priorIdentificationPrecise3D2024,
  title   = {Identification of {{Precise 3D CT Radiomics}} for {{Habitat Computation}} by {{Machine Learning}} in {{Cancer}}},
  author  = {Prior, Olivia and Macarro, Carlos and Navarro, V{\'i}ctor and Monreal, Camilo and Ligero, Marta and {Garcia-Ruiz}, Alonso and Serna, Garazi and Simonetti, Sara and Bra{\~n}a, Irene and Vieito, Maria and Escobar, Manuel and Capdevila, Jaume and Byrne, Annette T. and Dienstmann, Rodrigo and Toledo, Rodrigo and Nuciforo, Paolo and Garralda, Elena and Grussu, Francesco and Bernatowicz, Kinga and {Perez-Lopez}, Raquel},
  year    = 2024,
  month   = mar,
  journal = {Radiology: Artificial Intelligence},
  volume  = {6},
  number  = {2},
  pages   = {e230118},
  issn    = {2638-6100},
  doi     = {10.1148/ryai.230118},
  urldate = {2025-08-05},
  langid  = {english}
}

@article{razaTourUnsupervisedDeep,
  title    = {A {{Tour}} of {{Unsupervised Deep Learning}} for {{Medical Image Analysis}}},
  author   = {Raza, Khalid and Singh, Nripendra Kumar},
  abstract = {Interpretation of medical images for diagnosis and treatment of complex disease from highdimensional and heterogeneous data remains a key challenge in transforming healthcare. In the last few years, both supervised and unsupervised deep learning achieved promising results in the area of medical imaging and image analysis. Unlike supervised learning which is biased towards how it is being supervised and manual efforts to create class label for the algorithm, unsupervised learning derive insights directly from the data itself, group the data and help to make data driven decisions without any external bias. This review systematically presents various unsupervised models applied to medical image analysis, including autoencoders and its several variants, Restricted Boltzmann machines, Deep belief networks, Deep Boltzmann machine and Generative adversarial network. Future research opportunities and challenges of unsupervised techniques for medical image analysis have also been discussed.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\U99TU7IZ\Raza and Singh - A Tour of Unsupervised Deep Learning for Medical Image Analysis.pdf}
}

@article{rubbia-brandtImportanceHistologicalTumor2007,
  title     = {Importance of Histological Tumor Response Assessment in Predicting the Outcome in Patients with Colorectal Liver Metastases Treated with Neo-Adjuvant Chemotherapy Followed by Liver Surgery},
  author    = {{Rubbia-Brandt}, L. and Giostra, E. and Brezault, C. and Roth, A.D. and Andres, A. and Audard, V. and Sartoretti, P. and Dousset, B. and Majno, P.E. and Soubrane, O. and Chaussade, S. and Mentha, G. and Terris, B.},
  year      = 2007,
  month     = feb,
  journal   = {Annals of Oncology},
  volume    = {18},
  number    = {2},
  pages     = {299--304},
  issn      = {09237534},
  doi       = {10.1093/annonc/mdl386},
  urldate   = {2026-01-10},
  copyright = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid    = {english}
}

@article{schaddeLimitationsResectabilityColorectal2021,
  title    = {Limitations in Resectability of Colorectal Liver Metastases 2020 - {{A}} Systematic Approach for Clinicians and Patients},
  author   = {Schadde, Erik and Grunhagen, Dirk J and Verhoef, Cornelis and Krzywon, Lucyna and Metrakos, Peter},
  year     = 2021,
  month    = jun,
  journal  = {Semin. Cancer Biol.},
  volume   = {71},
  pages    = {10--20},
  issn     = {1044-579X},
  doi      = {10.1016/j.semcancer.2020.09.008},
  abstract = {Colorectal liver metastases (CRLM) affect over 50 \% of all patients with colorectal cancer, which is the second leading cause of cancer in the western world. Resection of CRLM may provide cure and improves survival over chemotherapy alone. However, resectability of CLRM has to be decided in multidisciplinary tumor boards and is based on oncological factors, technical factors and patient factors. The advances of chemotherapy lead to the abolition of contraindications to resection in favor of technical resectability, but somatic mutations and molecular subtyping may improve selection of patients for resection in the future. Technical factors center around anatomy of the lesions, volume of the remnant liver and quality of the liver parenchymal. Multiple strategies have been developed to overcome volume limitations and they are reviewed here. The least investigated topic is how to select the right patients among an elderly and frail patient population for the large variety of technical options specifically for bi-lobar CRLM to keep 90-day mortality as low as possible. The review is an overview over the current state-of-the art and a systematic guide to the topic of resectability of CRLM for both clinicians and patients.},
  keywords = {Colorectal liver metastases,Conversion chemotherapy,Parenchymal sparing hepatectomy,Peri-operative mortality,Regenerative liver surgery,Resectability,Two-stage hepatectomy}
}

@article{schirripaReplyCommentHistopathologic2013,
  title     = {Reply: {{Comment}} on '{{Histopathologic}} Evaluation of Liver Metastases from Colorectal Cancer Patients Treated with {{FOLFOXIRI}} plus Bevacizumab'},
  author    = {Schirripa, M and Loupakis, F and Pollina, L and Cremolini, C and Pasquini, G and Falcone, A},
  year      = 2013,
  month     = dec,
  journal   = {Br. J. Cancer},
  volume    = {109},
  number    = {12},
  pages     = {3129--3130},
  publisher = {{Springer Science and Business Media LLC}},
  issn      = {0007-0920},
  doi       = {10.1038/bjc.2013.652}
}

@article{schoenfeldPartialResidualsProportional1982,
  title   = {Partial Residuals for the Proportional Hazards Regression Model},
  author  = {Schoenfeld, David},
  year    = 1982,
  journal = {Biometrika},
  volume  = {69},
  number  = {1},
  pages   = {239--241},
  issn    = {0006-3444, 1464-3510},
  doi     = {10.1093/biomet/69.1.239},
  urldate = {2026-01-08},
  langid  = {english}
}

@article{schubertStopUsingElbow2023,
  title         = {Stop Using the Elbow Criterion for K-Means and How to Choose the Number of Clusters Instead},
  author        = {Schubert, Erich},
  year          = 2023,
  month         = jun,
  journal       = {ACM SIGKDD Explorations Newsletter},
  volume        = {25},
  number        = {1},
  eprint        = {2212.12189},
  primaryclass  = {stat},
  pages         = {36--42},
  issn          = {1931-0145, 1931-0153},
  doi           = {10.1145/3606274.3606278},
  urldate       = {2026-01-19},
  abstract      = {A major challenge when using k-means clustering often is how to choose the parameter k, the number of clusters. In this letter, we want to point out that it is very easy to draw poor conclusions from a common heuristic, the "elbow method". Better alternatives have been known in literature for a long time, and we want to draw attention to some of these easy to use options, that often perform better. This letter is a call to stop using the elbow method altogether, because it severely lacks theoretic support, and we want to encourage educators to discuss the problems of the method -- if introducing it in class at all -- and teach alternatives instead, while researchers and reviewers should reject conclusions drawn from the elbow method.},
  archiveprefix = {arXiv},
  keywords      = {Computer Science - Machine Learning,Statistics - Machine Learning},
  file          = {C\:\\Users\\oprio\\Zotero\\storage\\UJSNL3PI\\Schubert - 2023 - Stop using the elbow criterion for k-means and how to choose the number of clusters instead.pdf;C\:\\Users\\oprio\\Zotero\\storage\\ANF3Z5HV\\2212.html}
}

@article{schwarzEstimatingDimensionModel1978,
  title   = {Estimating the {{Dimension}} of a {{Model}}},
  author  = {Schwarz, Gideon},
  year    = 1978,
  month   = mar,
  journal = {The Annals of Statistics},
  volume  = {6},
  number  = {2},
  issn    = {0090-5364},
  doi     = {10.1214/aos/1176344136},
  urldate = {2025-12-01},
  file    = {C:\Users\oprio\Zotero\storage\YMSUKUPR\Schwarz - 1978 - Estimating the Dimension of a Model.pdf}
}

@article{segalDecodingGlobalGene2007,
  title     = {Decoding Global Gene Expression Programs in Liver Cancer by Noninvasive Imaging},
  author    = {Segal, Eran and Sirlin, Claude B and Ooi, Clara and Adler, Adam S and Gollub, Jeremy and Chen, Xin and Chan, Bryan K and Matcuk, George R and Barry, Christopher T and Chang, Howard Y and Kuo, Michael D},
  year      = 2007,
  month     = jun,
  journal   = {Nature Biotechnology},
  volume    = {25},
  number    = {6},
  pages     = {675--680},
  issn      = {1087-0156, 1546-1696},
  doi       = {10.1038/nbt1306},
  urldate   = {2026-01-19},
  copyright = {http://www.springer.com/tdm},
  langid    = {english}
}

@article{siegelColorectalCancerStatistics2020,
  title    = {Colorectal Cancer Statistics, 2020},
  author   = {Siegel, Rebecca L. and Miller, Kimberly D. and Goding Sauer, Ann and Fedewa, Stacey A. and Butterly, Lynn F. and Anderson, Joseph C. and Cercek, Andrea and Smith, Robert A. and Jemal, Ahmedin},
  year     = 2020,
  month    = may,
  journal  = {CA: A Cancer Journal for Clinicians},
  volume   = {70},
  number   = {3},
  pages    = {145--164},
  issn     = {0007-9235, 1542-4863},
  doi      = {10.3322/caac.21601},
  urldate  = {2025-12-15},
  abstract = {Abstract             Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3~years, the American Cancer Society provides an update of CRC occurrence based on incidence data (available through 2016) from population-based cancer registries and mortality data (through 2017) from the National Center for Health Statistics. In 2020, approximately 147,950 individuals will be diagnosed with CRC and 53,200 will die from the disease, including 17,930 cases and 3,640 deaths in individuals aged younger than 50~years. The incidence rate during 2012 through 2016 ranged from 30 (per 100,000 persons) in Asian/Pacific Islanders to 45.7 in blacks and 89 in Alaska Natives. Rapid declines in incidence among screening-aged individuals during the 2000s continued during 2011 through 2016 in those aged 65~years and older (by 3.3\% annually) but reversed in those aged 50 to 64~years, among whom rates increased by 1\% annually. Among individuals aged younger than 50~years, the incidence rate increased by approximately 2\% annually for tumors in the proximal and distal colon, as well as the rectum, driven by trends in non-Hispanic whites. CRC death rates during 2008 through 2017 declined by 3\% annually in individuals aged 65~years and older and by 0.6\% annually in individuals aged 50 to 64~years while increasing by 1.3\% annually in those aged younger than 50~years. Mortality declines among individuals aged 50~years and older were steepest among blacks, who also had the only decreasing trend among those aged younger than 50~years, and excluded American Indians/Alaska Natives, among whom rates remained stable. Progress against CRC can be accelerated by increasing access to guideline-recommended screening and high-quality treatment, particularly among Alaska Natives, and elucidating causes for rising incidence in young and middle-aged adults.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\6N5HKGFK\Siegel et al. - 2020 - Colorectal cancer statistics, 2020.pdf}
}

@article{siegelColorectalCancerYoung2020,
  title      = {Colorectal {{Cancer}} in the {{Young}}: {{Epidemiology}}, {{Prevention}}, {{Management}}},
  shorttitle = {Colorectal {{Cancer}} in the {{Young}}},
  author     = {Siegel, Rebecca L. and Jakubowski, Christopher Dennis and Fedewa, Stacey A. and Davis, Anjee and Azad, Nilofer S.},
  year       = 2020,
  month      = may,
  journal    = {American Society of Clinical Oncology Educational Book},
  number     = {40},
  pages      = {e75-e88},
  issn       = {1548-8748, 1548-8756},
  doi        = {10.1200/EDBK_279901},
  urldate    = {2026-01-18},
  abstract   = {Colorectal cancer (CRC) incidence rates in the United States overall have declined since the mid-1980s because of changing patterns in risk factors (e.g., decreased smoking) and increases in screening. However, this progress is increasingly confined to older adults. CRC occurrence has been on the rise in patients younger than age 50, often referred to as early-onset disease, since the mid-1990s. Young patients are more often diagnosed at an advanced stage and with rectal disease than their older counterparts, and they have numerous other unique challenges across the cancer management continuum. For example, young patients are less likely than older patients to have a usual source of health care; often need a more complex treatment protocol to preserve fertility and sexual function; are at higher risk of long-term and late effects, including subsequent primary malignancies; and more often suffer medical financial hardship. Diagnosis is often delayed because of provider- and patient-related factors, and clinicians must have a high index of suspicion if young patients present with rectal bleeding or changes in bowel habits. Educating primary care providers and the larger population on the increasing incidence and characteristic symptoms is paramount. Morbidity can further be averted by increasing awareness of the criteria for early screening, which include a family history of CRC or polyps and a genetic predisposition.},
  langid     = {english}
}

@article{simpsonPreoperativeCTSurvival2024,
  title    = {Preoperative {{CT}} and Survival Data for Patients Undergoing Resection of Colorectal Liver Metastases},
  author   = {Simpson, Amber L. and Peoples, Jacob and Creasy, John M. and Fichtinger, Gabor and Gangai, Natalie and Keshavamurthy, Krishna N. and Lasso, Andras and Shia, Jinru and D'Angelica, Michael I. and Do, Richard K. G.},
  year     = 2024,
  month    = feb,
  journal  = {Scientific Data},
  volume   = {11},
  number   = {1},
  pages    = {172},
  issn     = {2052-4463},
  doi      = {10.1038/s41597-024-02981-2},
  urldate  = {2025-12-11},
  abstract = {Abstract             The liver is a common site for the development of metastases in colorectal cancer. Treatment selection for patients with colorectal liver metastases (CRLM) is difficult; although hepatic resection will cure a minority of CRLM patients, recurrence is common. Reliable preoperative prediction of recurrence could therefore be a valuable tool for physicians in selecting the best candidates for hepatic resection in the treatment of CRLM. It has been hypothesized that evidence for recurrence could be found via quantitative image analysis on preoperative CT imaging of the future liver remnant before resection. To investigate this hypothesis, we have collected preoperative hepatic CT scans, clinicopathologic data, and recurrence/survival data, from a large, single-institution series of patients (n\,=\,197) who underwent hepatic resection of CRLM. For each patient, we also created segmentations of the liver, vessels, tumors, and future liver remnant. The largest of its kind, this dataset is a resource that may aid in the development of quantitative imaging biomarkers and machine learning models for the prediction of post-resection hepatic recurrence of CRLM.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\6HC96EFM\Simpson et al. - 2024 - Preoperative CT and survival data for patients undergoing resection of colorectal liver metastases.pdf}
}

@article{songArtificialIntelligenceDigital2023,
  title   = {Artificial Intelligence for Digital and Computational Pathology},
  author  = {Song, Andrew H. and Jaume, Guillaume and Williamson, Drew F. K. and Lu, Ming Y. and Vaidya, Anurag and Miller, Tiffany R. and Mahmood, Faisal},
  year    = 2023,
  month   = oct,
  journal = {Nature Reviews Bioengineering},
  volume  = {1},
  number  = {12},
  pages   = {930--949},
  issn    = {2731-6092},
  doi     = {10.1038/s44222-023-00096-8},
  urldate = {2026-01-21},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\F45GEFPC\Song et al. - 2023 - Artificial intelligence for digital and computational pathology.pdf}
}

@misc{songMorphologicalPrototypingUnsupervised2024,
  title     = {Morphological {{Prototyping}} for {{Unsupervised Slide Representation Learning}} in {{Computational Pathology}}},
  author    = {Song, Andrew H. and Chen, Richard J. and Ding, Tong and Williamson, Drew F. K. and Jaume, Guillaume and Mahmood, Faisal},
  year      = 2024,
  publisher = {arXiv},
  doi       = {10.48550/ARXIV.2405.11643},
  urldate   = {2025-08-21},
  abstract  = {Representation learning of pathology whole-slide images (WSIs) has been has primarily relied on weak supervision with Multiple Instance Learning (MIL). However, the slide representations resulting from this approach are highly tailored to specific clinical tasks, which limits their expressivity and generalization, particularly in scenarios with limited data. Instead, we hypothesize that morphological redundancy in tissue can be leveraged to build a task-agnostic slide representation in an unsupervised fashion. To this end, we introduce PANTHER, a prototype-based approach rooted in the Gaussian mixture model that summarizes the set of WSI patches into a much smaller set of morphological prototypes. Specifically, each patch is assumed to have been generated from a mixture distribution, where each mixture component represents a morphological exemplar. Utilizing the estimated mixture parameters, we then construct a compact slide representation that can be readily used for a wide range of downstream tasks. By performing an extensive evaluation of PANTHER on subtyping and survival tasks using 13 datasets, we show that 1) PANTHER outperforms or is on par with supervised MIL baselines and 2) the analysis of morphological prototypes brings new qualitative and quantitative insights into model interpretability.},
  copyright = {Creative Commons Attribution 4.0 International},
  keywords  = {Applications (stat.AP),Computer Vision and Pattern Recognition (cs.CV),FOS: Computer and information sciences,Machine Learning (cs.LG)}
}

@book{sprawlsPhysicalPrinciplesMedical1995,
  title     = {Physical Principles of Medical Imaging},
  author    = {Sprawls, Perry},
  year      = 1995,
  edition   = {2. ed},
  publisher = {Medical Physics Publ},
  address   = {Madison, Wis},
  isbn      = {978-0-944838-54-9},
  langid    = {english}
}

@article{stesselsBreastAdenocarcinomaLiver2004,
  title     = {Breast Adenocarcinoma Liver Metastases, in Contrast to Colorectal Cancer Liver Metastases, Display a Non-Angiogenic Growth Pattern That Preserves the Stroma and Lacks Hypoxia},
  author    = {Stessels, F and {Van den Eynden}, G and {Van der Auwera}, I and Salgado, R and {Van den Heuvel}, E and Harris, A L and Jackson, D G and Colpaert, C G and {van Marck}, E A and Dirix, L Y and Vermeulen, P B},
  year      = 2004,
  month     = apr,
  journal   = {Br. J. Cancer},
  volume    = {90},
  number    = {7},
  pages     = {1429--1436},
  publisher = {{Springer Science and Business Media LLC}},
  issn      = {0007-0920},
  doi       = {10.1038/sj.bjc.6601727},
  urldate   = {2025-04-12},
  abstract  = {Although angiogenesis is a prerequisite for the growth of most human solid tumours, alternative mechanisms of vascularisation can be adopted. We have previously described a non-angiogenic growth pattern in liver metastases of colorectal adenocarcinomas (CRC) in which tumour cells replace hepatocytes at the tumour-liver interface, preserving the liver architecture and co-opting the sinusoidal blood vessels. The aim of this study was to determine whether this replacement pattern occurs during liver metastasis of breast adenocarcinomas (BC) and whether the lack of an angiogenic switch in such metastases is due to the absence of hypoxia and subsequent vascular fibrinogen leakage. The growth pattern of 45 BC liver metastases and 28 CRC liver metastases (73 consecutive patients) was assessed on haematoxylin- and eosin-stained tissue sections. The majority of the BC liver metastases had a replacement growth pattern (96\%), in contrast to only 32\% of the CRC metastases (P{$<$}0.0001). The median carbonic anhydrase 9 (CA9) expression (M75 antibody), as a marker of hypoxia, (intensity x \% of stained tumour cells) was 0 in the BC metastases and 53 in the CRC metastases (P{$<$}0.0001). There was CA9 expression at the tumour-liver interface in only 16\% of the BC liver metastases vs 54\% of the CRC metastases (P=0.002). There was fibrin (T2G1 antibody) at the tumour-liver interface in only 21\% of the BC metastases vs 56\% of the CRC metastases (P=0.04). The median macrophage count (Chalkley morphometry; KP-1 anti-CD68 antibody) at the interface was 4.3 and 7.5, respectively (P{$<$}0.0001). Carbonic anhydrase 9 score and macrophage count were positively correlated (r=0.42; P=0.002) in all metastases. Glandular differentiation was less in the BC liver metastases: 80\% had less than 10\% gland formation vs only 7\% of the CRC metastases (P{$<$}0.0001). The liver is a densely vascularised organ and can host metastases that exploit this environment by replacing the hepatocytes and co-opting the vasculature. Our findings confirm that a non-angiogenic pattern of liver metastasis indeed occurs in BC, that this pattern of replacement growth is even more prevalent than in CRC, and that the process induces neither hypoxia nor vascular leakage.}
}

@article{subasingheInfarctNecrosisColorectal2022,
  title     = {Infarct like Necrosis of Colorectal Liver Metastasis without Chemotherapy: {{A}} Rare Phenomenon},
  author    = {Subasinghe, Duminda and Wijesinghe, Harshima and Abeygunasekera, Priyanka and Sarawanamuththu, Umagowry and Dassanayake, Vihara and Sivaganesh, Sivasuriya},
  year      = 2022,
  month     = jan,
  journal   = {Clin. Pathol.},
  volume    = {15},
  pages     = {2632010X221145537},
  publisher = {SAGE Publications},
  issn      = {2632-010X},
  doi       = {10.1177/2632010X221145537},
  urldate   = {2025-04-11},
  abstract  = {Usual type necrosis (UN) and infarct like necrosis (ILN) occur in CRLMs. ILN is a rare form of necrosis in colorectal liver metastases which is usually seen following chemotherapy. De novo occurrence of ILN is a very rare phenomenon. ILN in CRLM without adjuvant chemotherapy following colorectal resection was not described previously. We describe the presence of complete ILN in a solitary metachronous liver metastasis from right colonic adenocarcinoma without prior chemotherapy.},
  keywords  = {Adenocarcinoma,Colorectal liver metastases,Infarct like necrosis}
}

@article{subbiahCancerTreatmentParadigms2025,
  title   = {Cancer Treatment Paradigms in the Precision Medicine Era},
  author  = {Subbiah, Vivek and Curigliano, Giuseppe and Sicklick, Jason K. and Kato, Shumei and Tasken, Kjetil and Medford, Arielle and Rieke, Damian T. and Chen, Hui-Zi and Wahida, Adam and Buschhorn, Lars and Horgan, Denis and Kurzrock, Razelle},
  year    = 2025,
  month   = may,
  journal = {Nature Medicine},
  issn    = {1078-8956, 1546-170X},
  doi     = {10.1038/s41591-025-03711-w},
  urldate = {2025-08-13},
  langid  = {english}
}

@article{sujitEnhancingNSCLCRecurrence2024,
  title    = {Enhancing {{NSCLC}} Recurrence Prediction with {{PET}}/{{CT}} Habitat Imaging, {{ctDNA}}, and Integrative Radiogenomics-Blood Insights},
  author   = {Sujit, Sheeba J. and Aminu, Muhammad and Karpinets, Tatiana V. and Chen, Pingjun and Saad, Maliazurina B. and Salehjahromi, Morteza and Boom, John D. and Qayati, Mohamed and George, James M. and Allen, Haley and Antonoff, Mara B. and Hong, Lingzhi and Hu, Xin and Heeke, Simon and Tran, Hai T. and Le, Xiuning and Elamin, Yasir Y. and Altan, Mehmet and Vokes, Natalie I. and Sheshadri, Ajay and Lin, Julie and Zhang, Jianhua and Lu, Yang and Behrens, Carmen and Godoy, Myrna C. B. and Wu, Carol C. and Chang, Joe Y. and Chung, Caroline and Jaffray, David A. and Wistuba, Ignacio I. and Lee, J. Jack and Vaporciyan, Ara A. and Gibbons, Don L. and Heymach, John and Zhang, Jianjun and Cascone, Tina and Wu, Jia},
  year     = 2024,
  month    = apr,
  journal  = {Nature Communications},
  volume   = {15},
  number   = {1},
  pages    = {3152},
  issn     = {2041-1723},
  doi      = {10.1038/s41467-024-47512-0},
  urldate  = {2025-08-20},
  abstract = {Abstract                            While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplored. In our multi-institutional study of 394 NSCLC patients, we utilize pre-treatment computed tomography (CT) and               18               F-fluorodeoxyglucose positron emission tomography (FDG-PET) to establish a habitat imaging framework for assessing regional heterogeneity within individual tumors. This framework identifies three PET/CT subtypes, which maintain prognostic value after adjusting for clinicopathologic risk factors including tumor volume. Additionally, these subtypes complement ctDNA in predicting disease recurrence. Radiogenomics analysis unveil the molecular underpinnings of these imaging subtypes, highlighting downregulation in interferon alpha and gamma pathways in the high-risk subtype. In summary, our study demonstrates that these habitat imaging subtypes effectively stratify NSCLC patients based on their risk levels for disease recurrence after initial curative surgery or radiotherapy, providing valuable insights for personalized treatment approaches.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\QGNJCBTR\Sujit et al. - 2024 - Enhancing NSCLC recurrence prediction with PETCT habitat imaging, ctDNA, and integrative radiogenom.pdf}
}

@article{sullivanMetrologyStandardsQuantitative2015,
  title   = {Metrology {{Standards}} for {{Quantitative Imaging Biomarkers}}},
  author  = {Sullivan, Daniel C. and Obuchowski, Nancy A. and Kessler, Larry G. and Raunig, David L. and Gatsonis, Constantine and Huang, Erich P. and Kondratovich, Marina and McShane, Lisa M. and Reeves, Anthony P. and Barboriak, Daniel P. and Guimaraes, Alexander R. and Wahl, Richard L. and {For the RSNA-QIBA Metrology Working Group}},
  year    = 2015,
  month   = dec,
  journal = {Radiology},
  volume  = {277},
  number  = {3},
  pages   = {813--825},
  issn    = {0033-8419, 1527-1315},
  doi     = {10.1148/radiol.2015142202},
  urldate = {2025-12-01},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\WVWBFWVF\Sullivan et al. - 2015 - Metrology Standards for Quantitative Imaging Biomarkers.pdf}
}

@article{surovCorrelationApparentDiffusion2017,
  title      = {Correlation between Apparent Diffusion Coefficient ({{ADC}}) and Cellularity Is Different in Several Tumors: A Meta-Analysis},
  shorttitle = {Correlation between Apparent Diffusion Coefficient ({{ADC}}) and Cellularity Is Different in Several Tumors},
  author     = {Surov, Alexey and Meyer, Hans Jonas and Wienke, Andreas},
  year       = 2017,
  month      = aug,
  journal    = {Oncotarget},
  volume     = {8},
  number     = {35},
  pages      = {59492--59499},
  issn       = {1949-2553},
  doi        = {10.18632/oncotarget.17752},
  urldate    = {2025-12-23},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\24ML5QWR\Surov et al. - 2017 - Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tum.pdf}
}

@article{suttonTextureMeasuresAutomatic1972,
  title     = {Texture {{Measures}} for {{Automatic Classification}} of {{Pulmonary Disease}}},
  author    = {Sutton, R.N. and Hall, E.L.},
  year      = 1972,
  month     = jul,
  journal   = {IEEE Transactions on Computers},
  volume    = {C-21},
  number    = {7},
  pages     = {667--676},
  issn      = {0018-9340, 1557-9956, 2326-3814},
  doi       = {10.1109/T-C.1972.223572},
  urldate   = {2026-01-20},
  copyright = {https://ieeexplore.ieee.org/Xplorehelp/downloads/license-information/IEEE.html}
}

@article{swantonEmbracingCancerComplexity2024,
  title      = {Embracing Cancer Complexity: {{Hallmarks}} of Systemic Disease},
  shorttitle = {Embracing Cancer Complexity},
  author     = {Swanton, Charles and Bernard, Elsa and Abbosh, Chris and Andr{\'e}, Fabrice and Auwerx, Johan and Balmain, Allan and {Bar-Sagi}, Dafna and Bernards, Ren{\'e} and Bullman, Susan and DeGregori, James and Elliott, Catherine and Erez, Ayelet and Evan, Gerard and Febbraio, Mark A. and Hidalgo, Andr{\'e}s and {Jamal-Hanjani}, Mariam and Joyce, Johanna A. and Kaiser, Matthew and Lamia, Katja and Locasale, Jason W. and Loi, Sherene and Malanchi, Ilaria and Merad, Miriam and Musgrave, Kathryn and Patel, Ketan J. and Quezada, Sergio and Wargo, Jennifer A. and Weeraratna, Ashani and White, Eileen and Winkler, Frank and Wood, John N. and Vousden, Karen H. and Hanahan, Douglas},
  year       = 2024,
  month      = mar,
  journal    = {Cell},
  volume     = {187},
  number     = {7},
  pages      = {1589--1616},
  issn       = {00928674},
  doi        = {10.1016/j.cell.2024.02.009},
  urldate    = {2025-08-13},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\3AB3DSNM\Swanton et al. - 2024 - Embracing cancer complexity Hallmarks of systemic disease.pdf}
}

@article{takahashiPrognosticImplicationsHistologic2023,
  title     = {Prognostic Implications of Histologic Growth Patterns and Tumor-Infiltrating Macrophages in Colorectal Liver Metastases},
  author    = {Takahashi, Yuki and Matsuo, Kenichi and Shiozawa, Toshimitsu and Suzuki, Kaori and Shimizu, Hiroaki and Tanaka, Kuniya},
  year      = 2023,
  month     = jan,
  journal   = {Langenbecks Arch. Surg.},
  volume    = {408},
  number    = {1},
  pages     = {6},
  publisher = {{Springer Science and Business Media LLC}},
  issn      = {1435-2443},
  doi       = {10.1007/s00423-022-02741-z},
  urldate   = {2025-04-12},
  abstract  = {PURPOSE: Histopathologic patterns at the invasion fronts of tumors predict metastatic potential and prognosis in several cancers. We examined whether such patterns at the interface between colorectal liver metastases and hepatic parenchyma have similar prognostic value. METHODS: Microscopic growth patterns at edges of metastases including desmoplasia, pushing borders, and replacement of hepatocytes were retrospectively analyzed with respect to surgical outcomes in 142 patients who underwent hepatectomy for colorectal metastases. RESULTS: Patterns included desmoplasia in 58 patients (41\%), hepatocyte replacement in 41 (29\%), and pushing borders in 43 (30\%). Maximum metastasis diameter and serum carcinoembryonic antigen concentration in patients showing desmoplastic tumor growth were lower than those in others (P {$<$} 0.05 and P {$<$} 0.01). Disease-free survival and overall survival were better in patients showing desmoplastic growth, while a non-desmoplastic tumor growth pattern showed a negative influence. More cluster of differentiation (CD) 68-positive M1 macrophages and fewer CD206-positive M2 macrophages were demonstrated at interfaces of tumors with hepatic parenchyma when desmoplasia was present, although markers for proliferative activity (MIB1 index) and metastatic potential (E-cadherin expression) appeared uninfluenced by desmoplasia. CONCLUSION: Better long-term results were associated with metastatic tumors showing desmoplastic growth patterns at invasion fronts, which may reflect local immune state in a prognostically useful manner.},
  keywords  = {Colorectal cancer,Hepatectomy,Liver metastases,Tumor growth pattern}
}

@article{therasseNewGuidelinesEvaluate2000,
  title   = {New {{Guidelines}} to {{Evaluate}} the {{Response}} to {{Treatment}} in {{Solid Tumors}}},
  author  = {Therasse, Patrick and Arbuck, Susan G. and Eisenhauer, Elizabeth A. and Wanders, Jantien and Kaplan, Richard S. and Rubinstein, Larry and Verweij, Jaap and Van Glabbeke, Martine and Van Oosterom, Allan T. and Christian, Michaele C. and Gwyther, Steve G.},
  year    = 2000,
  month   = feb,
  journal = {JNCI: Journal of the National Cancer Institute},
  volume  = {92},
  number  = {3},
  pages   = {205--216},
  issn    = {0027-8874, 1460-2105},
  doi     = {10.1093/jnci/92.3.205},
  urldate = {2026-01-18},
  langid  = {english}
}

@article{thngPerfusionMagneticResonance2010,
  title   = {Perfusion Magnetic Resonance Imaging of the Liver},
  author  = {Thng, Choon Hua},
  year    = 2010,
  journal = {World Journal of Gastroenterology},
  volume  = {16},
  number  = {13},
  pages   = {1598},
  issn    = {1007-9327},
  doi     = {10.3748/wjg.v16.i13.1598},
  urldate = {2025-12-25},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\IM4N8ATN\Thng - 2010 - Perfusion magnetic resonance imaging of the liver.pdf}
}

@article{toftsMeasurementBloodbrainBarrier1991,
  title    = {Measurement of the Blood-brain Barrier Permeability and Leakage Space Using Dynamic {{MR}} Imaging. 1. {{Fundamental}} Concepts},
  author   = {Tofts, Paul S. and Kermode, Allan G.},
  year     = 1991,
  month    = feb,
  journal  = {Magnetic Resonance in Medicine},
  volume   = {17},
  number   = {2},
  pages    = {357--367},
  issn     = {0740-3194, 1522-2594},
  doi      = {10.1002/mrm.1910170208},
  urldate  = {2025-12-23},
  abstract = {Abstract                            Leakage of Gd-DTPA through a defective blood-brain barrier is measured quantitatively using dynamic MRI scanning, in which repeated scans are made after a bolus injection. Image registration artifacts are minimized; a dose of 0.1 m               M               /kg and an IR sequence enable enhancement to be measured quantitatively. The triexponential enhancement curve is fitted to a theoretical model based on compartmental analysis. The transfer constant, or permeability surface area product per unit volume of tissue               (k)               , and leakage space per unit volume of tissue (y) are measured. Estimates for a quickly enhancing multiple sclerosis lesion are               k               = 0.050 min               -1               ,               v               1               = 21\%; for a slow one               k               = 0.013 min               -1               ,               v               1               = 49\%. This implies permeability in the range 4-17 \texttimes{} 10               -6               cm s               -1               , in broad agreement with other physiological methods. The method is noninvasive and can be used to make serial measurements in patients and in experimental animal models. The time course of pathological aspects of diseases with blood-brain barrier breakdown, such as multiple sclerosis, tumors, and infections (e.g., HIV) can be studied, along with their response to therapy. The measurements are of physiological variables and are therefore independent of imaging equipment and field. \copyright{} 1991 Academic Press, Inc.},
  langid   = {english}
}

@article{toftsModelingTracerKinetics1997,
  title     = {Modeling Tracer Kinetics in Dynamic {{Gd}}-{{DTPA MR}} Imaging},
  author    = {Tofts, Paul S.},
  year      = 1997,
  month     = jan,
  journal   = {Journal of Magnetic Resonance Imaging},
  volume    = {7},
  number    = {1},
  pages     = {91--101},
  issn      = {1053-1807, 1522-2586},
  doi       = {10.1002/jmri.1880070113},
  urldate   = {2025-12-11},
  abstract  = {Abstract                            Three major models (from Tofts, Larsson, and Brix) for collecting and analyzing dynamic MRI gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) data are examined. All models use compartments representing the blood plasma and the abnormal extravascular extracellular space (EES), and they are intercompatible. All measure combinations of three parameters: (1) k               ps{$\rho$}               is the influx volume transfer constant (min               -1               ), or permeability surface area product per unit volume of tissue, between plasma and EES; (2) v               e               is the volume of EES space per unit volume of tissue (0 {$<$} v               e               {$<$} 1); and (3) k               ep               , the efflux rate constant (min               -1               ), is the ratio of the first two parameters (k               ep               = k               ps{$\rho$}               /v               e               ). The ratio k               ep               is the simplest to measure, requiring only signal linearity with Gd tracer concentration or, alternatively, a measurement of T1 before injection of Gd (T               10               ). To measure the physiologic parameters k               ps{$\rho$}               and v               e               separately requires knowledge of T               10               and of the tissue relaxivity R               1               (âï¸ in vitro value).},
  copyright = {http://onlinelibrary.wiley.com/termsAndConditions\#vor},
  langid    = {english}
}

@article{togaoMeasurementPerfusionFraction2018,
  title      = {Measurement of the Perfusion Fraction in Brain Tumors with Intravoxel Incoherent Motion {{MR}} Imaging: Validation with Histopathological Vascular Density in Meningiomas},
  shorttitle = {Measurement of the Perfusion Fraction in Brain Tumors with Intravoxel Incoherent Motion {{MR}} Imaging},
  author     = {Togao, Osamu and Hiwatashi, Akio and Yamashita, Koji and Kikuchi, Kazufumi and Momosaka, Daichi and Yoshimoto, Koji and Kuga, Daisuke and Mizoguchi, Masahiro and Suzuki, Satoshi O and Iwaki, Toru and Van Cauteren, Marc and Iihara, Koji and Honda, Hiroshi},
  year       = 2018,
  month      = may,
  journal    = {The British Journal of Radiology},
  volume     = {91},
  number     = {1085},
  pages      = {20170912},
  issn       = {0007-1285, 1748-880X},
  doi        = {10.1259/bjr.20170912},
  urldate    = {2025-12-23},
  abstract   = {Objective:               To evaluate the quantification performance of the perfusion fraction (f) measured with intravoxel incoherent motion (IVIM) MR imaging in a comparison with the histological vascular density in meningiomas.                                         Methods:               29 consecutive patients with meningioma (59.0 \textpm{} 16.8 years old, 8 males and 21 females) who underwent a subsequent surgical resection were examined with both IVIM imaging and a histopathological analysis. IVIM imaging was conducted using a single-shot SE-EPI sequence with 13 b-factors (0, 10, 20, 30, 50, 80, 100, 200, 300, 400, 600, 800, 1000 s mm- ~2) at 3T. The perfusion fraction (f) was calculated by fitting the IVIM bi-exponential model. The 90-percentile f-value in the tumor region-of-interest (ROI) was defined as the maximum f-value (f-max). Histopathological vascular density (\%Vessel) was measured on CD31-immunostainted histopathological specimens. The correlation and agreement between the f-values and \%Vessel was assessed.                                         Results:               The f-max (15.5 \textpm{} 5.5\%) showed excellent agreement [intraclass correlation coefficient (ICC) = 0.754] and a significant correlation (r = 0.69, p \&lt; 0.0001) with the \%Vessel (12.9 \textpm{} 9.4\%) of the tumors. The Bland-Altman plot analysis showed excellent agreement between the f-max and \%Vessel (bias, -2.6\%; 95\% limits of agreement, from -16.0 to 10.8\%). The f-max was not significantly different among the histological subtypes of meningioma.                                         Conclusion:               An excellent agreement and a significant correlation were observed between the f-values and \%Vessel. The f-value can be used as a noninvasive quantitative imaging measure to directly assess the vascular volume fraction in brain tumors.                                         Advances in knowledge:               The f-value measured by IVIM imaging showed a significant correlation and an excellent agreement with the histological vascular density in the meningiomas. The f-value can be used as a noninvasive and quantitative imaging measure to directly assess the volume fraction of capillaries in brain tumors.},
  copyright  = {https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\G9K3BRT5\Togao et al. - 2018 - Measurement of the perfusion fraction in brain tumors with intravoxel incoherent motion MR imaging.pdf}
}

@article{tomczakNeedReportEffect,
  title   = {The Need to Report Effect Size Estimates Revisited. {{An}} Overview of Some Recommended Measures of Effect Size},
  author  = {Tomczak, Maciej and Tomczak, Ewa},
  year    = 2014,
  journal = {Trends in Sport Sciences},
  volume  = {21},
  number  = {1},
  pages   = {19--25},
  issn    = {2299-9590},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\P5CQ4EAX\Tomczak and Tomczak - The need to report effect size estimates revisited. An overview of some recommended measures of effe.pdf}
}

@article{traversoMachineLearningHelps2020,
  title   = {Machine Learning Helps Identifying Volume-Confounding Effects in Radiomics},
  author  = {Traverso, Alberto and Kazmierski, Michal and Zhovannik, Ivan and Welch, Mattea and Wee, Leonard and Jaffray, David and Dekker, Andre and Hope, Andrew},
  year    = 2020,
  month   = mar,
  journal = {Physica Medica},
  volume  = {71},
  pages   = {24--30},
  issn    = {11201797},
  doi     = {10.1016/j.ejmp.2020.02.010},
  urldate = {2025-08-25},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\ECIEA92H\Traverso et al. - 2020 - Machine learning helps identifying volume-confounding effects in radiomics.pdf}
}

@article{traversoRepeatabilityReproducibilityRadiomic2018,
  title      = {Repeatability and {{Reproducibility}} of {{Radiomic Features}}: {{A Systematic Review}}},
  shorttitle = {Repeatability and {{Reproducibility}} of {{Radiomic Features}}},
  author     = {Traverso, Alberto and Wee, Leonard and Dekker, Andre and Gillies, Robert},
  year       = 2018,
  month      = nov,
  journal    = {International Journal of Radiation Oncology*Biology*Physics},
  volume     = {102},
  number     = {4},
  pages      = {1143--1158},
  issn       = {03603016},
  doi        = {10.1016/j.ijrobp.2018.05.053},
  urldate    = {2025-12-01},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\IURCK42W\Traverso et al. - 2018 - Repeatability and Reproducibility of Radiomic Features A Systematic Review.pdf}
}

@article{tsilimigrasLiverMetastases2021,
  title   = {Liver Metastases},
  author  = {Tsilimigras, Diamantis I. and Brodt, Pnina and Clavien, Pierre-Alain and Muschel, Ruth J. and D'Angelica, Michael I. and Endo, Itaru and Parks, Rowan W. and Doyle, Majella and De Santiba{\~n}es, Eduardo and Pawlik, Timothy M.},
  year    = 2021,
  month   = apr,
  journal = {Nature Reviews Disease Primers},
  volume  = {7},
  number  = {1},
  pages   = {27},
  issn    = {2056-676X},
  doi     = {10.1038/s41572-021-00261-6},
  urldate = {2025-08-12},
  langid  = {english}
}

@article{valderrama-trevinoHepaticMetastasisColorectal2017,
  title    = {Hepatic {{Metastasis}} from {{Colorectal Cancer}}},
  author   = {{Valderrama-Trevi{\~n}o}, Alan I and {Barrera-Mera}, Baltazar and {Ceballos-Villalva}, Jes{\'u}s C and {Montalvo-Jav{\'e}}, Eduardo E},
  year     = 2017,
  month    = dec,
  journal  = {Euroasian Journal of Hepato-Gastroenterology},
  volume   = {7},
  number   = {2},
  pages    = {166--175},
  issn     = {2231-5047, 2231-5128},
  doi      = {10.5005/jp-journals-10018-1241},
  urldate  = {2026-01-18},
  abstract = {ABSTRACT             The liver is the most common site of metastasis in patients with colorectal cancer due to its anatomical situation regarding its portal circulation. About 14 to 18\% of patients with colorectal cancer present metastasis at the first medical consultation, and 10 to 25\% at the time of the resection of the primary colorectal cancer. The incidence is higher (35\%) when a computed tomography (CT) scan is used.             In the last decades, a significant increase in the life expectancy of patients with colorectal cancer has been achieved with different diagnostic and treatment programs. Despite these improvements, the presence of metastasis, disease recurrence, and advanced local tumors continue to remain poor prognostic factors.             Median survival without treatment is {$<$}8 months from the moment of its presentation, and a survival rate at 5 years of 11\% is the best prognosis for those who present with local metastasis. Even in patients with limited metastatic disease, 5-year survival is exceptional. Patients with hepatic metastasis of colorectal cancer have a median survival of 5 to 20 months with no treatment. Approximately 20 to 30\% of patients with colorectal metastasis have disease confined to the liver, and this can be managed with surgery. Modern surgical strategies at the main hepatobiliary centers have proved that hepatectomy of 70\% of the liver can be performed, with a mortality rate of {$<$}5\%.             It is very important to have knowledge of predisposing factors, diagnostic methods, and treatment of hepatic metastasis. However, the establishment of newer, efficient, preventive screening programs for early diagnosis and adequate treatment is vital.                            How to cite this article               Valderrama-Trevi\~no AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Jav\'e EE. Hepatic Metastasis from Colorectal Cancer. Euroasian J Hepato-Gastroenterol 2017;7(2):166-175.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\AMBCTS69\Valderrama-TreviÃ±o et al. - 2017 - Hepatic Metastasis from Colorectal Cancer.pdf}
}

@article{vandeneyndenMultifacetedRoleMicroenvironment2013,
  title     = {The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications},
  author    = {{Van den Eynden}, Gert G and Majeed, Ali W and Illemann, Martin and Vermeulen, Peter B and Bird, Nigel C and {H{\o}yer-Hansen}, Gunilla and Eefsen, Rikke L{\o}vendahl and Reynolds, Andrew R and Brodt, Pnina},
  year      = 2013,
  month     = apr,
  journal   = {Cancer Res.},
  volume    = {73},
  number    = {7},
  pages     = {2031--2043},
  publisher = {American Association for Cancer Research (AACR)},
  issn      = {0008-5472},
  doi       = {10.1158/0008-5472.CAN-12-3931},
  urldate   = {2024-11-19},
  abstract  = {The liver is host to many metastatic cancers, particularly colorectal cancer, for which the last 2 decades have seen major advances in diagnosis and treatment. The liver is a vital organ, and the extent of its involvement with metastatic disease is a major determinant of survival. Metastatic cells arriving in the liver via the bloodstream encounter the microenvironment of the hepatic sinusoid. The interactions of the tumor cells with hepatic sinusoidal and extrasinusoidal cells (endothelial, Kupffer, stellate, and inflammatory cells) determine their fate. The sinusoidal cells can have a dual role, sometimes fatal to the tumor cells but also facilitatory to their survival and growth. Adhesion molecules participate in these interactions and may affect their outcome. Bone marrow-derived cells and chemokines also play a part in the early battle for survival of the metastases. Once the tumor cells have arrested and survived the initial onslaught, tumors can grow within the liver in 3 distinct patterns, reflecting differing host responses, mechanisms of vascularization, and proteolytic activity. This review aims to present current knowledge of the interactions between the host liver cells and the invading metastases that has implications for the clinical course of the disease and the response to treatment.}
}

@article{vangriethuysenComputationalRadiomicsSystem2017,
  title    = {Computational {{Radiomics System}} to {{Decode}} the {{Radiographic Phenotype}}},
  author   = {Van Griethuysen, Joost J.M. and Fedorov, Andriy and Parmar, Chintan and Hosny, Ahmed and Aucoin, Nicole and Narayan, Vivek and {Beets-Tan}, Regina G.H. and {Fillion-Robin}, Jean-Christophe and Pieper, Steve and Aerts, Hugo J.W.L.},
  year     = 2017,
  month    = nov,
  journal  = {Cancer Research},
  volume   = {77},
  number   = {21},
  pages    = {e104-e107},
  issn     = {0008-5472, 1538-7445},
  doi      = {10.1158/0008-5472.CAN-17-0339},
  urldate  = {2025-08-05},
  abstract = {Abstract             Radiomics aims to quantify phenotypic characteristics on medical imaging through the use of automated algorithms. Radiomic artificial intelligence (AI) technology, either based on engineered hard-coded algorithms or deep learning methods, can be used to develop noninvasive imaging-based biomarkers. However, lack of standardized algorithm definitions and image processing severely hampers reproducibility and comparability of results. To address this issue, we developed PyRadiomics, a flexible open-source platform capable of extracting a large panel of engineered features from medical images. PyRadiomics is implemented in Python and can be used standalone or using 3D Slicer. Here, we discuss the workflow and architecture of PyRadiomics and demonstrate its application in characterizing lung lesions. Source code, documentation, and examples are publicly available at www.radiomics.io. With this platform, we aim to establish a reference standard for radiomic analyses, provide a tested and maintained resource, and to grow the community of radiomic developers addressing critical needs in cancer research. Cancer Res; 77(21); e104--7. \copyright 2017 AACR.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\FLKELSRM\Van Griethuysen et al. - 2017 - Computational Radiomics System to Decode the Radiographic Phenotype.pdf}
}

@article{veraartDenoisingDiffusionMRI2016,
  title   = {Denoising of Diffusion {{MRI}} Using Random Matrix Theory},
  author  = {Veraart, Jelle and Novikov, Dmitry S. and Christiaens, Daan and {Ades-aron}, Benjamin and Sijbers, Jan and Fieremans, Els},
  year    = 2016,
  month   = nov,
  journal = {NeuroImage},
  volume  = {142},
  pages   = {394--406},
  issn    = {10538119},
  doi     = {10.1016/j.neuroimage.2016.08.016},
  urldate = {2025-12-11},
  langid  = {english},
  file    = {C:\Users\oprio\Zotero\storage\DS9HGGU7\Veraart et al. - 2016 - Denoising of diffusion MRI using random matrix theory.pdf}
}

@article{vermaTumorHabitatDerived2020,
  title      = {Tumor {{Habitat}}--Derived {{Radiomic Features}} at {{Pretreatment MRI That Are Prognostic}} for {{Progression-free Survival}} in {{Glioblastoma Are Associated}} with {{Key Morphologic Attributes}} at {{Histopathologic Examination}}: {{A Feasibility Study}}},
  shorttitle = {Tumor {{Habitat}}--Derived {{Radiomic Features}} at {{Pretreatment MRI That Are Prognostic}} for {{Progression-free Survival}} in {{Glioblastoma Are Associated}} with {{Key Morphologic Attributes}} at {{Histopathologic Examination}}},
  author     = {Verma, Ruchika and Correa, Ramon and Hill, Virginia B. and Statsevych, Volodymyr and Bera, Kaustav and Beig, Niha and Mahammedi, Abdelkader and Madabhushi, Anant and Ahluwalia, Manmeet and Tiwari, Pallavi},
  year       = 2020,
  month      = nov,
  journal    = {Radiology: Artificial Intelligence},
  volume     = {2},
  number     = {6},
  pages      = {e190168},
  issn       = {2638-6100},
  doi        = {10.1148/ryai.2020190168},
  urldate    = {2026-01-19},
  langid     = {english}
}

@article{waningerEvaluationPrognosticRole2023,
  title      = {Evaluation of the {{Prognostic Role}} of {{Liver Metastases}} on {{Patient Outcomes}}: {{Systematic Review}} and {{Meta-analysis}}},
  shorttitle = {Evaluation of the {{Prognostic Role}} of {{Liver Metastases}} on {{Patient Outcomes}}},
  author     = {Waninger, Jessica J. and Ma, Vincent T. and Chopra, Zoey and Pearson, Ashley N. and Green, Michael D.},
  year       = 2023,
  month      = sep,
  journal    = {The Cancer Journal},
  volume     = {29},
  number     = {5},
  pages      = {279--284},
  issn       = {1540-336X, 1528-9117},
  doi        = {10.1097/PPO.0000000000000683},
  urldate    = {2026-01-18},
  abstract   = {Abstract             The liver is a common site of metastasis for many primary malignancies, but the quantitative impact on survival is unknown. We performed a systematic review and meta-analysis of 83 studies (604,853 patients) assessing the overall hazard associated with liver metastases by primary tumor type and treatment regimen. The pooled overall survival hazard ratio (HR) for all included studies was 1.77 (95\% confidence interval [CI], 1.62--1.93). Patients with breast cancer primaries fared the worst (HR, 2.37; 95\% CI, 1.64--3.44), as did patients treated with immunotherapies (HR, 1.86; 95\% CI, 1.42--2.42). Liver metastases negatively impact survival, necessitating new approaches to disease management.},
  langid     = {english}
}

@article{waqarVisualisingSpatialHeterogeneity2022,
  title    = {Visualising Spatial Heterogeneity in Glioblastoma Using Imaging Habitats},
  author   = {Waqar, Mueez and Van Houdt, Petra J. and Hessen, Eline and Li, Ka-Loh and Zhu, Xiaoping and Jackson, Alan and Iqbal, Mudassar and O'Connor, James and Djoukhadar, Ibrahim and {van der Heide}, Uulke A. and Coope, David J. and Borst, Gerben R.},
  year     = 2022,
  journal  = {Frontiers in Oncology},
  volume   = {12},
  pages    = {1037896},
  issn     = {2234-943X},
  doi      = {10.3389/fonc.2022.1037896},
  abstract = {Glioblastoma is a high-grade aggressive neoplasm characterised by significant intra-tumoral spatial heterogeneity. Personalising therapy for this tumour requires non-invasive tools to visualise its heterogeneity to monitor treatment response on a regional level. To date, efforts to characterise glioblastoma's imaging features and heterogeneity have focussed on individual imaging biomarkers, or high-throughput radiomic approaches that consider a vast number of imaging variables across the tumour as a whole. Habitat imaging is a novel approach to cancer imaging that identifies tumour regions or 'habitats' based on shared imaging characteristics, usually defined using multiple imaging biomarkers. Habitat imaging reflects the evolution of imaging biomarkers and offers spatially preserved assessment of tumour physiological processes such perfusion and cellularity. This allows for regional assessment of treatment response to facilitate personalised therapy. In this review, we explore different methodologies to derive imaging habitats in glioblastoma, strategies to overcome its technical challenges, contrast experiences to other cancers, and describe potential clinical applications.},
  langid   = {english},
  pmcid    = {PMC9731157},
  pmid     = {36505856},
  keywords = {biomarker,glioblastoma,habitats,heterogeneity,imaging,MRI,preoperative},
  file     = {C:\Users\oprio\Zotero\storage\KJY5IT9K\Waqar et al. - 2022 - Visualising spatial heterogeneity in glioblastoma using imaging habitats.pdf}
}

@book{weinbergBiologyCancer2023,
  title        = {The Biology of Cancer},
  author       = {Weinberg, Robert A.},
  year         = 2023,
  edition      = {Third edition, international student edition},
  publisher    = {W. W. Norton \& Company},
  address      = {New York, N.Y. London},
  collaborator = {Goldsby, Richard A. and Hemann, Michael and Jacks, Tyler},
  isbn         = {978-0-393-88765-5 978-0-393-88766-2},
  langid       = {english}
}

@article{wongSpecificityIntraacinarNecrosis2007,
  title   = {Specificity of Intra-acinar Necrosis as a Marker of Colorectal Liver Metastasis},
  author  = {Wong, N A C S and Neville, L P},
  year    = 2007,
  month   = nov,
  journal = {Histopathology},
  volume  = {51},
  number  = {5},
  pages   = {725--727},
  issn    = {0309-0167, 1365-2559},
  doi     = {10.1111/j.1365-2559.2007.02837.x},
  urldate = {2025-12-15},
  langid  = {english}
}

@article{xuMultiorganCancerStudy2019,
  title   = {A Multi-Organ Cancer Study of the Classification Performance Using {{2D}} and {{3D}} Image Features in Radiomics Analysis},
  author  = {Xu, Lei and Yang, Pengfei and Yen, Eric Alexander and Wan, Yidong and Jiang, Yangkang and Cao, Zuozhen and Shen, Xiaoyong and Wu, Yan and Wang, Jing and Luo, Chen and Niu, Tianye},
  year    = 2019,
  month   = nov,
  journal = {Physics in Medicine \& Biology},
  volume  = {64},
  number  = {21},
  pages   = {215009},
  issn    = {1361-6560},
  doi     = {10.1088/1361-6560/ab489f},
  urldate = {2025-12-01}
}

@article{yamamotoMetastasisTumorInterior2023,
  title    = {Metastasis from the Tumor Interior and Necrotic Core Formation Are Regulated by Breast Cancer-Derived Angiopoietin-like 7},
  author   = {Yamamoto, Ami and Huang, Yin and Krajina, Brad A and McBirney, Margaux and Doak, Andrea E and Qu, Sixuan and Wang, Carolyn L and Haffner, Michael C and Cheung, Kevin J},
  year     = 2023,
  month    = mar,
  journal  = {Proc. Natl. Acad. Sci. U. S. A.},
  volume   = {120},
  number   = {10},
  pages    = {e2214888120},
  issn     = {0027-8424},
  doi      = {10.1073/pnas.2214888120},
  abstract = {Necrosis in the tumor interior is a common feature of aggressive cancers that is associated with poor clinical prognosis and the development of metastasis. How the necrotic core promotes metastasis remains unclear. Here, we report that emergence of necrosis inside the tumor is correlated temporally with increased tumor dissemination in a rat breast cancer model and in human breast cancer patients. By performing spatially focused transcriptional profiling, we identified angiopoietin-like 7 (Angptl7) as a tumor-specific factor localized to the perinecrotic zone. Functional studies showed that Angptl7 loss normalizes central necrosis, perinecrotic dilated vessels, metastasis, and reduces circulating tumor cell counts to nearly zero. Mechanistically, Angptl7 promotes vascular permeability and supports vascular remodeling in the perinecrotic zone. Taken together, these findings show that breast tumors actively produce factors controlling central necrosis formation and metastatic dissemination from the tumor core.},
  keywords = {angiopoietin-like 7,breast cancer,circulating tumor cells,metastasis,necrotic core}
}

@article{yanivSimpleITKImageAnalysisNotebooks2018,
  title      = {{{SimpleITK Image-Analysis Notebooks}}: A {{Collaborative Environment}} for {{Education}} and {{Reproducible Research}}},
  shorttitle = {{{SimpleITK Image-Analysis Notebooks}}},
  author     = {Yaniv, Ziv and Lowekamp, Bradley C. and Johnson, Hans J. and Beare, Richard},
  year       = 2018,
  month      = jun,
  journal    = {Journal of Digital Imaging},
  volume     = {31},
  number     = {3},
  pages      = {290--303},
  issn       = {0897-1889, 1618-727X},
  doi        = {10.1007/s10278-017-0037-8},
  urldate    = {2025-12-10},
  abstract   = {Abstract                            Modern scientific endeavors increasingly require team collaborations to construct and interpret complex computational workflows. This work describes an image-analysis environment that supports the use of computational tools that facilitate reproducible research and support scientists with varying levels of software development skills. The Jupyter notebook web application is the basis of an environment that enables flexible, well-documented, and reproducible workflows via literate programming. Image-analysis software development is made accessible to scientists with varying levels of programming experience via the use of the SimpleITK toolkit, a simplified interface to the Insight Segmentation and Registration Toolkit. Additional features of the development environment include user friendly data sharing using online data repositories and a testing framework that facilitates code maintenance. SimpleITK provides a large number of examples illustrating educational and research-oriented image analysis workflows for free download from GitHub under an Apache 2.0 license:               github.com/InsightSoftwareConsortium/SimpleITK-Notebooks               .},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\2PSN7266\Yaniv et al. - 2018 - SimpleITK Image-Analysis Notebooks a Collaborative Environment for Education and Reproducible Resea.pdf}
}

@article{yeStatisticalConsiderationsRepeatability2022,
  title    = {Statistical Considerations for Repeatability and Reproducibility of Quantitative Imaging Biomarkers},
  author   = {Ye, Shangyuan and Lim, Jeong Youn and Huang, Wei},
  year     = 2022,
  month    = jan,
  journal  = {BJR\textbar Open},
  volume   = {4},
  number   = {1},
  pages    = {20210083},
  issn     = {2513-9878},
  doi      = {10.1259/bjro.20210083},
  urldate  = {2025-12-10},
  abstract = {Quantitative imaging biomarkers (QIBs) are increasingly used in clinical studies. Because many QIBs are derived through multiple steps in image data acquisition and data analysis, QIB measurements can produce large variabilities, posing a significant challenge in translating QIBs into clinical trials, and ultimately, clinical practice. Both repeatability and reproducibility constitute the reliability of a QIB measurement. In this article, we review the statistical aspects of repeatability and reproducibility of QIB measurements by introducing methods and metrics for assessments of QIB repeatability and reproducibility and illustrating the impact of QIB measurement error on sample size and statistical power calculations, as well as predictive performance with a QIB as a predictive biomarker.},
  langid   = {english}
}

@article{yoshikawaRelationCancerCellularity2008,
  title     = {Relation between Cancer Cellularity and Apparent Diffusion Coefficient Values Using Diffusion-Weighted Magnetic Resonance Imaging in Breast Cancer},
  author    = {Yoshikawa, Miho I. and Ohsumi, Shozo and Sugata, Shigenori and Kataoka, Masaaki and Takashima, Shigemitsu and Mochizuki, Teruhito and Ikura, Hirohiko and Imai, Yutaka},
  year      = 2008,
  month     = may,
  journal   = {Radiation Medicine},
  volume    = {26},
  number    = {4},
  pages     = {222--226},
  issn      = {0288-2043, 1862-5274},
  doi       = {10.1007/s11604-007-0218-3},
  urldate   = {2026-01-14},
  copyright = {http://www.springer.com/tdm},
  langid    = {english}
}

@article{zamboniESREssentialsResponse2024,
  title      = {{{ESR Essentials}}: Response Assessment Criteria in Oncologic Imaging---Practice Recommendations by the {{European Society}} of {{Oncologic Imaging}}},
  shorttitle = {{{ESR Essentials}}},
  author     = {Zamboni, Giulia A. and Cappello, Giovanni and Caruso, Damiano and Gourtsoyianni, Sofia and Cyran, Clemens and Schlemmer, Heinz-Peter and D'Anastasi, Melvin and Fournier, Laure and Neri, Emanuele},
  year       = 2024,
  month      = aug,
  journal    = {European Radiology},
  volume     = {35},
  number     = {2},
  pages      = {674--683},
  issn       = {1432-1084},
  doi        = {10.1007/s00330-024-11006-w},
  urldate    = {2026-01-19},
  abstract   = {Abstract               Assessing the response to oncological treatments is paramount for determining the prognosis and defining the best treatment for each patient. Several biomarkers, including imaging, can be used, but standardization is fundamental for consistency and reliability. Tumor response evaluation criteria have been defined by international groups for application in pharmaceutical clinical trials evaluating new drugs or therapeutic strategies. RECIST 1.1 criteria are exclusively based on unidimensional lesion measurements; changes in tumor size are used as surrogate imaging biomarkers to correlate with patient outcomes. However, increased tumor size does not always reflect tumor progression. The introduction of immunotherapy has led to the development of new criteria (iRECIST, Level of Evidence (LoE) Ib) that consider the possibility that an increase in disease burden is secondary to the immune response instead of progression, with the new concept of Unconfirmed Progressive Disease (a first progression event which must be confirmed on follow-up). Specific criteria were devised for HCC (mRECIST, LoE IV), which measure only enhancing HCC portions to account for changes after local therapy. For GIST treated with imatinib, criteria were developed to account for the possible increase in size reflecting a response rather than a progression by assessing both tumor size and density on CT (Choi, LoE II). This article provides concise and relevant practice recommendations aimed at general radiologists to help choose and apply the most appropriate criteria for assessing response to treatment in different oncologic scenarios. Though these criteria were developed for clinical trials, they may be applied in clinical practice as a guide for day-to-day interpretation.                                         Key Points                                                                                               Response evaluation criteria, designed for use in clinical trials, might serve as a surrogate biomarker for overall survival                       .                                                                                                       RECIST 1.1 defines measurable and non-measurable disease among which target lesions and non-target lesions are selected at baseline as reference for follow-ups                       .                                                                                                       Some therapies and/or cancers require the use of different criteria, such as iRECIST, mRECIST, and Choi criteria                       .},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\3PRI6JEX\Zamboni et al. - 2024 - ESR Essentials response assessment criteria in oncologic imagingâpractice recommendations by the Eu.pdf}
}

@article{zeineddineSurvivalImprovementPatients2023,
  title    = {Survival Improvement for Patients with Metastatic Colorectal Cancer over Twenty Years},
  author   = {Zeineddine, Fadl A. and Zeineddine, Mohammad A. and Yousef, Abdelrahman and Gu, Yue and Chowdhury, Saikat and Dasari, Arvind and Huey, Ryan W. and Johnson, Benny and Kee, Bryan and Lee, Michael S. and Morelli, Maria Pia and Morris, Van K. and Overman, Michael J. and Parseghian, Christine and Raghav, Kanwal and Willis, Jason and Wolff, Robert A. and Kawaguchi, Yoshikuni and Vauthey, Jean-Nicolas and Sun, Ryan and Kopetz, Scott and Shen, John Paul},
  year     = 2023,
  month    = feb,
  journal  = {npj Precision Oncology},
  volume   = {7},
  number   = {1},
  pages    = {16},
  issn     = {2397-768X},
  doi      = {10.1038/s41698-023-00353-4},
  urldate  = {2025-12-15},
  abstract = {Abstract                            Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with               de novo               metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7\% for patients diagnosed from 2004 to 2006 to 26\% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with               BRAF                                V600E                              mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR\,=\,0.26, 95\% CI, 0.19--0.37), use of immunotherapy (HR\,=\,0.44, 95\% CI, 0.29--0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR\,=\,0.74, 95\% CI, 0.58--0.95), but not year of diagnosis (HR\,=\,0.99, 95\% CI, 0.98--1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\IWI77E2Y\Zeineddine et al. - 2023 - Survival improvement for patients with metastatic colorectal cancer over twenty years.pdf}
}

@article{zouStatisticalValidationImage2004,
  title     = {Statistical Validation of Image Segmentation Quality Based on a Spatial Overlap Index1},
  author    = {Zou, Kelly H. and Warfield, Simon K. and Bharatha, Aditya and Tempany, Clare M.C. and Kaus, Michael R. and Haker, Steven J. and Wells, William M. and Jolesz, Ferenc A. and Kikinis, Ron},
  year      = 2004,
  month     = feb,
  journal   = {Academic Radiology},
  volume    = {11},
  number    = {2},
  pages     = {178--189},
  issn      = {10766332},
  doi       = {10.1016/S1076-6332(03)00671-8},
  urldate   = {2025-12-10},
  copyright = {https://www.elsevier.com/tdm/userlicense/1.0/},
  langid    = {english},
  file      = {C:\Users\oprio\Zotero\storage\RSDVCNHB\Zou et al. - 2004 - Statistical validation of image segmentation quality based on a spatial overlap index1.pdf}
}

@article{zwanenburgAssessingRobustnessRadiomic2019,
  title    = {Assessing Robustness of Radiomic Features by Image Perturbation},
  author   = {Zwanenburg, Alex and Leger, Stefan and Agolli, Linda and Pilz, Karoline and Troost, Esther G. C. and Richter, Christian and L{\"o}ck, Steffen},
  year     = 2019,
  month    = jan,
  journal  = {Scientific Reports},
  volume   = {9},
  number   = {1},
  pages    = {614},
  issn     = {2045-2322},
  doi      = {10.1038/s41598-018-36938-4},
  urldate  = {2025-12-01},
  abstract = {Abstract             Image features need to be robust against differences in positioning, acquisition and segmentation to ensure reproducibility. Radiomic models that only include robust features can be used to analyse new images, whereas models with non-robust features may fail to predict the outcome of interest accurately. Test-retest imaging is recommended to assess robustness, but may not be available for the phenotype of interest. We therefore investigated 18 combinations of image perturbations to determine feature robustness, based on noise addition (N), translation (T), rotation (R), volume growth/shrinkage (V) and supervoxel-based contour randomisation (C). Test-retest and perturbation robustness were compared for combined total of 4032 morphological, statistical and texture features that were computed from the gross tumour volume in two cohorts with computed tomography imaging: I) 31 non-small-cell lung cancer (NSCLC) patients; II): 19 head-and-neck squamous cell carcinoma (HNSCC) patients. Robustness was determined using the 95\% confidence interval (CI) of the intraclass correlation coefficient (1, 1). Features with CI\,{$\geq$}\,0:90 were considered robust. The NTCV, TCV, RNCV and RCV perturbation chain produced similar results and identified the fewest false positive robust features (NSCLC: 0.2--0.9\%; HNSCC: 1.7--1.9\%). Thus, these perturbation chains may be used as an alternative to test-retest imaging to assess feature robustness.},
  langid   = {english},
  file     = {C:\Users\oprio\Zotero\storage\QZHP4FTV\Zwanenburg et al. - 2019 - Assessing robustness of radiomic features by image perturbation.pdf}
}

@article{zwanenburgImageBiomarkerStandardization2020,
  title      = {The {{Image Biomarker Standardization Initiative}}: {{Standardized Quantitative Radiomics}} for {{High-Throughput Image-based Phenotyping}}},
  shorttitle = {The {{Image Biomarker Standardization Initiative}}},
  author     = {Zwanenburg, Alex and Valli{\`e}res, Martin and Abdalah, Mahmoud A. and others},
  year       = 2020,
  month      = may,
  journal    = {Radiology},
  volume     = {295},
  number     = {2},
  pages      = {328--338},
  issn       = {0033-8419, 1527-1315},
  doi        = {10.1148/radiol.2020191145},
  urldate    = {2025-12-01},
  langid     = {english},
  file       = {C:\Users\oprio\Zotero\storage\3QFS6HMG\Zwanenburg et al. - 2020 - The Image Biomarker Standardization Initiative Standardized Quantitative Radiomics for High-Through.pdf}
}


